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ABSTRACT
JIN LEE: Polymeric Nanogels as Gene Carriers
(Under the direction of Moo J. Cho, PhD)
Developing efficient and safe vectors is one of the main challenges in gene therapy.
Multiple fatal incidences in applying virus have brought safety issues to the attention and
called for developing non-viral vectors, entailing lipoplex and polyplex. The present
dissertation mainly focuses on a polyplex system. Inverse microemulsion-derived nanogel
features a hydrophilic matrix, rendering the delivery of genes more compatible. Nanogel was
modified with acid-buffering weak base, redox-sensitive cleavable crosslinker, and folate
targeting ligand. Two types of plasmid DNA (pDNA)-nanogel formulations were assessed
for transfection efficiency. First, luciferase pDNA was added to the microemulsion prior to
the polymerization. It was hypothesized that pDNA will spontaneously reside in the aqueous
phase and be well compacted. The energetics involved was not, however, sufficient enough
to produce a stable system. Protamine-condensed pDNA increased the entrapment efficiency.
Unfortunately, addition of methanol to dissolve the disulfide crosslinker disturbed
microemulsion, reducing entrapment efficiency. Second, pDNA was mixed with pre-made
cationic nanogels containing folate targeting ligands. Although pDNA-nanogel complex did
not surpass the conventional transfecting reagents, it increased transfection efficiency in the
folate receptor-expressing KB cells compared to the naked pDNA. Targeted formulations
iii
represented superior transfection efficiency to the non-targeted counterparts. Disulfide-
containing crosslinker was necessary for an enhanced transfection. Incorporation of weak
base improved the transfection efficiency only in the formulation with low positive charges.
Most importantly, the targeting capacity was able to overcome non-specific binding only
when electrostatic interaction was minimal.
Comparing to the relatively well-established nanogels, PRINT particles are in the
early stage of development as a potential drug/gene carrier, featuring an unprecedented
monodispersity in various physicochemical properties. Better understanding of in vivo
pharmacokinetics of PRINT particles would lead to optimizing pharmacodynamics as a gene
carrier. [125I]-PRINT particles following an IV injection into the healthy mice accumulated in
liver and spleen. However, the relatively short blood circulation and the probable premature
decomposition called for further investigation. Also a more sensitive and reproducible
monitoring method is highly desirable. Due to its preliminary nature, the study results are
placed in Appendix.
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CHAPTER I
INTRODUCTION
1.1 Gene Vectors
Along with the increased attention to human gene therapy, much research effort has
been geared to the development of gene delivery vectors aiming for enhanced uptake of
genetic materials by target cells and the facile transport of the nucleic acids to the cytosol and
subsequently to the nucleus. As viruses can perform these tasks, early on viral vectors had
been developed in the gene therapy field (Culver et al. 1992; Kasahara et al. 1994; Gunzburg
and Salmons 1996). Although this strategy delivers genes in an efficient manner, it has been
limited due to general toxicity, carcinogenesis, immunogenicity, and low target tissue
penetration problems. For instance, the sudden death of an 18-year-old patient from activated
innate immunity in a gene therapy trial brought the safety issues into focus in using viruses as
gene carriers (Marshall 1999). The interest of investigators accordingly has been moved to
non-virus-derived vectors. Although non-viral vectors developed to date are inferior to their
viral counterparts with regard to efficiency, they are relatively safe and amenable to large-
scale production. Improving the efficiency and specificity will make non-viral vectors more
attractive tools in gene therapy. Non-viral vectors mostly consist of lipid- or polymer-based
formulations, commonly referred to as lipoplex and polyplex, respectively. They are in
2essence utilizing the electrostatic interaction between polyanionic charges of genes and
cationic carriers. However, in vivo application of these approaches is greatly compromised
by the unwanted interaction of positively charged vectors with the anionic serum components.
Ideally, for clinical applications gene vectors should be nontoxic, nonimmunogenic, and
serum compatible.
As depicted in Figure 1-1, non-viral gene vectors must overcome multiple transport
barriers to cellular gene delivery. Cellular binding and uptake represent the first obstacle
(steps 2 and 3). Endocytosis is the generally accepted mechanism by which gene vectors
enter the cell (Wattiaux et al. 2000). Polyanionic cell surface proteoglycans are believed to
play a role in the non-specific interaction with cationic vectors with excess positive charges.
Proteoglycan consists of a core protein and covalently linked highly anionic
glycosaminoglycan chains such as heparin and heparan sulfate (Hardingham and Fosang
1992). Many pieces of evidence can be found in early investigations with polylysine (Mislick
and Baldeschwieler 1996) and cationic lipid (Mounkes et al. 1998). In the presence of
glycosaminoglycan sulfation inhibitors such as sodium chlorate (NaClO3) or
glycosaminoglycan lyases such as heparinase II, gene expression was significantly reduced,
providing further evidence (Baeuerle and Huttner 1986).
At the tissue/organ level, it is often desirable to deliver a therapeutic gene to a
specific cell type. In theory, introducing a targeting ligand to the gene vector can enhance
transfection efficiency at lower and safer doses via more specific binding to the target cell
population and subsequent receptor-mediated endocytosis. Subsequent to use of
asialoorosomucoid (Wu and Wu 1987) and transferrin (Wagner et al. 1990) as targeting
3moieties, many other ligands have been exploited in this field, including growth factors
(Sosnowski et al. 1996), insulin (Huckett et al. 1990), integrin-binding motifs (Harvie et al.
2003), hereglulin (Medina-Kauwe et al. 2001), antibodies (Chen et al. 1994; Merwin et al.
1995; Kircheis et al. 1997), and small molecules such as folate (Lee and Huang 1996). See
Chapter IV for further discussions. The entry pathway upon cellular binding will be dictated
by the targeting ligand of choice and the cell type. As shown in Figure 1-2, endocytosis can
be divided into two broad categories depending on the involvement of receptors.
The classical clathrin-mediated endocytosis account for the majority of cellular entry
pathways of receptor-ligand complexes (Mukherjee et al. 1997). Upon receptor binding,
clathrin structures accumulate on the intracellular surface of the plasma membrane and
invaginate to form clathrin-coated pits. The coated pits are then pinched off into vesicles that
are later uncoated. After the vesicles containing cargos merge with early (or sorting)
endosomes, the destinations of these endosomes are two fold. They traffic either to
lysosomes through late endosomes upon further pH decrease or to recycling endosomes as
exemplified in transferrin and its receptor (Phillips 1995). Many studies demonstrated that
growth factors, hormones, lipoproteins and immune complexes use this pathway to enter the
cell (Ukkonen et al. 1986).
Many pathogens including SV40 and cholera toxin are believed to use the caveolar
pathway to avoid lysosomal degradation (Cohen et al. 2004). Caveolae are flask-shaped
invaginations of the plasma membrane with a diameter of 50-80 nm (Pelkmans and Helenius
2002). They are rich in cholesterol and sphingolipids and characterized by the integral
membrane protein, caveolin. Constitutive endocytic uptake mechanism mediated by caveolae
is, however, somewhat controversial (Hommelgaard et al. 2005) with endocytosis being
4down-regulated by caveolin itself (Le et al. 2002). Clathrin and caveolae independent yet
lipid raft mediated endocytosis is found to internalize cytokine receptors (e.g., IL-2 receptor)
(Lamaze et al. 2001) and glycosylphosphatidylinositol (GPI)-anchored proteins (Sabharanjak
et al. 2002). The clathrin independent, caveolae-mediated endocytic pathway appears to play
a role in the cellular uptake of folate and its conjugate via folate receptor-mediated
endocytosis. This process was used as a strategic modification of the nanogel in Chapter IV.
Large particulate vectors are internalized to the cell via macropinocytosis or
phagocytosis. Macropinosomes are large irregular vesicles of 0.5 – 5 µm in diameter that are
formed by actin-driven protrusion (ruffling) of the plasma membrane (Grimmer et al. 2002).
Membrane ruffling is nonclathrin-mediated. Rejman and colleagues (2004) suggested that
500-nm microspheres enter cells by macropinocytosis. Macropinosomes may provide an
alternative cell entry route by avoiding intersection with lysosomes and subsequent
lysosomal degradation (Conner and Schmid 2003). However, some negative role of
macropinocytosis was reported in transfecting HepG2 cells with histidinylated polyplex in
that the low transfection efficiency was attributed to a delayed translocation of the polyplex
from the macropinosome to the cytosol (Goncalves et al. 2004). Phagocytosis is initiated by
the interaction of cell surface receptor with foreign particles (Niedergang and Chavrier 2004).
Only professional antigen presenting cells such as macrophages and dendritic cells express
the large number of surface receptors that can initiate efficient phagocytosis (Aderem and
Underhill 1999; Allavena et al. 2004). The entrapment of foreign particles leads into
phagosomes that mature upon acidification and fuse with lysosomes (Swanson and Baer
1995). Strong enhancement of phagocytosis by cationic particles has been demonstrated in
macrophages and dendritic cells (e.g., Thiele et al. 2001). Cell type dependency of cellular
5entry pathway is also found in macropinosomes in that only immature dendritic cells carry
out this process constitutively (West et al. 2000). Specific cell types such as HepG2 cells
have been used to distinguish clathrin-mediated pathway from caveolae-associate route of
cationic vectors since this cell line is known to lack caveolae (Fujimoto et al. 2000).
The size of vectors is also a factor in determining a pathway of cellular entry. In
general virus sized particles (20-200 nm) are believed to take clathrin-dependent or caveolae
associated pathways considering the vesicle size of these routes. Along with Rejman’s
findings (2004) mentioned above, particles larger than 500 nm in diameter appear to enter the
cell via phagocytosis or receptor independent pathways such as pinocytosis (Simoes et al.
1999). Thus, particulate vectors can take any of these pathways depending on the size and
composition (e.g., incorporation of targeting ligands). It is also possible that multiple routes
concurrently contribute to the uptake of particulate vectors. As observed with the conjugates
of peptide derived from HIV transactivator of transcription, more complexity emerges with
the possibility for targeting ligand directed vectors to behave differently from the native
ligand in choosing the cellular uptake pathway (Eguchi et al. 2001; Wadia et al. 2004). More
importantly, avoiding lysosomes by taking alternative cell entry pathways do not necessarily
guarantee high levels of final gene expression as speculated in Goncalves et al. (2004).
The second barrier in cellular transfection is the endosome-to-cytosol translocation of
gene vectors or pDNA itself (step 4 in Figure 1-1). Endocytosed vectors containing pDNA
eventually traffic to lysosomes where they are degraded by lysosomal proteases. As the
luminal pH decreases from ~6 to ~ 5, early endosomes mature to late endosomes that fuse
with lysosomes (Luzio et al. 2001). Endocytosis via alternative pathways discussed earlier
6can avoid lysosomes but likely ends up with entrapping in endosomes. The clever way of
virus in utilizing pH decrease in escaping endosomal compartment has been adopted in gene
vectors. The conformational change in virus proteins yields an amphipathic helical structure
that is capable of inducing membrane fusion (Klasse et al. 1998). Thus, the main idea was
that vectors possessing endosomolytic components should ensure early escape from endo-
lysosomal compartment, resulting in enhanced transfection efficiency. This hypothesis was
supported by the observation that neutral phospholipid dioleylphosphatidylethanolamine
(DOPE) incorporated into lipoplex enhanced transfection efficiency (Farhood et al. 1995).
Transition from bilayer to inverted hexagonal structures and membrane destabilizing activity
are thought to be the main characteristics of DOPE that render this phospholipid more
fusogenic than other neutral phospholipids such as dioleoylphosphatidylcholin (DOPC)
(Koltover et al. 1998). Lipoplex containing DOPE showed indeed better transfection
efficiency that DOPC-derived counterpart (Mok and Cullis 1997). The hypothesized
mechanism of lipoplex fusion and the subsequent DNA release was proposed by Xu and
Szoka (1996). This report suggested that flip-flop movements of anionic phospholipid from
the cytoplasmic facing monolayer of the endosomal membrane into the inner endosomal
lumen induced the formation of a neutral ion pair with cationic lipid of lipoplex. However,
the number of anionic lipids theoretically calculated in a given endosomal membrane surface
was not high enough to facilitate the membrane fusion, compromising the aforementioned
hypothesis (Barron and Szoka Jr 1999).
Unlike cationic lipid, cationic polymers lack hydrophobic domains and therefore are
incapable of fusing with or destabilizing endosomal membrane. One strategy has been
conjugation of pore-forming peptide domains with polyplexes. The examples are diphtheria
7toxin translocation domain chemically coupled to polylysine (Fisher and Wilson 1997),
melittin incorporated in poly(ethylenimine) (PEI) (Ogris et al. 2001a) and GALA (a Glu-Ala-
Leu-Ala repeat) conjugated to dendrimers (Haensler and Szoka 1993). These studies also
demonstrated that endosomolytic activities of the pore-forming peptides are still intact when
linked covalently to the polymers.
An alternative approach was PEI. Its efficiency was attributed to the so-called ‘proton
sponge effect’ (Boussif et al. 1995). Tertiary amine moieties with pKa of 5.5-7.0 in PEI and
dendrimers are believed to responsible for this effect by absorbing protons in the endosomes,
subsequently delaying the trafficking to lysosomes and eventually disrupt endosomal
membrane. Although this hypothesis was once challenged (Godbey et al. 2000), more recent
findings reaffirmed the theory (Merdan et al. 2002; Thomas and Klibanov 2002) and a
mechanistic explanation was well documented by Sonawane et al. (2003). More delineated
speculation as well as a methodological application of this hypothesis is also presented in
Chapter II.
Following endosomal escape, gene vectors may encounter another obstacle before
reaching perinuclear area. Since the cytosolic space is a full of viscous fluids, the passive
diffusion of the particulate systems within this milieu may be extremely slow (Luby-Phelps
et al. 1987). It was reported that the mobility of DNA in the cytoplasm is indeed dependent
on DNA size with 6 kbp DNA remaining cytoplasm while 21 bp DNA diffusing into the
nucleus in 5 min after microinjection into the cytoplasm (Lukacs et al. 2000). Gene vectors
therefore will need some type of assistance from active cytosolic transport systems to
approach the vicinity of the nucleus. Molecular motors associated with the microtubule
network or actin filaments are known to transport vesicles, organelles and other colloidal
8structures in the cytoplasm (Hamm-Alvarez 1998). One of these systems may well contribute
to the transport of the gene vectors. Dynesin system is one of the motor proteins and
normally associated with the endocytic pathway (Walker and Sheetz 1993). In this context, if
the gene vectors exit the endosome too early, the probability for them to reach the nucleus,
the deeper site of the cell, could be lower.
DNA has must dissociate from the vector to allow the access of the transcription
apparatus of the cell. Although the exact site is still not clear, vector unpacking or
dissociation is certainly another hurdle for the gene vector to overcome (step 5 in Figure 1-1).
As far as lipoplex is concerned, the uncoupling between cationic lipids and pDNA seems to
be required prior to the transport into the nucleus. For example, the direct injection of
lipoplex into the nucleus or even into the cytoplasm resulted in very low levels of gene
expression (Zabner et al. 1995). This study also implies that vector unpacking occurs during
normal endocytic pathway. Early investigations suggested that lipoplex dissociates through
the interaction (including fusion process) with the cytosolic membrane network such as
endoplasmic reticulum, Golgi, mitochondria, and nuclear membrane (El Ouahabi et al. 1999;
Cornelis et al. 2002).
In the case of polyplex, the site of dissociation appears to be more complicated.
Pollard and colleagues (1998) suggested that the dissociation could occur in the nucleus. This
is based on their findings that polyplex directly injected into the nucleus showed a significant
gene expression. However, later study demonstrated that the population of polyplexes
detected inside the nucleus did not contribute to the gene expression measured (Bieber et al.
2002). Nevertheless, this group and other investigators (Schaffer et al. 2000) still observed
9high concentration of polyplexes in the perinuclear region. Although the site of dissociation
has yet to be determined, the molecular weight of polymers in the polyplex system seems to
affect the kinetics of vector unpacking. High molecular weight poly(L-lysine) was found to
remain bound to pDNA in the perinuclear region while majority of shorter version of this
polymer was found as free form around the nucleus (Schaffer et al. 2000). This observation
implies that low-molecular-weight-polymer-based polyplex has faster dissociation compared
to its larger counterpart-based polyplex. The dissociation kinetics appears to reflect the
transfection efficiency. Shorter poly(L-lysine)-based polyplex showed a higher transfection
while longer ones exhibited more sustained gene expression (Ziady et al. 1999). The
dissociation of PEI-based polyplex seems relatively slow. A few studies suggested that it
might occur between 4 hrs and 18 hrs after incubation with the cells (Ogris et al. 2001b;
Bieber et al. 2002). Poly(ethylenimine) also showed a similar correlation between the size
and the transfection efficiency (Turunen et al. 1999; Bieber and Elsasser 2001), probably due
to the faster dissociation in the smaller polymer-based polyplex systems. Once again, the site
of dissociation of gene vectors is still poorly understood.
Another key limiting factor in transfection is an inefficient nuclear entry of pDNA
(step 6 in Figure 1-1). The size of the nucleus pore complex is approximately 25 nm and 9
nm in outer and inner diameters, respectively (Pante and Aebi 1996). This narrow opening
permits transport of relatively small molecules (less than 40 kDa) (Stoffler et al. 1999) and is
also expected to limit the translocation of pDNA across the nuclear membrane. Nuclear entry
of pDNA can be speculated in two ways in the light of the mechanism. A passive pDNA
entry into the nucleus is possible during cell division when the nuclear membrane is
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temporarily decomposed. Brunner and colleagues (2000) found that cells transfected with
lipoplex and polyplex near the M phase (mitosis) (i.e., G2 or late S phase) showed much
higher transfection efficiency than when transfected at quiescent cell cycle phases such as G1
or early S phase. These authors also demonstrated that different types of gene vectors showed
nonidentical sensitivity toward cell cycle status with regard to transfection efficiency
(Brunner et al. 2002). Several other investigations suggested that the dependence of nuclear
entry on cell division cycle is also cell type specific (Dowty et al. 1995; Ludtke et al. 2002).
A second type of pDNA nuclear entry can be achieved by coupling of nuclear
localization sequence (NLS) containing peptides to pDNA. Short clusters of basic amino
acids such as lysine or arginine comprise NLS as shown in Table 1-1. These sequences are
recognized by cytoplasmic proteins known as karyopherins or importins and form a pore
targeting complex (Imamoto 2000). This complex bind to nuclear pore complex to
translocate through the pore (Gorlich and Mattaj 1996). As discussed in Chapter IV, M9-
and SV40-derived NLSs have been applied in the gene delivery field. Pollard and colleagues
(1998) suggested the existence of a different nuclear entry mechanisms involved in lipoplex
and polyplex systems as evidenced by the findings that polyplex was superior to lipoplex
when microinjected to the cytoplasm. Interestingly, other investigators speculate a possibly
additional role of endocytosis in the nuclear entry of lipoplex system by transporting pDNA
from near the plasma membrane to the perinuclear region (Dowty et al. 1995; Cornelis et al.
2002).
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1.2 Lipoplex
Direct intra-tissue injection of naked pDNA demonstrated gene expression in vivo
(Wolff et al. 1990), however, a reasonable efficiency has been achieved only when this
approach was applied through the limited sites of the body such as intramuscular therapy
(Rolland and Mumper 1998). Thus, gene therapy still requires vectors when other routes of
administration are needed such as intratracheal and intravenous injection. As of January 2007,
8 % of ongoing gene therapy clinical trials were based on lipoplex (http://www.wiley.co.uk/
genetherapy/clinical/).
Cationic lipids are amphiphilic molecules consisting of a polar headgroup, a linker
and a hydrophobic domain. The head groups utilized are quaternary ammonium salt, amine,
amidine, guanidium, pyridinium, and more recently developed sugar-based gemini moiety
(Johnsson et al. 2003). Linker chemistries involve ethers, esters, amides, carbamates, and
disulfides. Hydrophobic tail groups usually consist of saturated or unsaturated alkyl chains
(12-18 carbons in length) or cholesteryl groups. The effect of these variations on the
physicochemical and transfection properties of lipoplexes has been previously reviewed
(Zuhorn and Hoekstra 2002). The first successful in vitro transfection using cationic lipid
was reported by Felgner et al. (1987). The replacement of the ether linker of this earlier
cationic lipid by ester bonds demonstrated low cytotoxicity. The introduction of protonatable
amine groups to the lipoplex was also intended to reduce the side effects of the lipid-based
systems and led this formulation to the clinical trial (Caplen et al. 1995).
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The amine incorporation to the cationic lipid for the lipoplex system was first
proposed by Behr and his colleagues (Behr et al. 1989). Amine-containing cationic lipids,
lipoamines, are known to have pH-buffering functions (Zuidam and Barenholz 1998) and this
property may well contribute to the effective transfection efficiency shown by the
Lipofectamine, one of the most effective transfecting reagent in the market. Lipofectamine
is composed of multiamine containing lipid, N,N–dimethyl–N–[2–(sperminecarboxamido)
ethyl]–2,3–bis(dioleyloxy)–1–propaniminium pentahydrochloride, and a neutral helper lipid,
1,2-dioleyl phosphatidylethanolamine (DOPE). While amines in the head group in
Lipofectamine provide strong interaction with DNA along with pH-buffering effect
mentioned earlier, it is speculated that DOPE is more responsible for the enhanced
transfection efficiency by this lipoplex (Wheeler et al. 1996). 1,2-dioleyl
phosphatidylethanolamine was found to favor the formation of inverted hexagonal phases,
which provides the fusogenic activity to the endocytosed lipoplex (Koltover et al. 1998). A
slight excess of positive charges is known to confer a higher transfection efficiency probably
due to more efficient interaction with negatively charged cell surface (Sakurai et al. 2000).
Many studies demonstrated that the cationic lipid-to-DNA charge ratio determines the size of
the ensuing structures (e.g., Eastman et al. 1997). In terms of transfection efficiency,
lipoplexes in a certain range of sizes (0.4-1.4 µm in diameter) have been superior to the
smaller or larger ones (Kawaura et al. 1998; Ross and Hui 1999).
In vivo application of lipoplexes via intravenous injection, for example, showed high
protein expression in the lung (Ishiwata et al. 2000) probably due to endothelial
accumulation of the systems. Diverting biodistribution of lipoplexes has been attempted in
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several ways and include incorporation of synthetic cholic acid analog into the lipoplex
(Niedzinski et al. 2000), polymerization of cationic acrylamide lipid (Wu et al. 2001) and
coating with poly(ethylene glycol) (PEG) (Zhang et al. 1999; Harvie et al. 2000). These
approaches demonstrated improved stabilization of lipoplexes in plasma and the PEG coating
also allowed improved gene expression in the distal tumors (Anwer et al. 2000).
Complexation between cationic lipids and nucleic acids appears a simple mixing.
However, the preparation of the lipoplex formulations using aforementioned cationic lipids
requires carefully optimized conditions such as concentrations of components, temperature,
reaction environment and kinetics of mixing. Any changes or differences in these factors can
determine the outcome of gene therapies utilizing lipoplexes. In this context, Gao and Huang
(1996) developed an alternative formulation by incorporating small amount of a multivalent
cationic polymer such as polylysine or protamine into a lipoplex, so-called LPD, to generate
pDNA particles. This system presented superior gene expression efficiency to a conventional
lipoplex in vitro as well as in vivo. Although being less sensitive to the preparational
protocols, polyplexes will also need similar formulating optimizations. This subject on
polyplexes will be discussed in the following section and is also intensively speculated in the
Chapters III and IV.
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1.3 Polyplex
Compared to cationic lipids, cationic polymers condense DNA more efficiently
(Ruponen et al. 1999). Cationic polymers are also superior in the macroscopic stabilities such
as size and shape over time especially in the dispersed state since polyplex assembly does not
entail interactions among the polycations as seen in the case of lipid-based formulation
(Simberg et al. 2001). Polyplexes rarely need adjuvants and easily manipulated by chemical
modification to achieve higher transfection efficiency compared to lipid-containing
counterparts (Gebhart and Kabanov 2001). One of the first applications of synthetic cationic
polymer in gene delivery can found in 1960’s with diethylaminoethyl-modified dextran
(Vaheri and Pagano 1965). The polymer-based DNA complex now termed ‘polyplex’
involves polycations in the formulation.
Polycations include naturally occurring proteins such as histones (Esser et al. 2000),
cationized human albumin (Fischer et al. 2001) as well as polysaccharides such as chitosan
and its derivatives. Chitosan consists of glucosamine units having an apparent pKa of 6.5 and
has been known to enhance the transport of peptide drugs across the cell membrane (Thanou
et al. 2001). Chitosan as a gene vector was firstly proposed by Mumper et al. (1995) and
further characterized by Jane (2001) and Borchard (2001) regarding the effect of molecular
weight, DNA or salt concentration, pH of media, and charge ratio on the final size of
chitosan-DNA complex. The derivatives of chitosan as gene vectors were also reviewed by
Liu and Yao (2002) and include self-aggregating deoxycholic acid conjugates, dodecylated
chitosan for improved stability, quaternized derivatives for enhanced solubility, and targeting
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ligand conjugates such as galactose- or transferrin-modified chitosans. Chitosan was also the
first orally active gene delivery system (Roy et al. 1999).
Among synthetic cationic polymers are poly(L-lysine), PEI, polyamidoamine
dendrimers, and other polymers such as poly(L-ornithine) (Pouton et al. 1998), poly(4-
hydroxy-L-proine ester) (Lim et al. 1999), polylactide co-glycolide (Cohen et al. 2000), and
poly(-aminoester) (Lynn et al. 2001). Chemical structures of some representative cationic
polymers are shown in Figure 1-3.
One of the polycations used for gene delivery in early stage was polylysine. The gene
transfer efficiency of polylysine-containing polyplex is relatively poor and most of the
polylysine-derived formulations involve cell or tissue specific ligands such as
asialoorosomucoid for hepatocellular gene targeting (Wu and Wu 1987) or the addition of
endosomolytic agents such as chloroquine (Wadhwa et al. 1997). Many of polylysine
derivatives entail the conjugation of histidine moiety for endosomal buffering capacity (e.g.
Midoux and Monsigny 1999), or incorporation of cysteines for facile DNA release
(McKenzie et al. 2000a). Polylysine polyplex showed protection of DNA from serum
nucleases (Chiou et al. 1994) but found to be cleared from the blood rapidly by serum protein
opsonization upon the intravenous injection (Dash et al. 1999).
One of the most promising polycations up to date is PEI. Since Bousiff and
colleagues (1995) introduced its potential versatile efficiency in vitro as well as in vivo, both
branched and linear PEI have been utilized as effective tools in delivering of various genes
(Boussif et al. 1996; Chemin et al. 1998). Branched PEI consists of approximately 25, 50 and
25 % of primary, secondary, and tertiary amines, respectively. Primary amines seem to
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participate in the complexation with DNA by an electrostatic interaction while secondary and
tertiary amines contribute to the endosomal disruption after endocytosis due to their buffering
effect. High-molecular-weight (generally higher than 25 kDa) PEI showed enhanced
transfection efficiency but increased cytotoxicity (Fischer et al. 1999; Godbey et al. 1999)
while smaller counterparts (less than 1.8 kDa) displayed minimal transfection efficiency with
negligible toxicity. In the light of these observations, small version of PEI flanked with PEG
linker was developed and used in cellular pDNA delivery (Ahn et al. 2002). This strategy
demonstrated marginally improved transfection with significantly reduced cytotoxicity.
Modification of PEI with PEG has also been used for manipulating in vivo biodistribution of
PEI-containing polyplexes (Nguyen et al. 2000). Polyethylene oxide conjugate of 25-kDa
PEI rendered significantly improved gene expression in mouse liver while lung was the
primary organ of gene expression when injected with unmodified PEI-derived polyplex.
Poly(ethylene glycol) coating, however, reduced in vitro cellular uptake and transfer of
polyplex (Harvie et al. 2000). Targeting ligand incorporation to this polymer has shown
enhanced transfection in some cell lines (Zanta et al. 1997; Ogris et al. 2001b).
Various generations (G4-G9) of polyamidoamine dendrimers have been studied as
gene delivery systems (Bielinska et al. 1997; Du et al. 1998). The generation of dendrimer is
determined by the number of tertiary amine centers. Surface primary amines of dendrimers
contribute to DNA binding and the increase in this terminal amines appears to enhance gene
delivery (Toth et al. 1999). Similarly to PEI, the internal tertiary amines seem to neutralize
acidic pH environment of the endosome after internalization via endocytosis and induce the
eventual DNA release into the cytosol (Tang et al. 1996). These authors and others (Hudde et
al. 1999) speculated that the hydrolytic degradation of amide bond in polyamidoamine
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dendrimers in aqueous milieu could increase the flexibility of the polymer in the endosome
and improved transfection.
1.4 Cleavable Linkers
In the application of cleavable linkers in the gene vectors, it is important that the
environment-stimulated response must be sensitive enough to be triggered at the appropriate
time and place during the cellular trafficking process to avoid premature or too delayed
response. To trigger the linker breakage, cleavable vectors used various stimuli such as
decrease in pH, change in redox potential, enzymes, and more recently photosensitivity.
Biological rationale for redox-sensitive lipoplex is that the lipoplex located within the
cell is presented with relatively high concentration of reductive substances such as reduced
glutathione (Meister and Anderson 1983). The practical application of the redox-sensitive
linkers in lipoplexes can found in Tang and Hughes (1998) and Balakirev et al. (2000).
Dauty and colleagues (2001) used thiol-disulfide reaction to create gemini surfactants from
cationic cysteine detergents. Disulfide linkages have been also applied in polyplex systems
containing polylysine or PEI (McKenzie et al. 2000b; Gosselin et al. 2001; Oupicky et al.
2001) and more deliberate contemplation on this redox-sensitive linker is conducted in
Chapter II.
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The incorporation of cleavable linkers has been a very promising strategy to improve
the therapeutic index of drug-macromolecule conjugates, especially in the field of cancer
therapy. For instance, doxorubicin was conjugated to N-(2-hydroxypropyl)methacrylamide
copolymer through a tetrapeptide linker, Gly-Phe-Leu-Gly. This peptide is known to be
susceptible to lysosomal enzymes such as cathepsin B (Putnam and Kopecek 1995; Pechar et
al. 2000). Preclinical study demonstrated that the level of lysosomal enzyme expression in
solid tumors correlated with the activity of this formulation (Loadman et al. 1999). Another
example of cleavable linker used in drug-macromolecular conjugates is acid-sensitive
carboxylic hydrazone bond. Hydrazone derivative of doxorubicin showed improved efficacy
with reduced toxicity profile by selectively binding to circulating albumins upon intravenous
administration (Mansour et al. 2003).
Gene vectors have also adopted cleavable linkers to facilitate the release of their
cargos, usually pDNA, under specific environment. The pH in the endosomal compartment is
lowered gradually upon endosomal maturation to 5-6 by ATP-dependent proton pumps of
endosomal membrane (Mukherjee et al. 1997). Thus, the incorporation of pH-sensitive bonds
in the lipoplex will destabilize lipoplex structure and release entrapped or bound pDNA. Acid
sensitive functionalities applied in lipoplexes include vinyl ethers (Boomer et al. 2002),
ketal/acetal (Zhu et al. 2002), ortho esters (Zhu et al. 2000), and hydrazone groups (Aissaoui
et al. 2004). There are also multiple applications of ester bonds in lipoplexes. The utilization
of these hydrolysis-prone bonds was initiated in an attempt to face the cytotoxicity problem
encountered in the non-cleavable vector systems. Since Leventis and Silvius (1990) firstly
developed hydrolysable ester containing cationic lipid, many studies have applied this
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strategy to improve the lipoplex systems (van der Woude et al. 1997; Aberle et al. 1998).
Nagasaki and colleagues (2003) developed photoresponsive cationic lipid. In this study,
COS-1 cells transfected with the photosensitive lipoplex was shortly irradiated using UV
(365 nm) and these cells showed enhanced transfection efficiency.
In the polyplex systems, biodegradable ester bonds have been utilized in crosslinking
low molecular weight polymers as seen in polylysine derivatives by Lim et al. (2000). These
strategies achieved reduced cytotoxicity but suffer from inferior transfection efficiency. Poor
transfection was attributed to too fast a hydrolysis and lack of endosomal escape. In the later
study, these authors obtained improved transfection efficiency by using a branched network
of amino esters (Lim et al. 2002).
1.5 DNA Condensation
One of the tasks gene vectors are expected to perform is compacting DNA into small
particles of virus-like dimensions. This compaction will help to protect DNA from its
premature degradation before reaching the intracellular target sites such as nucleus. The term
‘condensation’ is sometimes indistinguishably used from aggregation or precipitation.
Generally, condensation is limited for the states in which the aggregate forms in more orderly
morphology with a finite size (Bloomfield 1996). DNA packaging by virus and chromatin
implies the importance of DNA compaction into condensed structures in the field of non-
viral gene vector for its success. The condensation of DNA involves the neutralization of
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phosphate groups to reduce the repulsion among DNA substructures. Efficient DNA
condensation has been represented by a variety of substances including divalent ions (e.g.,
Mn2+, Ca2+ and Mg2+), naturally occurring basic proteins (e.g., histones), neutral polymers
such as PEG, alcohols, cationic surfactants, and multivalent cations such as spermine and
protamine. Polymeric cations such as polylysine and cationic liposomes also showed DNA
condensing capacities (Gustafsson et al. 1995; Tang and Szoka 1997).
Melnikov et al. (1995) investigated DNA structure change induced by cationic
surfactant. This study demonstrated that DNA chains transited from random coil to compact
globular state in a discrete manner as the concentration of the surfactant
(cetyltrimethylammonium bromide) increased. The self-assembly of DNA has been under
intense investigation by several different groups. Blessing and colleagues (1998) developed a
cysteine-containing detergent of 10 carbons in a length and demonstrated this cationic
surfactant condensed DNA into an individual particle, which were converted to a lipoplex
upon air-induced dimerization of the surfactants. Szoka and his colleagues (2000)
synthesized a novel cationic surfactant containing an isothiuronium moiety in the headgroup.
This moiety was cleaved under basic conditions, which rendered sulfhydryl group exposed to
the subsequent oxidation to form a stable DNA complex. This surfactant was also found to
possess relatively high critical micelle concentration (> 10 mM), allowing larger amount of
DNA complexed in this formulation. Based on this observation, pursuit and application of
various cationic surfactants to form fine DNA condensates will be discussed in Chapter III.
Another noticeable observation in the both aforementioned studies is that the final DNA
assemblies had net negative charges. The authors implied that this feature might favor the in
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vivo situations due to the probable reduction in the interaction between blood proteins and
the formulation, which usually causes the rapid clearance of gene vectors from the systemic
circulation.
The effect of the structure of spermine derivatives on the DNA condensation has been
elucidated by several groups (e.g., Wilson and Bloomfield 1979; Schellman and
Parthasarathy 1984; Vijayanathan et al. 2001). These studies report that there is an optimal
carbon number in the structure of spermine derivatives (i.e., 4-8 carbons) and DNA
compaction is achieved when approximately 90% of the negative charges of DNA are
neutralized by multivalent cations.
Protamine has been used as an excellent DNA condenser and proposed to possess
nuclear localization sequence-like region (Sorgi et al. 1997; Li et al. 1998). Recently, the role
of protamine in condensing DNA as well as in nuclear transport was intensively investigated
by Masuda et al. (2005). This study demonstrated that the presence of protamine in the
polyplex system indeed increased the access to intra-nuclear transcription.
Representative substances among those discussed above were tested for their capacity
in condensing pDNA and the possible application of the pre-condensed pDNA in preparing
pDNA-entrapped nanogel formulation was speculated, which is the main context of Chapter
III.
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1.6 Statement of Purpose
Most of the pre-existing gene vectors introduced in the sections 1.2 and 1.3 only
partially satisfy the requirements in overcoming multiple transport barriers to the intracellular,
nuclear-targeted, gene delivery discussed in the section 1.1. The present dissertation work
was undertaken as an effort to develop a multifunctional polymer-based gene vector that is
responding to the different intracellular environment. Chemical modifications of the
polymeric nanogel entail incorporating acid-buffering weak bases, redox-sensitive disulfide
crosslinkers, and folate targeting ligands to the nanogel. Weak base is expected to promote
endosome-to-cytosol translocation of polyplexes by proton sponge effect (see section 1.3).
Disulfide-containing crosslinker should facilitate pDNA release from the nanogel through
facilitated breakage of nanogel structure in the intracellular reducing environment as
exemplified by the previous gene vector formulations (see section 1.4). The synthesis and the
characterization of the two aforementioned components in the nanogel modification are
discussed in Chapter II. Incorporation of folic acid ligand renders the nanogel containing
pDNA binding to the cell in a specific manner. The synthetic strategy to graft nanogel with a
folate ligand is shown in Chapter IV.
Chapter III and IV are concerned with two different pDNA-nanogel formulations.
Conventional polyplex systems usually utilize an electrostatic interaction between pre-made
cationic polymers and polyanionic pDNA. An alternative formulation suggested in the
present dissertation is to literally entrap pDNA inside the nanogel matrix. It could provide
additional advantages such as an enhanced protection of pDNA from premature degradation
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by nucleases in vivo, a reduced cytotoxicity that is usually caused by the extra positive
charges of polyplex systems, and improved physical stability as a pharmaceutical formulation.
Thus, the entrapment formulation is intensively explored in Chapter III. In this chapter,
several condensation reagents among those introduced in the section 1.5 are utilized to
reduce the hydrodynamic diameter of pDNA prior to the entrapment and consequently to
increase entrapment efficiency. In this context, Chapter IV deals with a second pDNA-
nanogel formulation, i.e., a complexation of pDNA with the pre-made targeted cationic
nanogel. Here, folate-grafted nanogels complexed with luciferase-expressing pDNA at
certain N/P (amine-to-phosphate or positive-to-negative) ratios are treated to the folate
receptor-overexpressing cell. Luciferase protein expression is then monitored as a measure of
the gene delivery efficiency of a given test formulations, in comparison with commercial
transfection reagents such as Lipofectamine 2000 and poly(ethylenimine).
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Figure 1-1: Various transport barriers involved in gene delivery: 1, formation of
plasmid DNA (pDNA)-vector complex; 2, cellular binding of pDNA-vector
complex; 3, cellular uptake via endocytosis; 4, endosome-to-cytosol translocation
(endosomal escape); 5, dissociation of pDNA-vector complex (release of pDNA
from the vector); 6, trafficking of pDNA through the cytosol and nuclear entry; and
7, transcription in the nucleus.
25
Figure 1-2: Various endocytosis pathways as proposed from Xiang et al. (2006).
Some examples of each pathway are presented.
Endocytosis
Receptor-Mediated Receptor Independent
Clathrin Dependent Clathrin Independent
Lipid-Raft Dependent Lipid-Raft Independent
Caveolae Dependent Caveolae Independent
Clathrin-Mediated
Endocytosis
Caveolae-Mediated
Endocytosis
Caveolae Independent
Lipid-Raft-Mediated
Endocytosis
Phagocytosis Fluid-Phase
Endocytosis/
Macropinocytosis
Lipoproteins
Growth factors
Hormones
Immune complexes
Toxins
Folate conjugates
Cytokines
GPI-anchored proteins
Mycobacteria
Particles > 0.5 µm
Bacteria
(e.g., Salmonella)
Particles 0.5-5 µm
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Type
Monopartite NLS
Bipartite NLS
Nonclassical NLS
Source
SV40 T Antigen
SV40 Vp3
Adenovirus E1a
Human c-myc
Nucleoplasmin
Xenopus N1
Mouse FGF3
PARP
M9 of hnRNP A1
Sequence
PKKKRKV
KKKRK
KRPRP
PAAKRVKLD, RQRRNELKRSP
KRPAATKKAGQAKKKK
VRKKRKTEEESPLKDKDAKKSKQE
RLRRDAGGRGGVYEHLGGAPRRRK
KRKGDEVDGVDECAKKSKK
NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY
Table 1-1: Nuclear Localization Sequences (NLS)a
a; reproduced from Martin and Rice (2007). Monopartite and bipartite contain one and
two clusters of basic amino acids, respectively. The abbreviations used represent the
followings: SV, simian virus; FGF3, fibroblast growth factor 3; PARP, poly (ADP-
ribose) polymerase; and hnRNP, heterogeneous nuclear ribonucleoprotein.
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Figure 1-3: Structures of some representative polymers used in polyplex systems.
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CHAPTER II
SYNTHESIS AND CHARACTERIZATION OF MONOMERS AND
CROSSLINKERS
2.1 Introduction
2.1.1 Overview
Previous studies (McAllister et al. 2002) indicated that nanogels enter the cell via an
endocytic process. As such pDNA-carrying nanogels require: (1) a strategy for transferring
the nanogel formulation from the port of entry to the cell (i.e., endosomes) to its main body
(i.e., cytosol) for subsequent entry to the nucleus; and (2) the release of entrapped pDNA
from the nanogels at some appropriate site during endocytosis. In essence, these subjects
comprise the independent variables in preparing nanogel formulations while gene expression
in various cell lines is the dependent variable in the experimental design.
2.1.2 Endosome-to-Cytosol Translocation and Proton Sponge Hypothesis
Similar to macromolecules, submicron particulates are unable to penetrate cell
membranes. They enter cells via endocytosis involving invagination of plasma membrane.
Upon endosomal maturation, various enzymes become activated with concurrent decrease in
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pH to as low as 4.5 in the lysosomal compartment. Unless timely escape of the luminal
content to cytosol is guaranteed, endocytosed particulates are eventually directed to lysosome
in which biochemical degradation occurs. Permeabilization of endosomal membrane has thus
become a subject of intense investigations in the field (Asokan and Cho 2003; Chen et al.
2003). Polyplex systems entail electrostatic association between cationic polymer and
polyanionic pDNA and they are effective in transfecting various cells in vitro, when an
excess positive charge is maintained in the complex (Behr 1993). While positive charges are
necessary to condense the DNA (Bloomfield 1996), the excess charges are believed to
promote binding of the complex to cells via negatively charged proteoglycans on the cell
surface such as heparan sulfates (Garnett 1999). For efficient gene transfection, excess
positive charges would be a necessary but not a sufficient condition since there is a large
discrepancy in transfection efficiency among various cationic polymers. Poly(ethylenimine)
(PEI) (Kichler et al. 2001) or dendrimers (Haensler and Szoka 1993) showed significantly
superior transfection efficiency to poly(lysine), implying presence of some other key
element(s) yet to be clearly elucidated. Poly(ethylenimine), linear or branched, is a cationic
polymer optimally suited for condensing pDNA. Its high buffering capacity at the acidic
environment of the endosome enables the PEI-pDNA complex to escape endosomes into
cytosol and gain an access to the nucleus (Zanta et al. 1997; Li et al. 1998) via so-called
proton sponge effect described below.
Widely accepted proton sponge hypothesis involves the sequential events depicted in
Fig 2-1. The polyplex binds the cell plasma membrane to initiate adsorptive endocytosis. As
the luminal pH decreases due to membrane-bound H+-ATPase, the H3O+ introduced is
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continuously used up in protonating the weak base moieties on the polymer. Since the
protonated polymer cannot diffuse out of the endosome due to its size and polarity, influx
and accumulation of anions, mainly Cl-, take place in accordance of charge balance. This
process continues with osmotic swelling and eventual rupture of endosomes. The net result is
discharge of the endosome luminal content to cytosol prior to being delivered to lysosome for
degradation. The above mechanism has been unambiguously supported by a series of
mechanistic studies by Sonawane and his colleagues (2003). In essence, weak bases that are
present in the cationic polymer play a major role in promoting the endosome-to-cytosol
translocation of polyplexes. Endosomes show pH values between 4.3 and 6.9, mostly
frequently pH ~ 5.0, due to an endosomal acidification process (Lee et al. 1996). Thus, in
order to make this scenario work, the weak base should remain neutral at pH 7.4 but
protonated at the pH of early endosomes, ideally pKa ~ 6.5 (Asokan and Cho 2002). There is
an expectation that electrostatic repulsion between the pre-existing positive charges (i.e., in
case of cationic monomer-incorporated nanogel) and incoming protons will reduce the
basicity of the weak base, resulting in a decrease of its apparent pKa (Onufriev et al. 2001).
The selection of weak base in a positively charged polymer system will thus favor the one
with a higher pKa in bulk phase. Imidazole or N,N-dimethylethanolamine derivatives would
be an ideal candidate for this purpose since they have bulk phase pKa of 6.8 and 8.4,
respectively. The latter monomer would be preferred at a high concentration of permanent
positive charges in the polymer network since the more cationic monomer exists the more
decrease in apparent pKa is expected to occur. Along the line with this anticipation,
imidazole derived monomer will be more suitable at low content of cation in terms of
protonation in the endosome.
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2.1.3 Release of Plasmid DNA from Nanogels
Polyplex systems, or the polyelectrolyte complexes of pDNA with polycations, have
been widely used to develop polymer-based gene vectors. Colocalization studies that
employed confocal fluorescence microscopy and numerous probe molecules clearly
demonstrated that the nucleic acids delivered by nanogels should be dissociated from the
carrier at some point during endocytosis to exert biological function (McAllister et al. 2002).
Incorporation of ability of responding to environmental changes or stimuli into polyplex
would promise a significant improvement of the delivery efficacy. Not only external stimuli
such as ultrasound, heat, magnetic field, light but also endogenous changes such as pH
decrease can facilitate spatial and temporal control of the release of gene cargos. Another
example of the latter is the redox potential gradient existing between extracellular space and
various subcellular organelles. Incorporation of a disulfide bond(s) into the backbone of the
delivery devices provides them with a capability to disintegrate themselves in the reducing
subcellular space. Most likely, glutathione (GSH, -glutamyl-L-cysteinylglycine) and
thioredoxin, either alone or in combination with redox enzymes, play a major role in the
intracellular reduction of disulfide bonds. GSH is the most abundant intracellular sulfhydryl
and the concentration of GSH is an additive function of both the oxidized (GSSG) and the
reduced forms (GSH). Cytosol is the principal site of GSH synthesis and the concentration of
GSH here is 1-11 mM (Kosower and Kosower 1978; Gilbert 1990; Hwang et al. 1995). This
is significantly higher than extracellular (i.e., blood plasma) GSH concentration (~ 1.5 µM)
(Jones et al. 1998). The overall cellular GSH/GSSH ratio (30/1 to > 100/1) is also higher
than that of extracellular space (~ 7/1) (Jones et al. 1998). The level of GSH varies in
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different subcellular organelles. The highest reducing capacity is usually found in the nucleus
and the nucleus GSH levels can reach up to 20 mM (Smith et al. 1996) . Mitochondria is
another major pool of GSH (~ 5 mM) in the cell (Wahllander et al. 1979) while endoplasmic
reticulum is more oxidizing than the cytosol (Hwang et al. 1992).
While the possibility of endosomal-lysosomal reduction of disulfide bonds has been
reported (Collins et al. 1991; Fivaz et al. 2002; Saito et al. 2003), recent report (Austin et al.
2005) suggests that both the endosomal and lysosomal environments are rather oxidizing
environment and disulfide bond reduction occurs rather inefficiently. A most recent study on
the subject was again supportive of reductive endosome (Yang et al. 2006), creating more
controversies. Much earlier, Feener and colleagues (1990) suggested that the reduction
process might involve Golgi apparatus instead of being associated with lysosomes or
endosomes. This and other studies (Sahaf et al. 2005) also implied that cellular plasma
membrane is a possible site of reduction by surface proteins such as protein disulfide
isomerase. Even though one cannot rule out the possibility that the enzymatic reduction in
the endosome could play a role in disulfide bond cleavage by acid-activated enzymes such as
Gamma-interferon-inducible lysosomal thiol reductase (Arunachalam et al. 2000), current
understanding of subcellular trafficking of polyplexes suggests that intracellular reduction of
disulfide bonds will proceed preferentially in the cytosol and nucleus.
The main purpose of incorporating disulfide bonds in the polyplexes is to increase a
transient stability by enhancing the affinity of a polycation to the nucleic acid. Disulfide
bonds can be introduced into the structure of polyplexes by using: (1) cationic molecules
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containing more than two sulfhydryl functionalities and their in situ oxidation (McKenzie et
al. 2000; Soundara Manickam et al. 2005); (2) commercially available disulfide containing
crosslinking agents (e.g., dimethyl-3,3’-dithiobispropionimidate) (Gosselin et al. 2001;
Oupicky et al. 2001); or (3) construction of disulfide containing polymers prior to polyplex
formation (Oishi et al. 2005). The cleavage of disulfide bond incorporated in the backbone of
the polyplex systems can induce a facile release of the cargo (e.g., pDNA) by physical
breakdown of the carrier matrix and/or by reducing the affinity of nucleic acids (i.e.,
polyanioins) to the polycationic polymers (Pichon et al. 2002; Carlisle et al. 2004). The
former approach using neutral nanogels in delivering pDNA was investigated in Chapter III
(entrapment of pDNA inside neutral nanogel matrix) and the latter was described in Chapter
IV (polyplex formation of pDNA with cationic nanogel) in this dissertation.
In this chapter, the preparation and characterization of weak base monomers and
nanogels are described. The characterization is mainly in terms of pKa of starting monomers
as well as after polymers are formed. Also discussed are the synthetic strategies for a
disulfide-containing crosslinker.
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2.2 Materials and Methods
2.2.1 Materials
Acryloyl chloride, isobutylamine, 1,1’-carbonyldiimidazole (CDI), PEG
monomethacrylate (PEGmA, Mn of PEO = 375 g/mol), 2-hydroxyethyl acrylate (HEA),
N,N,N-triethylamine (TEA), CDCl3 (deuterochloroform), sodium sulfate, cystamine2HCl, 1-
(3-aminopropyl) imidazole, 2-(dimethylamino)ethyl acrylate (DMAEA), PEI (25 kDa,
branched), anhydrous acetonitrile and anhydrous dioxane were purchased from Sigma-
Aldrich. All ACS grade organic solvents such as methanol, chloroform, n-butanol and
heptane were purchased from Fisher Scientific and used without any further purification.
Standard solutions (1 N NaOH and 12 N HCl) were purchased from Fisher Scientific.
Poly(ethylene glycol) diacrylate (PEGdiA, Mn of PEO = 375 g/mol), PEG monoacrylate
(PEG-A, Mn of PEO = 200 g/mol or 375 g/mol) and 2-acryloxyethyltrimethylammonium
chloride (AETMAC) at 80% in water, and 2-N-mopholinoethyl acrylate (MEA) were
purchased from Polysciences, Inc. (Warrington, PA) and used as received. Di(2-ethylhexyl)
peroxydicarbonate (Trigonox EHP) was purchased from Akzo Nobel (Chicago, IL) and
stored at - 20oC until used. Laureth-3 was purchased from Heterene, Inc. (Paterson, NJ) and
filtered through 0.22 µm PTFE syringe filter (Fisher Scientific) before used.
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2.2.2 Preparation of Imidazole-Containing Monomer (IPAA)
Into a 25-mL round-bottom flask, 1 mmol of 1-(3-aminopropyl) imidazole (122 µL),
1 mmol of TEA (140 µL) and 1.5 mL of anhydrous acetonitrile were added. Acryloyl
chloride (85 µL, 1 mmol) in 0.5 mL of acetonitrile was then added to the flask. The reaction
took place in the ice bath for the first 30 min and continued at room temperature thereafter.
Additional 0.2 mmol of acryloyl chloride (17 µL) was added to the reaction at 4 hrs and the
reaction was stirred overnight under an atmosphere of nitrogen. The resulting product was
filtered through a filter paper (Whatman, Florham Park, NJ) and the filtrate was further
purified by a column chromatography on silica gel using NH4OH:methanol:chloroform
(1%:15%:84% v/v) as a mobile phase.
2.2.3 Measurement of pKa of Weak Base-Containing Monomer and Nanogel
Weak base monomers (0.25 mmol) were dissolved in 5 mL of distilled water. Two
mol-equivalent of HCl in 5 mL water was added into the weak base solution. After brief
vortex-mixing, acidified weak base solutions were titrated by gradual addition of 0.1 N
NaOH solutions. Blank titration was performed by titrating 0.05 N HCl with 0.1 N NaOH
solution. The blank titration was subtracted from the monomer or nanogel titration, resulting
in the net titration. Nanogels were prepared by the method described in elsewhere
(McAllister et al. 2002) with a modification to incorporate weak base monomers (also see
Figure 2-10). An optically transparent inverse microemulsion was prepared by combining
heptane, surfactant (laureth-3) and aqueous monomer solution in the typical weight ratio of
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86:4:10. The aqueous solution contains all polar acrylates such as HEA, PEGdiA
(crosslinker), AETMAC (cationic monomer), and one of the three weak base monomers
mentioned above. The composition of nanogels for the measurement of pKa was fixed at
25% (w/w) weak base, 12% crosslinker, 25% cationic monomer if required, and the rest was
HEA. A small amount of free radical initiator (Trigonax EHP) in heptane (~ 5 mM as a final
concentration) was added to the microemulsion. The reaction mixture was then stirred at
room temperature overnight, under argon atmosphere and protected from light. After the
polymerized emulsion was diluted with a biphasic water/heptane mixture, the aqueous phase
was collected and washed with n-butanol several times to extract the surfactant. The residual
surfactant was removed using dialysis with a dialysis bag of 100 kDa MWCO (Spectrum
Laboratories, Inc., Rancho Dominguez, CA). The final preparation was sterile filtered using a
0.22 µm PVDF syringe filter (Fisher Scientific) and stored at 4°C until further analysis.
Regular nanogels containing PEGdiA (12%) and HEA (88%) were prepared as a control for
pKa determination. Nanogels containing approximately 0.25 mmol of weak bases in 5 mL of
water were mixed with 0.1 N HCl solution (5 mL) and titrated by adding 0.1 N NaOH
solution gradually. PEI of 25 kDa, one of the standard polymeric transfecting reagents in the
field, was also titrated similarly to nanogels.
2.2.4 Disulfide-Containing Crosslinker
As shown in the Figure 2-11, pre-fractionated PEG-based materials were activated
with CDI followed by a coupling with free base form of disulfide-containing amine
compound (cystamine). The details are described as follows.
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Fractionation of PEGmA one milliliter (1.101 g) of PEGmA (Mn of PEO ~ 375
g/mol) was loaded on Sephadex G-50 medium column (Sigma). Flow rate and fraction size
were 7 mL/ 4 min/ tube. Water served as the eluent. Fraction number 20 through 26 were
collected and dried thoroughly in a rotary evaporator prior to further processing. PEGmA
fractionated (~ 10 mg) was dissolved in 0.75 mL of CDCl3 and identified in 1H-NMR. The
average molecular weight was estimated based on the mass spectrometry via an electrospray
ionization coupled with a subsequent quadrupole ion-trap and was approximately 450 g/mol.
Total yield of fractionation was approximately 73%.
Optimization of CDI activation CDI (1.2 mmol) and PEGmA (0.3 mmol, Mn of PEO
~ 200 g/mol) were added into a 25-mL round bottom flask containing 4 mL of anhydrous
dioxane under magnetic stirring. The reaction mixture was stirred at room temperature for the
specified time (0, 15, 30 min, 1, 2, 4, 8, 12, 18, and 24 hrs). Equivalent volume of water and
chloroform were then added and the mixture was stirred vigorously. The reaction mixture
was additionally washed with water and chloroform layer was collected. Two equivalent of
isobutylamine was added to the chloroform layer and the mixture was gently stirred at room
temperature. After 14 hrs, 1.5 mL of water was added to extract imidazole generated from the
reaction (Figure 2-7). Aqueous layer containing imidazole was collected, washed with
equivalent volume of chloroform, and subject to UV spectrometry at 206 nm to determine the
amount of imidazole.
CDI activation Into 1.6 mmole of previously fractionated PEGmA in 5 mL of
anhydrous dioxane, 4.8 mmole of CDI as powder was added and the reaction was stirred at
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room temperature. After 3 hrs, 40 mL of brine (saturated NaCl solution in water) was added
to the reaction to degrade unreacted CDI followed by multiple inversions and the addition of
10 mL of chloroform. The reaction mixture was then shaken vigorously to extract imidazole
generated from the reaction into aqueous layer. Chloroform layer was collected and another
40 mL of brine was added for the second extraction. Chloroform layers were combined
together, dried with sodium sulfate, evaporated under vacuum to dryness and redissolved in a
mobile phase (methanol:chloroform = 10:90). Reaction mixture was then loaded on a silica
gel column and the chromatography was performed at 4oC.
Free base formation of cystamine Into 11.1 mL of water, 1.1 g (8.88 mmol as HCl)
of cystamine2HCl was dissolved and the solution was put into a 500-mL separation funnel.
Chloroform (80 mL) and 1 N NaOH (8.9 mL) were added to the cystamine solution followed
by vigorous shaking. Chloroform layer was then collected to a clean 1000-mL beaker and the
extraction was repeated 4 times by adding fresh 80 mL of chloroform to the remained upper
aqueous layer. Combined chloroform layers were dried with sodium sulfate, transferred to a
tare-weighed 500-mL round bottom flask, and evaporated to dryness. Free base form of
cystamine extracted was stored at 4oC under nitrogen atmosphere until further usage.
Coupling Into 25-mL round bottom flask placed on an ice bath, 0.3 mmol of CDI-
activated PEGmA (CDI-PEGmA) and 2 mL of anhydrous acetonitrile were added. Free base
form of cystamine (0.3 mmol) dissolved in 1 mL anhydrous acetonitrile was added to the
flask dropwise (i.e., initial net stoichiometry of CDI-PEGmA:cystamine = 1:2). Reaction
mixture was stirred at 4oC for 18 hrs and additional CDI-PEGmA (0.27 mmole) was then
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added to the reaction in that the final net stoichiometry of CDI-PEGmA to cystamine was 1.9
to 2.0. The reaction was kept stirred for additional 24 hrs at 4oC. The reaction mixture was
then evaporated thoroughly and redissolved in 8 mL of chloroform. To extract imidazole
from the reaction into aqueous layer, 24 mL of brine was added followed by vigorous
inversion. Chloroform layer was collected, dried using sodium sulfate, evaporated and
redissolved in a mobile phase (methanol:chloroform = 10:90). The reaction mixture was
further purified in a column chromatography on silica gel using above-mentioned mobile
phase. The final product was a clear viscous liquid and stored at 4oC until used.
2.3 Results and Discussion
2.3.1 Imidazole-Containing Monomer (IPAA)
The imidazole-containing monomer was prepared as shown in Figure 2-2A. The
reaction yield was approximately 80%. Upon adding acryloyl chloride to the reaction,
yellowish precipitation was formed as a byproduct in 5 min. Alternative solvent such as
methylene chloride could be used instead of acetonitrile to avoid the precipitation. It may
also improve the reaction yield. The final product was a yellow viscous liquid and the
chemical structure was identified with 1H-NMR spectrometry as shown in Figure 2-2. NMR
showed all of the anticipated peaks including the protons from imidazole (peaks b, c, and d)
and acrylate moieties (peaks e, f, and g). It was stored at 4oC and protected from light until
used.
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2.3.2 pKa’s of Weak Base-Containing Monomers and Nanogels
As the pH decreases in the endosome, protonation of one base moiety can reduce the
basicity of the adjacent one, in effect resulting in a series of weak bases with continuously
changing apparent pKa along with protonation (Fischer et al. 2002). Such an effect was first
investigated with the morpholine-containing monomer, MEA (see Table 2-1 for structure)
with pKa 6.2. The issues addressed here were: 1) how protonation of a given site affects the
pKa of adjacent base when a neutral polymer was processed; and 2) how the presence of
quaternary ammonium cations affects the overall pKa of the weak base. As shown in Figure
2-4C, MEA at 20 mM titrated with NaOH in the presence of HCl represented a single half-
neutralization point, or pKa at 6.20. In contrast, when MEA was incorporated by 25% (w/w)
into neutral and cationic nanogels (Figure 2-3), the net titration curves demonstrated two
apparent pKa values, 3.8 and 6.2 for the former and 3.8 and 6.0 for the latter. A similar
phenomenon of approximating two populations of weak bases was also reported when N,N-
dimethylaminoethyl methacrylate was introduced to PEI (Funhoff et al. 2004). The extra pKa
observed in nanogels (Table 2-1) may indicate the presence of weaker base population and
can be explained by the effect of pre-protonated weak base moieties in the polymers as
discussed earlier. That is, the protons initially bound to weak bases will repulse the upcoming
protons, inhibit their binding into the adjacent weak bases and show decreased apparent pKa,
whereas the change in the first pKa from 6.2 in Figure 2-3A to 6.0 in Figure 2-3B is due to
the effect of pre-existing quaternary ammonium ions. Titration of DMAEA as monomer and
when incorporated in the nanogel (Figure 2-4G and H) showed a similar pattern of change in
apparent pKa (i.e., 8.41 in monomer and 4.06/8.35 in nanogel). Imidazole-containing
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monomer (IPAA) showed 6.83 of pKa as expected from the intrinsic pKa of imidazole
moiety (Figure 2-4E). Interestingly, the apparent pKa (6.30) of IPAA-containing nanogel
(Figure 2-4F) decreased significantly compared to that of monomer. It might be due to a
stronger electrostatic repulsion by previously-protonated sites than in the case of other weak
base-containing nanogels. When neutral nanogels dispersed at a concentration of ~ 5 mg/ml
in 10 ml of 0.05 N HCl were titrated with 0.1 N NaOH (Figure 2-4B) the profile of titration
curve was similar to the blank titration of the same HCl solution with the same titrant
(Figure 2-4A). As shown in the panels D, F, and H on Figure 2-4, nanogels containing weak
bases showed buffer capacity around their respective pKa, which is not observed in regular
nanogels (Figure 2-4B) composed of only PEGdiA and HEA. Taken together, the data
indicates that pKa values of monomers in bulk phase can be used in predicting those in
polymers.
According to Van Slyke’s equation, the buffer capacity is highest at the pKa of the
buffer component. The titration curves obtained from weak base containing neutral nanogels
were superimposed with one another in Figure 2-5. The highest buffer capacity at pH 6.5
(i.e. pH of early endosome), the reciprocal of the slope of the tangent line on the titration
curve at pH 6.5, was observed in the nanogels prepared with morpholine-derivatives with
pKa 6.2 or imidazole-derivative with pKa 6.3. When compared to that of PEI, these two
nanogels possessed almost two-fold higher buffer capacity. Another nanogel prepared using
dimethylethanolamine-derivative with pKa 8.3 showed an almost identical buffer capacity as
the other two but the maximal capacity appeared at a higher pH, reflecting its higher pKa. It
might be less optimal to serve as a proton sponge inside endosome. Altogether, these data
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support that the nanogels prepared using weak base monomers selected here can be superior
to PEI in terms of transfection efficiency, one of the best polyplex systems available in the
field.
2.3.3 Disulfide-Containing Crosslinker
In a typical procedure to prepare nanogels, the average MW of PEO moiety in
PEGdiA used as a crosslinker was approximately 200 g/mol. In order to increase the
solubility of the final product, longer chain of PEG-containing monoacrylate, PEG-A (Mn of
PEO ~ 375 g/mol), was used as the starting material. However, CDI activated PEG-A turned
out to degrade during coupling reaction due to a nucleophilic attack by the primary amine of
the cystamine toward acrylate moiety (i.e., multiple bands showed up on thin layer
chromatography). Thus, PEGmA that contains sterically-hindered acrylate moiety by the
addition of methyl group was used for the reaction to prevent this problem. Since PEG-based
compound is a mixture of different length of species, PEGmA was first fractionated using
Sephadex G-50 (Figure 2-6). The population of higher molecular weight was collected and
used as the starting material for the activation with CDI.
The reaction condition of CDI activation was optimized by measuring the amount of
imidazole produced from the reaction of CDI-PEGmA with a primary amine-containing
model compound, isobutylamine. As shown in Figure 2-7, the amount of imidazole
represented by an optical density at 206 nm reached a maximum level when the CDI
activation continued approximately for 2 hrs and remained almost identical thereafter up to
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24 hrs. Accordingly, the activation of PEGmA with CDI was carried out for 3 hrs at room
temperature for the reaction. Since the water solubility of CDI-PEGmA was found to be very
poor, purification and separation were performed by extracting with brine followed by a
silica gel column chromatography. The purified CDI-activated PEGmA was identified with
thin layer chromatography (TLC) and 1H-NMR. One single spot was detected on the TLC
(data not shown) and the 1H-NMR spectrum of CDI-PEGmA is shown in Figure 2-8. As
indicated in the Figure 2-8, both moieties of the polyethylene (c) and acrylate (b) remained
intact but hydroxyl group (a) of PEGmA has disappeared in CDI-activated intermediate with
gaining of imidazole moiety (d). Yield of CDI activation was approximately 46%.
Initially, a two-phase solvent system such as aqueous buffer-acetonitrile mixture was
attempted for the coupling reaction to dissolve both CDI-PEGmA (intermediate product) and
cystamine2HCl. In order to facilitate the reaction, free base form of cystamine was first
prepared by repeated chloroform extractions of free base form from pH-adjusted (i.e., pH
8.5) cystamine dihydrochloride aqueous solution. Extraction yield of free base form of
cystamine using total 20-volume of chloroform was close to 100%. After extraction,
cystamine was verified in 1H-NMR (data not shown) and no structural change was observed.
The yield of coupling reaction was approximately 73%. The structural verification of the
final product was performed using 1H-NMR and mass spectrometry (Figure 2-9), confirming
a disulfide-containing, PEG-based diacrylate compound.
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2.4 Conclusions
When weak bases are incorporated in the nanogel (i.e., polymer system), the weak
bases possess widely spread pKa values and become weaker in the presence of permanent
positive charges. Nanogels prepared using morpholine- and imidazole-derivative showed
almost 2-fold higher buffer capacity at pH 6.5 (i.e., pH of early endosome) than PEI.
Disulfide containing, PEG-based crosslinker was successfully synthesized and served as a
cleavable crosslinker when incorporated in the nanogel. The monomers synthesized in this
chapter were used to test proton sponge hypothesis using the nanogel system and to assess
how the presence of degradable crosslinker affects gene transfection, which are discussed in
the following chapters.
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Figure 2-1: Illustration of proton sponge hypothesis. [1] Polyplex is internalized by
invagination of the cell membrane. [2] As the endosomal compartment is acidified by
the proton pumps located in the endosomal membrane, chloride counter ion comes in
for a charge valence, and [3] increased osmolarity inside the endosome results in the
influx of water. [4] Consequently, endosomal vesicle swells with the increasing
volume of water, leading to an eventual rupture and [5] the release of the content into
the cytosol.
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Figure 2-2: Synthetic scheme (A) and 1H-NMR spectrum (B) of imidazolypropyl-
acrylamide (IPAA).
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Morpholine containing neutral NG
(25% MEA, 12% PEGdiA, 63% HEA)
(pKa1: 3.82, pKa2: 6.19)
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Figure 2-3: Titration of neutral (A) and cationic (B) nanogels containing morpholine
moiety. Both nanogels were prepared with 25% (w/w) 2-N-morpholinoethyl acrylate
(MEA), 12% PEG diacrylate (PEGdiA, crosslinker), 25% 2-acryloxyethyltrimethyl-
ammonium chloride (AETMAC, only for B) and 2-hydroxyethyl acrylate (HEA) for the
rest. Nanogels (0.25 mmol as MEA) were mixed with HCl and titrated with 0.1 N
NaOH. Blank titration (i.e., HCl titrated with NaOH) was subtracted from the nanogel
titration, resulting in net titration curves shown above. The second end point of the
titration curve was set at one unit equivalency.
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Figure 2-4: Potentiometric titration of monomers and nanogels containing weak bases.
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titration curve.
Imidazole prophylacrylamide, IPAA (pKa=6.83)
0
2
4
6
8
10
12
-0.25 0.00 0.25 0.50 0.75 1.00 1.25
Equivanlency
pH
E
H
N
O
N
N
IPAA-NG (25% IPAA, 12% PEGdiA, 63% HEA)
pKa: 6.30
0
2
4
6
8
10
12
-0.25 0.00 0.25 0.50 0.75 1.00 1.25
Equivalency
pH
F
H
N
O
N
N
63
Table 2-1: Summary of pKa’s of Weak Base-Containing Monomers and Nanogels.
Weak Base pKa ofMonomer
pKa of
Nanogel
2-N-morpholinoethylacrylate
(MEA)
6.21 3.82 / 6.19
Imidazoylpropylacrylamide
(IPAA)
6.83 6.30
2-(dimethylamino)ethylacrylate
(DMAEA)
8.41 4.06 / 8.35
N
O
O
O
H
N
O
N
N
O
O
N
64
Figure 2-5: Titration of PEI (25 kDa, branched) and nanogels prepared with weak
base-containing monomers 1 (2-N-morpholinoethyl acrylate), 2 (imidazolypropyl
acrylamide), or 3 [2-(dimethylamino)ethyl acrylate]. Nanogels were prepared
using 25% (w/w) of a weak base-containing monomer, 12% PEG diacrylate
(crosslinker), and 63% 2-hydroxyethyl acrylate. All samples contained an identical
amount of HCl and titrated with NaOH. The buffer capacity at pH 6.5 is the
reciprocal of the slope of the tangent lines shown in the curve.
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Figure 2-6: Fractionation of PEG monomethacrylate (PEGmA) by a size exclusion
chromatography. PEGmA (average Mn of PEO ~ 375 g/mol) was loaded on
Sephadex G-50 column using water as an eluant. PEGmA was monitored using UV
spectrometry at 205 nm (upper square dots) as well as thin layer chromatography
(TLC, lower band containing small dots) in a silica-coated aluminum plate.
Fractions 16 through 26 were collected, dried under vacuum and used as a starting
material for the subsequent carbonyldiimidazole activation.
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Figure 2-7: Reaction of carbonyldiimidazole (CDI)-activated PEG
monomethacrylate with isobutylamine (A). The reaction time of the first step
(activation) varied from 0 min up to 24 hrs as shown in B. Imidazole was produced
as a byproduct from the second step of the reaction, extracted in water, and
measured at 206 nm using UV spectrometer (B). The amount of imidazole
generated from second step (substitution reaction) was considered to reflect the
extent of CDI activation (i.e., first step).
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Figure 2-8: 1H-NMR spectrum of PEG monomethacrylate, PEGmA (A) and CDI-
activated PEGmA, CDI-PEGmA (B). Disappearance of peak a in A (hydroxyl group of
PEGmA) and advent of peaks d in B (imidazole moiety of CDI-PEGmA) was mainly
monitored.
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Figure 2-9: 1H-NMR spectrum (A) and mass spectrum (B) of a disulfide
containing, PEG-based diacrylate crosslinker. The compound was dissolved in
CDCl3 and methanol for NMR analysis and mass spectrometry, respectively.
Mass spectrometry was performed via an electrospray ionization coupled with
a subsequent quadrupole ion-trap.
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Figure 2-10: Schematic illustration of a typical polymerization reaction. W/O inverse
microemulsion is formed by adding aqueous layer (~ 4% w/w) containing all of the water-
miscible acrylate monomers into the mixture of heptane (i.e., continuous phase) and 10%
(w/w) surfactant (laureth-3). Polymerization is initiated by the subsequent addition of a
free radical initiator (Trigonax EHP, 2-ethylhexyl peroxydicarbonate). The reaction runs
overnight and the final nanogels are purified using heptane extraction, n-butanol washing,
and dialysis or size exclusion chromatography. Exemplary monomers and part of the
polymerized nanogels are shown in the lower panel.
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Figure 2-11: Synthetic scheme of a disulfide-containing, PEG-based crosslinker.
PEGmA (average Mn of PEO ~ 375 g/mol) was activated with CDI (step 1) and the
intermediate was coupled with the free base form of cystamine (step 2). The final
product was purified using a column chromatography on silica gel.
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CHAPTER III
ENTRAPMENT OF PLASMID DNA IN NANOGEL
3.1 Introduction
Since cationic polymers were introduced in the 1980s by Wu and colleagues (1987)
as a non-viral vector, numerous polycations have been used for formulating DNA and other
nucleic acids into complexes now termed polyplexes (Felgner et al. 1997). These
formulations are based on electrostatic association between polyanionic DNA and positively
charged polymers (e.g., Brown et al. 2001). However, the heterogeneous morphology of the
polyplex system can make this type of formulation less favorable for practical applications.
For instance, the molecular complexes as a pharmaceutical formulation suffer greatly from
instability and the lack of reproducibility in their function as well as production. In theory
and concept these problems associated with the polyplex system can be resolved by
entrapping DNA inside the polymer matrix.
Polymeric nanoparticles are commonly prepared by polymerizing monomers
present in the dispersed phase of a microemulsion system. A microemulsion is an
optically isotropic and a thermodynamically stable micellar system comprised of water,
oil and amphiphile (Danielsson and Lindman 1981). Unlike regular emulsions, they form
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spontaneously without addition of mechanical energy. When polymerized, resulting
nanoparticles show some of the properties of gels as well as colloids. As such they are
often referred to as ‘nanogels’. In terms of size, the nanoparticles derived from the
microemulsions adopted in this dissertation work are similar to virus, which is
significantly smaller than liposomes or O/W macroemulsions of 200 to 300 nm.
Entrapment of nucleic acids in the nanogel would be feasible if one uses an inverse water-
in-oil (W/O) microemulsion. Since pDNA with thousands of negative charges will not
partition into the organic phase in the inverse microemulsion system, pDNA is to likely
condense itself to reside in the aqueous phase along with monomers and crosslinkers. The
model nucleic acid to be entrapped in nanogels in present study is plasmid DNA (pDNA)
of 5-6 kbp. It was thought that the hydrophilic matrix of nanogels may render pDNA to
coil itself into the aqueous droplets.
There are some potential hurdles in preparing pDNA-entrapped nanogel formulation.
First, drug loading could be limited due to the small size of nanogel and the diluted nature of
the system. However, pDNA as a cargo may have an advantage over other therapeutic
molecules in that only a few copies are to be delivered. Secondly, the pDNA should remain
intact during polymerization. This is important issue because the present polymerization
involves free radical reaction (see results section 3.3.2 for detailed discussion on this subject).
In addition, the polymer network enclosing pDNA should break down at some point during
endocytic pathway or cytosolic trafficking so that the cargo can be released. As demonstrated
by Budker et al. (2002), when pDNA of 5.9 kbp is entrapped in the aqueous phase of inverse
microemulsions, pDNA is condensed as a ring or toroid structure. This finding is consistent
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with the fact that the limited bendability of double stranded DNA tends to keep them in
solution as a stiff rod up to about 150 bp, or 50 nm (Blackburn and Gait 1996). When forced
to bend, the radius of curvature depends on the energetics involved. Since this diameter is
close to that of individual nanogel particles, pDNA will likely dissociate from the nanogel
only when the latter breaks down resulting in a complete loss of structural integrity. The
synthetic strategy for cleavable linker was addressed in Chapter II.
In this chapter, the main topics of discussion are preparation of pDNA-entrapped
nanogels and a series of efforts aimed for improving the entrapment efficiency. The latter
includes the application of DNA condensing reagents as well as various radiolabeling
methods in monitoring pDNA as a cargo and nanogel as a carrier.
3.2 Materials and Methods
3.2.1 Materials
Luciferase-encoding plasmid DNAs such as pGL3 Control Vector (5.2 kbp) and
pCMV-Luc (6.2 kbp) were purchased from Promega (Madison, WI) and Elim
Biopharmaceutical, Inc. (Hayward, CA), respectively. Laureth-3 was purchased from
Heterene, Inc. (Paterson, NJ). Span 80 and Tween 80 were purchased from Aldrich. These
surfactants were filtered through 0.22 µm syringe filter (Fisher Scientific) before used.
Mineral oil and all the organic solvents in ACS reagent grade were purchased from Fisher
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Scientific. Poly(L-lysine)HCl of 30-70 kDa or 4-15 kDa, poly(L-lysine)HBr of 25 kDa,
2,2’-azobis (2-methylpropionitril) (AIBN), acetic anhydride, Tris-EDTA (TE) buffer of pH
7.4, ethidium bromide (EB) at 10 mg/mL, spermine4HCl, antibiotics, protamine sulfate salt
from salmon (Grade X), and all alkyltrimethylammonium bromides were purchased from
Sigma. Poly(ethylene glycol) diacrylate (PEGdiA, Mn of PEO = 375 g/mol), PEG
monoacrylate (PEG-A, Mn of PEO = 375 g/mol) and 2-acryloxyethyltrimethylammonium
chloride (AETMAC) at 80 % in water were purchased from Polysciences (Warrington, PA).
All monomers were used without any further purification. Poly(ethylene glycol)
monomethacrylate (PEGmA, Mn of PEG = 375 g/mol), 2-hydroxyethyl acrylate (HEA),
N,N,N-triethylamine (TEA), and 4-dimethylaminopyridine were purchased from Aldrich.
Di(2-ethylhexyl) peroxydicarbonate (Trigonox EHP) was purchased from Akzo Nobel
(Chicago, IL) and stored in - 20oC until used. [5,5`-3H]-deoxycytidine 5`-triphosphate,
tetrasodium salt, (dCTP, specific activity; 60 Ci/mmol) and S-[methyl-3H]-adenosyl-L-
methionine (SAM, specific activity; 85 Ci/mmol) at 0.55 mCi/mL in 10 mM sulfuric acid
solution:ethanol (9:1) were purchased from Perkin Elmer Life and Analytical Sciences,
Inc.(Waltham, MA). [1-14C]-Acetic anhydride (specific activity; 5 mCi/mmol) at 3 mCi/mL
in dimethylformamide was purchased from American Radiolabeled Chemicals, Inc. (St.
Louis, MO). Linear polyacrylamide at 5 mg/mL in water was purchased from Ambion
(Austin, TX) and stored in - 20oC until used. NE buffer (10 X), CpG methylase (M. Sss I) at
20,000 U/mL and BstU I at 10,000 U/mL were purchased from New England Biolabs, Inc.
(Ipswich, MA). Microspin G-25 column was purchased from Amersham Biosciences
(Piscataway, NJ). SYBR Gold (10 X) was purchased from Molecular Probe (Eugene, OR).
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Opti-MEM, Hanks’ balanced salt solution (HBSS), Minimum Essential Medium (MEM) and
fetal bovine serum (FBS) were purchased from Gibco BRL (Gaithersburg MD).
3.2.2 Preparation of pDNA-Entrapped Nanogel from Inverse Microemulsion
Microemulsion-derived polymeric nanogel was developed earlier (McAllister et al.
2002) and for this part of study, a mixture of [3H]-pDNA and cold pDNA was added to
aqueous phase along with other monomers to form microemulsion. Detailed procedures are
as follows and depicted in Figure 3-1. An optically transparent inverse microemulsion is
prepared by combining heptane as a continuous phase, surfactant [laureth-3,
CH3(CH2)12O(CH2CH2O)3H] and aqueous monomer solution in the typical weight ratio of
86:10:4. The aqueous solution contained all polar acrylates such as HEA, PEGdiA as a
crosslinker, and AETMAC as positively charged monomer if needed. At this point, one of
the weak base-containing monomers and pDNA were also added to the aqueous solution. For
the test formulations, a disulfide crosslinker substituted the regular PEG crosslinker, PEGdiA.
A small volume of the initiator, Trigonax EHP, in heptane with a final concentration of
approximately 5mM was added to the microemulsion. The reaction mixture was then stirred
at room temperature overnight, under argon atmosphere and protected from light. After the
polymerized microemulsion was diluted with a biphasic water/heptane mixture, the aqueous
phase was collected by centrifugation for 15 min at 2,500 x g (GS-6R, Beckman, Fullerton,
CA) and washed with n-butanol several times to extract the surfactant. The residual
surfactant and unreacted monomers were further removed using dialysis with a dialysis bag
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of MWCO 100 kDa (Pierce Biotechnology, Rockford, IL). The final preparation was stored
at 4°C until used.
3.2.3 Transmission Electron Microscopy (TEM) of pDNA-Entrapped Nanogel
Procedure for electron microscopy was based on the method described earlier
(Budker et al. 2002) but modified partly to obtain an improved resolution. A drop of poly-L-
lysine (30-70 kDa) solution in water (10 mg/mL) was put onto Formvar-coated 200-mesh
grid for 1 min. After the solution was removed by blotting on the filter paper and the grid
was dried for a few min, a drop of sample was placed on the grid. After 4-5 min, the solution
was removed and the grid was washed three times with n-butanol and one time with
isopropanol followed by a single water washing. The staining was performed with 2% uranyl
acetate for 30 sec. The samples were examined using a Philips CM12 electron microscope
(Eindhoven, Netherlands) with 100 kv accelerating voltage. Digital images were made with a
Gatan 780 DuoScan camera system attached to the microscope.
3.2.4 Preparation of Macroemulsion-Derived, pDNA-Entrapped Nanogel
In order to explore a possibility to prepare nanogels that entrap pDNA,
polymerization was also attempted using a regular inverse emulsion. The procedure was
based on Kriwet et al.(1998). Aqueous phase accounted for 30% (w/w) of whole formulation
and consisted of monomers such as HEA or PEGmA and pDNA (pGL3 or pCMV-Luc) in
diluted TE buffer. Continuous phase was mineral oil by 70 weight percent including 2% of
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surfactants, Span 80:Tween 80 (3:1). Aqueous phase was added gradually into oil phase
while magnetic stirring. Emulsion was the heated to 50oC in water bath and purged with
argon for 20 min. 2,2’-azobis (2-methylpropionitril) in benzene was added to the reaction by
0.125% and the reaction was kept stirred at 50oC for 4 hrs. After cooling down at room
temperature, reaction mixture was diluted with equivalent volume of distilled water followed
by centrifugation at 14,000 x g for 10 min on Eppendorf Model 5415D Microcentrifuge
(Eppendorf, Westbury, NY). Aqueous layer (bottom layer) was collected and washed with
hexane four times. Plasmid DNA was extracted using ethanol precipitation, reconstituted in
TE buffer and subject to electrophoresis on 0.75% agarose gel.
3.2.5 Radiolabeling of pDNA
3.2.5.1 Nick Translation
Plasmid DNA labeling was performed using commercially available kit from
Amersham Biosciences (N5000) as described below. Into a clean 2-mL microcentrifuge tube
containing 1 µg of pDNA (pGL3) diluted in distilled water at 100 ng/µL, 20 µL of
nucleotide-containing buffer (dNTP), 15 µL of [3H]-dCTP, 10 µL of enzyme solution (0.5
units/µl DNA polymerase I and 10 pg/µl DNase I), and 45 µL of sterile distilled water were
added. Following gentle mixing and brief spinning, the mixture was incubated at 15oC for 2
hrs. The reaction was stopped by adding 10 µL of 0.2 M EDTA (pH 8.0). Unincorporated
nucleotides were removed using Sephadex G-25 spin column (Amersham Biosciences,
Piscataway, NJ) at 800 x g for 2 min.
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Further purification was performed by phenol/chloroform extraction and ethanol
precipitation. In general, oligonucleotides larger than 20-mer (i.e., 20 nucleotides)
precipitates out, leaving unincorporated nucleotides in solution. A pre-mixture of
phenol/chloroform (Sigma) was added to an equal volume of aqueous pDNA solution. The
mixture was vortexed and placed on dry ice for 1 min followed by centrifugation at 12,000 x
g for 5 min at 4oC. Equivalent volume of fresh chloroform was added to the aqueous layer.
Mixture was then vortexed briefly, placed on dry ice for 1 min, centrifuged at 12,000 x g for
5 min at 4oC and the top layer was subject to ethanol precipitation. Into the aqueous layer
collected previously, 1 µL of linear polyacrylamide (5mg/mL), one volume of 4 M
ammonium acetate (pH 4.5), and four volumes of 95% ethanol were added while gentle
mixing by inversion. The mixture was chilled for 15 min on dry ice before centrifuged at 14,
000 x g for 30 min at 4oC. The pellet obtained was washed with 500 µL of 80% ethanol, air-
dried and re-dissolved in 100 µL of TE buffer. The specific activity was measured using
Nanodrop Model 1000 (NanoDrop Technologies, Wilmington, DE) and a Packard Model
Tri-Carb 2900TR liquid scintillation counter (Packard Bioscience Company, Meriden, CT).
The yield was 65-90% and specific activity was 0.5-2 x 107 dpm/µg of pDNA.
3.2.5.2 Methylation
Enzymatic methylation was utilized to radiolabel pDNA (Bureau et al. 2004). Into a
2-mL microcentrifuge tube containing 100 µCi of [3H]-SAM (a substrate of CpG methylase
and the source of methyl group) and 10 X NE buffer, 4 µg of template pDNA (pCMV Luc,
6.2 kbp), CpG methylase (10 U/µg pDNA), and 16 µL of 1 M Tris free base in water were
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added. Total final volume was made to 40 µL using distilled water. [3H]-SAM (180 µL)
originally dissolved in the mixture of 10mM H2SO4 and ethanol (9:1) was added to the
reaction tube and concentrated (final volume was 1-3 µL) using a Speed Vac Model Savant
SC 110 (Global Medical Instrumentation, Inc, Ramsey, MN). To adjust pH of the reaction to
7-8, Tris solution was added to the reaction in such a way 8.5 µL of Tris solution was added
to 100 µL of SAM. The reaction was incubated at 37oC water bath for 2 hrs. Unincorporated
[3H]-SAM was removed using Sephadex G-25 microspin column. Tritium labeled pDNA
was further purified by phenol/chloroform extraction and ethanol precipitation. Specific
activity and yield were calculated in the same manner as described in section 3.2.4.1. The
specific activity thus achieved was ~ 2 x 106 dpm/µg of pDNA.
3.2.6 Radiolabeling of Nanogel
Nanogel was radiolabeled by incorporating [14C]-labeled, PEG-based monomer that
was synthesized as follows. Mixture of [14C]-acetic anhydride and cold acetic anhydride was
added to 25-mL round bottom flask containing 1.5-mole equivalent of PEG-A (average Mn of
PEO =375) in 5 mL of anhydrous methylene chloride. One mole equivalent of TEA as a
proton scavenger and one-tenth mole equivalent of 4-dimethylaminopyridine as a catalyst
were added and the reaction was kept under magnetic stirring for 2 hrs at room temperature.
In the anhydride mixture used, the mole ratio of hot to cold acetic anhydride was
approximately 0.006 to 1 and the initial amount of hot acetic anhydride was 1.3 x 107 dpm (6
µCi). After 2 hrs, the product was purified in a column chromatography on silica gel using
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the mixture of methanol and chloroform (15:85% v/v) as a mobile phase. The reaction yield
was approximately 90% and the specific activity thus obtained was 1.7 x 105 dpm/mg.
3.2.7 Entrapment Efficiency
Subsequent to concentration in Speed Vac, nanogels entrapping pDNA were
electrophoresed on agarose gel (0.8% w/v) (Denville Scientific, Metuchen, NJ) for 45 min at
90 volts in Tris-acetate-EDTA (TAE) buffer. Ethidium bromide was included in the gel at a
final concentration of 0.5 µg/mL to monitor the location of pDNA using a Bio-Rad Versa
Doc Model 1000 Imaging System (Bio-Rad Laboratories, Inc., Hercules, CA). To assess the
entrapment efficiency of pDNA in nanogel, each lane of an agarose gel was cut into 3-5
segments from the top to the bottom. Gel segments were put into 20-mL glass vials
containing 9 mL of scintillation cocktail solution (UltimaTM Gold XR, Sigma) and incubated
overnight on the rocker at room temperature before reading radioactivity in a Packard Model
Tri-Carb 2900TR liquid scintillation counter (Packard Bioscience Company, Meriden, CT).
3.2.8 Size Measurement
Hydrodynamic diameter was measured at 23oC using viscosity of 0.933 centipoise
and refraction index of 1.333 on a NICOMP Model 370 dynamic light scattering instrument
(Particle Sizing Systems, Santa Barbara, CA), equipped with a 30-mW laser (632.8-nm
wavelength) and an Avalanche photodiode detector. The scattered light intensity detected at a
90o angle was treated using the Gaussian or multimodal Nicomp analysis, depending on the
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polydispersity of the samples. Data presented here corresponds to the volume-weighted
distribution. The mean diameters shown were averages of duplicate measurements performed
on different samples for periods of time long enough (from 10 to 40 min) to collect
statistically reliable data.
3.2.9 Condensation of pDNA
For this portion of the present study, pCMV-Luc purchased from Elim
Biopharmaceutical (Hayward, CA) was used as received.
3.2.9.1 Spermine: NH2(CH2)3NH(CH2)4NH(CH2)3NH24HCl
Spermine4HCl was considered to have 4 positive charges per molecule at
physiological pH. At various charge ratios (i.e., 0.01 – 1,000), spermine was mixed with 1 µg
of pDNA in 0.5 X TE buffer and incubated for 30 min at room temperature. SYBR Gold (1
X) was added to the mixture and the mixture was briefly vortexed and put on a rocker for 20
min before fluorescence measurement at 495nm/537nm (Ex/Em) using a Perkin Elmer
Model LS50B spectrofluorometer (Perkin Elmer Life and Analytical Sciences, Inc., Waltham,
MA). For the size measurement of spermine-pDNA complex, 20 µg of pDNA was added
into a glass cuvette containing varying amount of spermine dropwise under vortex-mixing
and the mixture was subject to size analysis on NICOMP for 10 min.
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3.2.9.2 Poly(L-lysine) (PLL)
The average molecular weight of PLL (4-15 kDa) used was 9,500 g/mol. Into 10 µg
of pDNA in 600 µL of 0.5 X TE buffer, a constant amount of PLL was consecutively added
until the charge ratio (positive to negative) reached 0.8 with 5-min vortexing and 10-min size
measurement after each addition.
3.2.9.3 Alkyltrimethylammonium Bromide
Constant amount (9 µg) of cetyltrimethylammonium bromide [CH3(CH2)15N(CH3)3Br,
CTAB] was consecutively added to 80 µg of pDNA in 500 µL of 0.5 X TE until the N/P
ratio reached 1.1. After each addition, the mixture was vortex-mixed briefly and the size
measurement was performed for 10 min. Into a separate tube, 40 µg of pDNA was added
dropwise into a glass cuvette (Fisher Scientific) containing different amount of
dodecyltrimethylammonium bromide [CH3(CH2)11N(CH3)3Br, DDTAB] and the size of
complex was measured in NICOMP for 10 min. The complex formation was performed in
500 µL of a mixture of TE buffer and water. The portion of TE buffer (10mM Tris/1mM
EDTA, pH 8) in the mixture varied from 0 to 100 %. Into a glass cuvette containing varying
amount of decyltrimethylammonium bromide [CH3(CH2)9N(CH3)3Br, DTAB], 20 µg of
pDNA in distilled water or 0.5 X TE was added dropwise under vortex-mixing and the
mixture was subject to NICOMP.
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3.2.9.4 Protamine
Protamine used for this study is a basic protein of 5.1 kDa derived from salmon. It
consists of 31 amino acids (H-PRRRSSSRPVRRRRRPRVSRRRRRRGGRRRR-OH) and
most of them are arginine (i.e., 21 R per molecule). Condensation of pDNA by protamine
was monitored using dye exclusion assay and displacement assay. In the former, protamine
was complexed with pDNA at various N/P ratios (i.e., 0 to 5), followed by 20-min incubation
at room temperature before 1 X SYBR Gold was added. Fluorescence was measured after a
thorough mixing for 10 min using a Perkin Elmer Model LS50B spectrofluorometer. In the
latter assay, ethidium bromide was mixed with pDNA first such that the mole ratio between
ethidium bromide and base pair of pDNA was 1 to 1. The mixture was then incubated for 3
min at room temperature before and after the consecutive addition of constant amount of
protamine followed by fluorescence measurement. The data was represented by relative
fluorescence (FR), which was calculated from the following equation.
For the size measurement of protamine-condensed pDNA, 10 µg of pDNA was added
dropwise into a series of glass cuvettes containing different amount of protamine under
vortex mixing and the size of complex was measured in NICOMP for 10 min. The complex
(FM - FE)
FR (%) =  × 100
(FED - FE)
Where FM, Fluorescence of pDNA-EtBr in the presence of protamine; FE, Fluorescence of EtBr
alone; and FED, Fluorescence of pDNA-EtBr in the absence of protamine.
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formation was performed in 500 µL of a mixture of TE buffer and water. The portion of TE
buffer (10mM Tris/1mM EDTA, pH 8) in the mixture varied from 0 to 100%.
3.2.10 Recovery of Condensed pDNA in Aqueous Layer from Biphasic Heptane/Water
System
The mixture of [3H]-pCMV Luc and cold pDNA was added slowly into the water
solution of protamine or other cationic lipids (CTAB, DDTAB, and DTAB) and 40-volume
of heptane was added to the complex solution followed by brief vortex and centrifugation.
The aqueous layer was collected and subject to DPM reading using a liquid scintillation
counter. Various N/P ratios (i.e., 0.2 to 100) and different adding orders (i.e., pDNA to
protamine or vice versa) were tested in forming protamine-pDNA complex to compare
recovery efficiency under the specified reaction conditions. Pre-coating of vessels was
performed by multiple rinsing of 2-mL tubes and tips with 1 mL of PLLHBr (25 kDa) at 5
mg/mL and drying at a 50oC-oven for 2 hrs. Into a pre-coated tube, DDTAB was added first
followed by the consecutive addition of pDNA and heptane. The layer collection and DPM
reading were performed in the same manner as described above.
3.2.11 Transfection
Human colon carcinoma HeLa cells from ATCC (Manassas, VA) were seeded at 5 x
104 cells per well in 0.5 mL of MEM in 24-well flask (Corning, Inc., Corning, New York) 18
hrs prior to transfection. Immediately before transfection, cells were rinsed with HBSS and
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supplemented with 0.5 mL of Opti-MEM. The nanogel formulations containing plasmid
DNA were diluted in 100 µL of Opti-MEM, vortexed and added to the cells. After 4-hr
incubation, the medium was removed, rinsed with HBSS and supplemented with normal
growth medium (MEM) containing 10% fetal bovine serum and 1% antibiotics
(penicillin/streptomycin). Luciferase gene expression was monitored 48 hrs later by using a
commercial kit (Promega Corporation, Madison, WI). Briefly, the culture medium was
discarded and cell lysate was harvested after incubation of cells for 5 min at room
temperature in 100 µL of 1 X lysis reagent (Promega). The cell lysate was vortexed gently
and centrifuged for 2 min at 12,000 x g at 4oC. Twenty microliters of supernatant was diluted
into 100 µL of luciferase reaction buffer (Promega) and the luminescence was integrated
over 10 sec in a Monolight Model 3010 luminometer (Analytical Luminescence Laboratory,
Sparks, MD). Each transfection experiment was run in quadruplicate and was expressed as
relative light unit per microgram of cell protein. The total protein content was measured
using bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL).
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3.3 Results and Discussion
3.3.1 Preparation of pDNA-Entrapped Nanogel and Characterization by TEM
Figure 3-1 illustrates how pDNA was entrapped in nanogel formulation. As indicated
in Chapter II, one of the key features of nanogels derived from W/O inverse microemulsion
is its hydrophilic matrix, which enables the entrapment of polar substances such as nucleic
acids. As expected, pDNA was compatible with other monomer components in the aqueous
phase and did not form any precipitates when mixed with heptane, the continuous phase.
Polymerization and purification were performed similarly to what discussed in the Chapter
II. Further investigation such as entrapment efficiency, interaction with monomers, and
stability of pDNA under free radical reaction will be discussed in the latter sections in the
present chapter.
In an early stage of the development of this formulation, pDNA-entrapped nanogel
was examined under microscope. Figure 3-2 shows microemulsion (arrows in A-C) and
polymerized nanogels (D-F) entrapping pGL3 of 5.2 kbp negatively stained using 2% uranyl
acetate. As shown in A, B and C in Figure 3-2, multiple ring-like structures (arrows) were
observed, demonstrating that pDNA was indeed entrapped in the formulation. Similar
observation was reported in earlier works by other investigators (e.g., Budker et al. 2002).
Since no purification step was attempted for the present microemulsion formulation,
significant amount of other substances, mostly surfactants, co-existed. The bottom panels (D,
E and F) in Figure 3-2 represented TEM of purified nanogels containing pDNA. Sephadex
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G-15 (Sigma) column was used for the additional purification of nanogels in the present
study. The diameters of the purified nanogel formulations in the figures ranged from 100 to
300 nm. However, the size represented here must have represented the flattened structures of
the nanogel on the grids even though they contained 12% of crosslinker (i.e., PEGdiA). The
monolithic appearance of pDNA-containing nanogel (D, E, and F) may well represent one of
the following possibilities: (1) even though negative staining was attempted using uranyl
acetate, the actual staining performed could be a positive staining under the condition carried
out in this study; (2) the probable collapse of the top part of the specimen into the center
might decrease the resolution in the center. This is particularly feasible considering that the
specimen was dried rather intensively. Trace amount of unwanted substances observed in
purified nanogel formulations (arrow heads in Figure 3-2D) could be an artifact derived
from the specimen preparation or staining processes. Taken together, TEM pictures presented
here demonstrated that pDNA was indeed entrapped in the formulation.
3.3.2 Stability of pDNA under Free Radical-Initiated Polymerization
DNA can be degraded by both oxygen- and carbon-centered free radicals that can
attack both sugar and base moieties (Breen and Murphy 1995). The initiator used in
polymerizing water-soluble acrylates was lipid-soluble Trigonax EHP. Thermal hemolytic
degradation at room temperature generates CO2 and oxygen-centered radicals, which abstract
hydrogen from the terminal ethylene carbon of acrylate. The resulting carbon-centered
radicals then propagate to form polymer chains. As a result, both types of radicals will
bombard nucleic acids residing in the aqueous phase of microemulsion along with monomers.
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Naked pDNA also could be susceptible to radical attack but, there is a substantial protection
of DNA from radicals by components in a formulation such as ascorbic acid (Quick and
Anseth 2003). Since radical scavengers works against polymerization, unrelated small yeast
RNA was used as a radical “decoy” that may interact with radicals at reactivity similar to that
of pDNA but based on the law of mass action may protect pDNA. In this part of the study,
regular emulsion containing one of the acrylate monomers along with pDNA was used in
testing the effect of free radicals on the stability of pDNA. The reason why regular emulsion
system, instead of microemulsion, was utilized here was because polymerization derived
from microemulsion is taking significant amount of time and involves so many purification
steps. By adopting the procedures of Kriwet et al.(1998), series of tests could be performed
in more efficient fashion. The concentration of pDNA in aqueous phase of emulsion was set
to 40 µg/mL, which is the lowest end of the concentration range (i.e., 40-200 µg/mL) that
will be used in the eventual preparation of pDNA-entrapped nanogel for transfection study.
As shown in Figure 3-3, pDNA under AIBN-initiated radical reaction (lane 4 through
11) appeared to remain intact and no decomposed DNA fragment at lower part of gel was
observed. The pDNAs recovered from the radical-mediated polymerization showed very
similar mobility on the gel to that of pDNA extracted from the mixture with pre-made
polymers (lane 12). Interestingly, the formulation with larger amounts of monomers (lane 4)
showed improved recovery of pDNA than in the formulations containing less amounts of
monomers (lane 6 and 8). The addition of yeast RNA did not make much difference (lane 10
vs. 4) under the present condition. All pDNA extracted from the reaction were identified
using a corresponding restriction enzyme, Hind III (odd numbered lanes). The effect of
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monomer in different concentrations on the recovery of pDNA from polymerization was
further investigated using pCMV-Luc of 6.2 kbp and another monomer, HEA.
As shown in Figure 3-4A, the recovery of pDNA in aqueous layer after emulsion
polymerization increased in HEA concentration-dependent manner (see lane 3 through 6).
This is in agreement with the previous findings with PEGmA (Mn of PEO=375 g/mol).
Another noticeable observation was that pDNA transformed toward open relaxed circular
form after being through polymerization while control pDNA (lane 2) and pDNA extracted
from a simple mixture with pre-made polymer (lane 7) showed a typical ratio between open
relaxed circular (upper band) and supercoiled form (lower band). Since there was no apparent
degraded fragments on the gel when pDNA extracted after polymerization loaded, it is
difficult to attribute the low recovery of pDNA with less amount of monomers to degradation
of pDNA under this condition. Thus, in the following investigation, interface was also
included for examination of pDNA recovery. Figure 3-4B demonstrated that the presence of
HEA rendered more pDNA to stay in the aqueous layer (lane 5) while most of pDNA resided
in the interface (lane 7) rather than aqueous phase. Taken together, pDNA was stable under
radical polymerization when formulated at 40 µg/mL in aqueous phase. The recovery of
pDNA in aqueous phase improved in the presence of monomers such as HEA and PEGmA.
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3.3.3 Radiolabeling of pDNA
To facilitate the detection of pDNA in the next series of experiments, pDNA was
labeled with radioisotopes. Two different methodologies in radiolabeling were applied and
described in the present section.
The first method attempted was nick translation reaction. Nick translation employs
two enzymes as described earlier by other investigators (Kelly et al. 1970; Rigby et al. 1977).
As illustrated in Figure 3-5A, pancreatic deoxyribonuclease (DNase I) creates random nicks
on the strands. E. coli DNA polymerase I has three distinct activities; 5’-3’ template-
dependent DNA polymerase activity, 5’-3’ exonuclease activity, and 3’-5’ exonuclease
activity. The nick translation uses the first two of these activities. DNA polymerase I adds
sequentially new nucleotides on 3’-end of a nick within a DNA duplex while removing
nucleotides from the adjacent 5’-terminus of the nick. During this procedure, radiolabeled
nucleotides, [3H]-dCTPs, are incorporated into the pDNA to produce a uniformly-labelled
population of pDNA. The specific activity achieved was 1.8 x 107 dpm/µg, which agrees
with that reported by the kit supplier (Amersham Biosciences, Piscataway, NJ). However,
when the integrity of tritium labeled pDNA was tested on the agarose gel, the labeled pDNA
was found to be fragmented during the labeling and showed up as 200-500 base pair
fragments on the gel (lane C and D in Figure 3-5B). This is approximately one tenth of the
original pDNA in size. Although nick translation has been applied in labeling PCR products
as in situ hybridization probes for immunocytochemistry (e.g., Baldini et al. 1992; Parrilla et
al. 2003), this method is patently not suitable for the present investigation, where an intact,
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non-degraded radiolabeled pDNA is needed in assessing the behavior in nanogel
formulations.
The second attempt to radiolabel pDNA was methylation. A typical procedure for
preparing [3H]-pDNA using this method can be found in Bureau et al. (2004). The enzyme
CpG methylase (M. Sss I) methylates specifically C-5 positions of cytosine residues within
the double-stranded dinucleotide (C-G) recognition sequences (Figure 3-6A) using SAM
(Figure 3-6B) as a methyl donor. This enzymatic methylation only occurred at pH 7-8 and
Tris base needed to be added to neutralize sulfuric acid coming from [3H]-SAM stock
solution. Tritium labeled pDNA appeared very similar to the unmodified pDNA when run on
0.8% agarose gel in terms of the movement of two different biological structures, open
relaxed and supercoiled form, on the gel (upper and lower band in the lane B of Figure 3-6D,
respectively). The gel segment corresponding to [3H]-pDNA (B2 in Figure 3-6E) showed
almost 100% DPM level of total input.
The specific activity achieved was 1.81 x 106 DPM /µg of pDNA. Unmethylated CpG
motifs are prevalent in bacterial but not vertebrate DNAs (Nur et al. 1985). Methylation on
CpG sites protects pDNA from digestion by restriction enzymes whose recognition sites
either contain the sequence CG or overlap the dinucleotide. As shown in Figure 3-6C,
unmethylated pDNA was susceptible to BstU I derived from Bacillus stearothermophilus and
produced 5 to 6 smaller fragments (lane 3). The complete blocking of cleavage was achieved
when the substrate, SAM, was used in 5-fold molar excess of the CpG acceptor sites to
methylate constant amount of pDNA (lane 9). Considering pCMV-Luc derived from firefly
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was labeled in the presence of excess amount of substrate (SAM) and the CpG acceptor sites
counted in one molecule of pDNA was 309, the maximum achievable specific activity would
be 1 x 107 dpm/µg. It thus appears to indicate that only part of CpG sites, approximately 15-
20%, is originally unmethylated and generates the present specific activity. Taken together,
the present data demonstrated the integrity of [3H]-pDNA labeled by methylation would be
suitable with the subsequent studies.
3.3.4 Radiolabeling of Nanogel
Radiolabeling of nanogel with different isotopes makes it possible to monitor nanogel
and pDNA independently during in situ entrapment. It was achieved by radiolabeling one of
the monomers and incorporating it into the polymerization. Unfortunately, however, the
acetylated HEA (Figure 3-7A), which initially attempted to be labeled, was too hydrophobic
to partition into aqueous phase during microemulsion formation even when 50% methanol
was added to the aqueous phase. A PEG-based monomer, more polar compound, was thus
selected and acetylated with [14C]-acetic anhydride. As shown in Figure 3-7B, PEGmA with
MW of ~ 400 g/mol was acetylated with [14C]-acetic anhydride to prepare the radiolabeled
monomer, acryloylPEGacetate. It indeed remained in the aqueous phase, implying that this
monomer is compatible with microemulsion polymerization. The specific activity was 1.7 x
105 DPM/mg of monomer. This was hot enough for analysis when incorporated to nanogel.
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3.3.5 Entrapment of Uncondensed pDNA
First attempt to entrap pDNA in nanogels is summarized in Figure 3-8. Mixture of
[3H]-pDNA and cold pDNA was introduced to microemulsion system. The composition of
microemulsion was either 10% crosslinker (PEGdiA)/90% HEA or 10% PEGdiA/65%
HEA/25% cationic monomer, AETMAC. The former formulation produced neutral nanogel
entrapping pDNA while the latter generated pDNA-entrapped cationic nanogel. In the neutral
nanogel (Figure 3-8, lane B), pDNA traveled the same distance as the control pDNA (lane
E). About 44 % of radioactivity was recovered at the top of the gel (right panel, B1),
indicating that close to a half of pDNA was entrapped in the nanogel and retained at the
loading well. The present level of entrapment, 44%, is in agreement with what Goh and
colleagues reported with pDNA-entrapped microparticle system (2004). In case of the
cationic nanogels, no significant pDNA was detected in the middle part of the gel for both
entrapment (lane C) and mixture formulations (lane D). In a closer examination, pDNA in
these two formulations appeared to move upward, implying that the net charge of these
formulations was positive. In these two groups, above 80% of radioactivity was found at the
top of the gel (right panel, C1 and D1), while only 10% of radioactivity was detected in the
middle of the gel. In the entrapment formulation using cationic nanogel (lane C), part of
pDNA could be entrapped inside of nanogel and another part of them bound on the surface
by electrostatic interaction. In the mixture of pDNA with cationic nanogel (lane D), which
served as a control group for this study, majority of pDNA remained bound to the nanogel,
similar to the case of entrapment formulation.
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In the next series of experiments (Figure 3-9), nanogels were prepared by
incorporating [14C]-PEG acrylate (4% w/w) and the amount of pDNA was reduced compared
to the previous experiment (i.e., pDNA:monomers = 1:10,000 vs. 1:3,000 in Figure 3-8).
The main objective of this study was to see if there would be any improvement in entrapment
efficiency under this set of conditions. Here, the charge ratio between cationic monomers and
phosphate groups of pDNA was adjusted in such a way that the formulations contained 0-, 1-,
or 10-fold excess amount of positive charges. In the previous experiment (Figure 3-8), the
charge ratio (N/P ratio) was found to be approximately 1,000 (i.e., large excess of positive
charge). Three out of the five test groups were entrapment formulations (Figure 3-9, lane B-
D) and designed to have different charge ratios. The other two test groups were mixtures of
pDNA with pre-made neutral (lane E) or cationic nanogel (lane F). As shown in the right
panel of Figure 3-9, the radioactivity for 14C (open bars) was measurable only in the loading
well of the gel. The total recovery of 14C radioactivity was as low as 10-13%. Although the
net reaction yield of polymerization is known to be around 45 %, the low level of 14C
recovery found here may represent that the incorporation of [14C]-PEG acrylate into nanogel
was not as good as the other monomers probably due to its limited water solubility.
As to pDNA in the entrapment formulations (lane B-D), a trace amount of pDNA was
barely observed on the middle part of the gel. Radioactivity reading of 3H was also very low
(8-12% of initial amount) at the top of the gel (right panel, B1, C1, and D1), indicating a
limited amount of pDNA entrapped in the nanogel in all test groups. Unexpectedly,
significant amount of radioactivity from 3H (25-60% of initial amount) was detected at the
lower part of the gel in all test groups (right panel, B3, C3, and D3) while only 3-4% of
98
initial input of radioactivity was measured in the mixtures (E3 and F3). This could well be
due to degradation of pDNA during polymerization. The concentrations of pDNA in TE
buffer of aqueous phase were 333 and 100 µg/mL in the previous (Figure 3-8) and present
experiments, respectively. Since pDNA was found to be stable even at a concentration as low
as 40 µg/mL in an emulsion system (Figures 3-3 and 3-4), the condition that the pDNA
encountered during EHP-initiated microemulsion polymerization might have been much
harsher than with the emulsion system. Even though there was some success in entrapping
pDNA in the nanogel (44% in the first experiment), the result was not reproducible when
reduced amount of pDNA used. The incidence of probable degradation of pDNA during the
processing was also observed, indicating that some additional efforts for tuning the reaction
condition will be needed. Overall, pDNA entrapment was less favorable in this system than
once expected.
3.3.6 Entrapment of Condensed pDNA and Transfection Study
In order to increase the pDNA entrapment efficiency, condensation of pDNA was
attempted prior to polymerization. Condensing reagents tried in the present study included
multivalent cationic molecules such as spermine, PLL, and protamine as well as cationic
surfactants such as alkyltrimethylammonium bromide. Polyamines such as spermine
(tetravalent) and spermidine (trivalent) have been utilized in precipitating or condensing
DNA for the past several decades (Hoopes and McClure 1981; Porschke 1984; Raspaud et al.
1999; de Frutos et al. 2001; Vijayanathan et al. 2001; Kral et al. 2002). Dye exclusion by
pDNA-spermine complex was utilized to monitor pDNA condensation (Figure 3-10A). Even
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at N/P ratio=1,000, however, the level of fluorescence stayed high and never reduced to
baseline level (i.e., approximately 20 by SYBR Gold alone), implying that the condensation
was not completed with spermine. Size measurement of spermine-pDNA complex at various
N/P ratios also supported the observation. The size of complex was smallest at N/P=1 with
approximately 500 nm, however, increased significantly with higher N/P ratios (Figure 3-
10B). The present data clearly indicate that spermine is not suitable since the size of complex
was still too large and complete condensation was not obtained.
Many examples of utilizing PLL as a condensing reagent can be seen in previous
studies (Hansma et al. 1998; Kogure et al. 2004; Masuda et al. 2005). In most of these
investigations used PLL of ~ 25 kDa to condense pDNA of 5-6 kbp. As shown in Figure 3-
10C, the size of PLL (25 kDa)-pDNA (6.2 kbp) complex ranged from 180 nm to over 2
microns depending on N/P ratio applied. However, the N/P ratio that produced relatively
small complex (i.e., less than 200 nm) was too narrow a range, 0.4 to 0.6 in N/P. In addition,
the size of complex abruptly increased outside of this range even up to over micron size,
implying that aggregation of the complex at high N/P ratio.
Interaction of pDNA with cationic surfactants such as cetyltrimethylammonium
bromide (CTAB) have been extensively investigated as exemplified by Melnikov et al.
(1995). This study demonstrated that the DNA-CTAB complex changes from coil-like to
globular state depending on the concentration of CTAB and that aggregation occurs when the
surfactant concentration further increased and became close to its critical micellar
concentration (CMC). Table 3-1 represents the change in size of pDNA-CTAB complex
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with varying N/P ratios. The concentration of CTAB was 5 x 10-5 M at N/P=1, which is
approximately 18-fold lower than its CMC, 9 x 10-4 M. Most of the complexes showed
multiple size populations and none of the major populations were smaller than 200 nm. Since
a surfactant forms micelle at a concentration above its CMC, the actual amount of
unassociated surfactant available for the complexation with pDNA will be limited by its
CMC. In addition, the interaction of pDNA with micelles leads to aggregations. Thus, the
higher CMC a surfactant has, the more pDNA can be added in the complex formation,
leading to a higher yield of entrapment of DNA. Ouyang et al. (2000) also suggested that
CMC must be higher than 10-2 M for cationic surfactant to become a practically useful DNA
condensing reagent. Dodecyltrimethylammonium bromide (DDTAB) and decyltrimethyl-
ammonium bromide (DTAB) are with CMC of 1.6 x 10-2 M and 6.8 x 10-2 M, respectively
(Rosen 1978). With this high CMC values, these agents were tried in condensing pDNA in
the follow-up studies.
As shown in Figure 3-11A, not only N/P charge ratio but also the concentration of
pDNA was a factor in determining the final size of condensed pDNA with lower
concentration generating smaller size. The concentration of TE buffer was also a critical
function in that the size increased almost linearly with TE buffer concentration (panel C).
The most reproducible result by DDTAB was yielded when pDNA condensed in water at
N/P=4 as represented in panel B. The final concentration of pDNA was as high as 80 µg/mL.
In the case of DTAB (C10), a much higher N/P ratio (i.e., 80) was needed to achieve small
size of condensed pDNA (~ 50 nm) in both TE and water solution (panel D).
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Protamines, which package DNA in vertebrate sperm cells, have been showing
promising results in condensing pDNA as demonstrated in previous investigations (e.g.,
Allen et al. 1995; Vilfan et al. 2004; Masuda et al. 2005) and have been used for gene
delivery (Li and Huang 1997; Faneca et al. 2004; Maruyama et al. 2004). The condensation
of pDNA with protamine was monitored using both dye exclusion assay (Figure 3-12A) and
displacement assay (Figure 3-12B). The methodology applied here to monitor DNA
condensation was exemplified in Budker et al. (2002) and Geall and Blagbrough (2000).
Ethidium bromide is known to intercalate into base pairs of DNA intensifying fluorescence at
least 20-fold probably due to the blockage of transferring a proton to the polar solvent in the
more hydrophobic intercalated environment (Olmsted and Kearns 1977). SYBR Gold is
presumed to act in the same way when bound to DNA. At N/P=2, protamine-condensed
pDNA excluded the access of dye and showed almost same value of fluorescence as that of
dye alone (panel A). Ethidium bromide that was previously bound to pDNA is displaced by
protamine, resulting in a decreased fluorescence intensity. As shown in panel B, the relative
fluorescence intensity of pDNA bound-ethidium bromide reached almost baseline (i.e., that
of unbound ethidium bromide) when N/P ratio approached 2.0. Taken together, the present
set of data indicates that protamine is very efficient in condensing pDNA even at a relatively
low N/P ratio.
As shown in Figure 3-13, the resulting protamine-pDNA complex formed in water
was 110 nm even at N/P ratio 0.2 (panel A). At this N/P ratio, the net charge of the complex
remains negative rendering its partition to the aqueous phase favorable. The concentration of
pDNA in panel A was 20 µg/mL in water. At the same concentration but in TE buffer, the
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size of complex increased by TE-concentration dependent manner (panel C). The extent of
complex size growing in TE buffer was more profound than the case with DDTAB shown
earlier in Figure 3-11C. If the upper size limit of the complex favorable in microemulsion is
assumed to be around 200 nm, the maximum concentration of pDNA complexed with
protamine in aqueous phase would be close to 200 µg/mL as represented in panel B of
Figure 3-13. Another interesting finding was that the order of mixing between protamine and
pDNA also determined the final size of the complex. The size of complex formed by slowly
adding pDNA to protamine (open bars in panel B) was significantly larger than the case of
reverse-ordered addition (i.e., adding protamine to pDNA, gray or closed bars in panel B),
especially at high pDNA concentration. The complex size remained close to 200 nm even at
N/P ratio 1.0 and at 200 µg pDNA/mL in water. The present observation suggests that 1 mL
of aqueous phase can accommodate up to 200 µg of pDNA when complexed with protamine
by N/P ratio 0.2 -1.0.
DNA condensation is a dynamic decrease in the volume occupied by a DNA
molecule and is difficult to clearly distinguish from aggregation or precipitation.
Condensation is a general term for the situations in which the aggregate is of finite size and
orderly morphology such as toroids, rods, or spheroids (Bloomfield 1996). Thus
condensation of pDNA by multivalent cationic molecules or surfactants is basically
aggregation phenomenon in some sense. However, if aggregation occurs too aggressively in
the formulation, it will affect not only the size of complex but also the recovery of the
condensed pDNA in aqueous phase since the original polar property of pDNA will change
when complexed with condensing reagents.
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Figure 3-14A shows the percent recovery of pDNA condensed with various
compounds, assessed by monitoring radioactivity in the aqueous phase. The latter was
collected from the biphasic system consisting of 950 µL of heptane and 50 µL of water as
described in Methods section. The N/P ratio used in each different condensing reagent was
the ratio at which the smallest complex was observed (e.g., protamine condensed pDNA of
60 nm at N/P=100 as shown in Figure 3-13A). In the case of CTAB, the N/P ratio 20 was
selected based on the investigation of Melnikov et al. (1995). In general, the recovery of
condensed pDNA in aqueous layer was very low and ranged from 5% in CTAB to 36% in
protamine. Since no measurable radioactivity was detected in heptane layer, the rest of
condensed pDNA probably stayed in the interface or remained stuck on the wall of vessels or
tips used to transfer sample solution. As proven in the subsequent experiment, the
assumption was correct and as much as 60% of initial amount of radioactivity was measured
in the tubes (data not shown). To resolve this problem, tubes was pre-coated using PLL (25
kDa) solution before pDNA condensation was performed. The recovery of pDNA condensed
with DDTAB indeed improved and 75% of initial radioactivity was measured in aqueous
layer in the pre-coated tube while only 17% recovered in the uncoated tube (Figure 3-14B).
Although the recovery of condensed pDNA in the precoated tube was still lower than that of
uncondensed pDNA (92%), this investigation demonstrated that condensed pDNA loses its
hydrophilicity and results in adsorption onto the vessel and that pre-coating with another
polycations can prevent the loss due to adsorption.
Based on this discovery, inverse microemulsion with the pre-condensed pDNA in
aqueous phase was then polymerized with 20% crosslinker (PEGdiA) and 80% HEA. Percent
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pDNA entrapped in this ‘neutral’ nanogel was assessed with the agarose gel electrophoresis
by reading [3H] radioactivity. As shown in Figure 3-15, as much as 56% of the initial loaded
pDNA was detected at loading well (D1 in the right panel, also see lane D in the left panel).
When uncondensed pDNA used, only approximately 27% of pDNA was entrapped in the
nanogel (B1 and lane B). As expected, in a simple mixture of pDNA and pre-made neutral
nanogel (lane E), unassociated pDNA moved similarly to the control pDNA on the gel (lane
F). With DDTAB (C12), the total recovery was minimal (lane C). Although pDNA was
condensed with DDTAB in pre-coated tubes as in previous investigation, the adsorption of
DDTAB-condensed pDNA toward vessels still remained relatively high during
polymerization resulting in a low recovery. Alternatively this low recovery could be
attributed to the higher affinity of DDTAB in the heptane-water interface than toward pDNA
during polymerization, which must have produced unsatisfactory condensation of pDNA. But,
no further investigation was performed to address this issue.
The study involving protamine was carried out at an N/P ratio 0.2 in which the
complex itself carries a net negative charge. As illustrated by Figure 3-16, under this
situation the proton sponge effect may not be fully realized. In the endosome protons
introduced by proton pump (square symbol in the figure) will protonate weak base moiety
(triangle symbol in the figure) and the accompanying chloride ions will have two different
destinations. They can bind to protonated weak base moiety on the nanogel and remain inside
of endosome. This will facilitate endosomal rupture by increased osmotic pressure, a
desirable pathway (Pathway 1 in the figure). Alternatively, chloride ions could bind to the
counter cations of the complex (Pathway 2), which may leave the endosome via some
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transporter or carrier system (Pathway 3). This pathway cannot provide osmotic pressure. In
short, condensation of pDNA at N/P ratio 0.2 would be countereffective in the overall vector
design. Since it is difficult to estimate how much weak base is enough for overcoming the
above dilemma and what the upper limit of base incorporation is, it would be more desirable
if a higher N/P ratio such as 1.0, instead of 0.2, can be used to keep the net charge of
condensed pDNA neutral. For this reason, the recovery of condensed pDNA in aqueous layer
was further investigated using protamine at various N/P ratios. As shown in Figure 3-14C,
the recovery of pDNA decreased as N/P ratio increased. For instance, only 30% was
recovered when the ratio reached 1.0. Note, however, that in a reduced concentration of
pDNA (i.e., 200 µg/mL in water), the recovery remained as high as 96% before and after
adding heptane. The addition of alcohols decreased the recovery especially after adding
heptane (60%) and significant amount of radioactivity (12-18%) was detected in tubes,
implying alcohols affect the physical property of protamine-condensed pDNA. This is
important to know because methanol will need to be added to aqueous layer to improve the
solubility of disulfide crosslinker (see Chapter II). Finally, the effect of pDNA
concentration on the recovery was further investigated represented in Figure 3-14D. Up to
200 µg/mL, the recovery of pDNA remained high (~ 95%) and was close to that of
uncondensed pDNA at the concentration of 100 µg/mL.
The integrated efforts have thus yielded several nanogel formulations that entrap
protamine-condensed pDNA for transfection study in the cell. Figure 3-17 shows the agarose
gel electrophoresis of various nanogel formulations containing [3H]-pDNA. Nanogels were
crosslinked using either disulfide crosslinker (SSXL; lane B-E) or PEGdiA (lane F) and
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contained 25% (w/w) weak base, morpholinoethylacrylate (MEA). In the pre-condensation,
pDNA was complexed with protamine at various N/P ratios (i.e., 0 to 4). Bright bands were
detected in all nanogels that contained SSXL at near the loading wells, which was not the
case in PEGdiA-derived nanogel. Radioactivity was, however, minimal in all the
formulations (right panel), implying not much pDNA was entrapped in the nanogel. Indeed
fact, no significant radioactivity was detected throughout the gel (i.e., less than 1%). It is
possible that most of pDNA was not able to stay in aqueous phase in the microemulsion
and/or during polymerization. This fairly low pDNA recovery can be attributed to the
interference of pDNA condensation and the possible instability of microemulsion due to the
presence of a significant amount of methanol. Methanol was necessary in improving the
solubility of the disulfide-containing crosslinker, SSXL. Alternatively, the presence of MEA
might not be compatible with the pre-condensed pDNA under this reaction condition. In the
left panel of Figure 3-17, the bright bands observed on the top of the gel probably came from
the disulfide moiety incorporated in the nanogel. Disulfide derivatives indeed show up under
UV lamp when loaded on thin layer chromatography.
As shown in Figure 3-18, when HeLa cells were treated with these formulations, no
significant transfection was observed in all test groups (B-F). This was most likely due to
small amount of pDNA delivered to the cell. When calculated from the entrapment efficiency
in the gel data, it was as low as 0.01 µg per well. Each well in 24-well plate contained 5 x 104
HeLa cells. PEI of 25 kDa was used as positive control for this study and showed a high gene
expression. In PEI-transfected cells, two different amounts of pDNA (0.2 in I and J; 1 µg in
G and H) were complexed with PEI at two different N/P ratios (4 in G and I; 10 in H and J).
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Although the difference in pDNA amount treated to constant number of cells was only 5 fold,
the improvement in gene expression was more profound (i.e., 200 fold at N/P=4 and 10,000
fold at N/P=10). The N/P ratio dependency in gene expression was also reported by other
investigators (e.g., Boussif et al. 1995).
3.4 Conclusions
Entrapment of pDNA in a neutral nanogel would have some potential advantage over
conventional polyplex system, in which pDNA is simply mixed with pre-made polymeric
particles. Because of the net charge of the formulation is neutral, it would reduce cytotoxicity
to the cell. Since the pDNA is theoretically present inside the polymer matrix, the protection
of pDNA from biochemical degradation by nucleases in the serum in vivo would have been
better realized. However, the preparation becomes a challenging task. The first issue was to
do with the stability of pDNA under free radical-initiated polymerization. It was shown that
pDNA can be intact so long as its concentration is greater than approximately 100 µg/mL and
pDNA stays in aqueous layer in the emulsion system. For the purpose of monitoring, pDNA
and nanogel were successfully radiolabeled using methylation and acetylating, providing
relatively high specific activities, 2 x 106 DPM/µg and 2 x 105 DPM/mg, respectively.
Various reagents were employed to condense pDNA prior to entrapment. Here,
protamine-condensed pDNA showed improved entrapment efficiency in the nanogel; 56% of
initial loaded pDNA. However, the final formulation of nanogel entrapping pre-condensed
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pDNA was difficult to achieve mainly because of possible instability of the microemulsion in
the presence of added methanol. No positive data were obtained in the transfection study
when the present formulation was fed to the cell. This is in turn due to the low entrapment of
pDNA in the nanogel. Instead of further investigation on the entrapment formulation, an
approach with a mixture formulation of pre-made nanogel with pDNA was pursued in
Chapter IV.
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Figure 3-1: Preparation of pDNA-entrapped nanogel. Monomer stock and pDNA
solution are mixed into aqueous phase, which is then added to heptane phase
containing 10%, w/w surfactant (laureth-3). Microemulsion is formed by brief
vortexing and polymerized by adding free radical initiator, EHP. Nanogel is water-
extracted from heptane layer and further purified using dialysis with 100 kDa MW
cut off dialysis bag. Abbreviations used are: WB, weak base; AETMAC, 2-
acryloxyethyltrimethylammonium chloride; HEA, 2-hydroxyethyl acrylate; and TE,
Tris-EDTA.
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Figure 3-2: Transmission electron micrographs of pDNA-entrapped inverse
microemulsion (A, B, and C) and polymerized neutral nanogels (D, E, and F). Plasmid
DNA (pGL3 Control Vector, 5.2 kbp) was added into aqueous layer along with monomers
(12% PEGdiA and 88% HEA) to form microemulsion (arrows in A, B and C). Free
radical-initiated polymerization was conducted overnight at room temperature and
nanogel was purified using water extraction, n-butanol washing, and size exclusion
chromatography on Sephadex G-15 (D, E, and F). The concentration of pDNA was 5 µg
in 1 mL of heptane/surfactant and the microemulsion was used as it is for microscopic
examination without further purification. In both cases, negative staining was adopted
using 2% uranyl acetate. Trace amount of unidentifiable substances were observed in
purified nanogel formulations (arrow heads in D) and could be an artifact derived from the
specimen preparation or staining processes.
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Figure 3-3: Stability of pDNA in emulsion-derived, free radical-initiated
polymerization. pGL3 Control Vector (Promega) was added to aqueous phase
containing monomers such that concentration of pDNA was 40 µg/mL in TE buffer.
The aqueous phase (30%, w/w) was mixed with mineral oil (68%, w/w) containing 2%
surfactants (Span 80:Tween 80=3:1). Polymerization was initiated by adding 0.125%
AIBN and kept stirred for 4 hrs at 50 oC. Plasmid DNA was water-extracted from the
reaction mixture, washed with hexane, and precipitated with 95% ethanol before gel
electrophoresis on 0.75% agarose gel. Emulsion contained various amount of PEG
monomethacrylate (Lanes 4, 5, 10, and 11; 20% of aqueous phase: Lanes 6 and 7; 5%
of aqueous phase: Lanes 8 and 9; 1.25% of aqueous phase). Excess amount of yeast
RNA was added in lane 10 and 11. As a mixture formation, pDNA was added to pre-
made polymer solution (Lane 12 and 13) and extracted as described above. Incubation
with Hind III (37oC, 1 hr) generated linear form of pDNA (odd numbered lanes).
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Figure 3-4: Effect of HEA on the pDNA recovery in free radical-mediated emulsion
polymerization. Plasmid DNA (pCMV-Luc) was added to aqueous phase containing
monomers such that concentration of pDNA was 40 µg/mL in TE buffer. The
composition of emulsion, the procedure in polymerization, and purification were the
same as described in Figure 3-3. [A] The extracted pDNA was electrophoresed on
0.75% agarose gel. Emulsion contained various amount of HEA (lanes 3-6). Lane 7
represents a mixture of pDNA and pre-made polymer derived from 40% HEA-
containing aqueous phase. Control pDNA showed two bands, supercoiled and open
relaxed circular form (Lane 2). [B] Emulsion contained 40% of HEA (lanes 3-5) or
no HEA (lanes 6-8) in aqueous phase. In the absence of HEA, pDNA was recovered
in the interface mostly as supercoiled form (lane 7) while majority of pDNA showed
up in aqueous phase apparently as open relaxed circular form in the presence of
HEA (lane 5).
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Figure 3-5: Radiolabeling of pDNA using nick translation. [A] DNase I
creates random nicks on the strands. E.coli DNA polymerase I adds
sequentially new nucleotides to the 3’-end of a nick within a DNA duplex
while removing nucleotides from the adjacent 5’-terminus. During this
procedure, radiolabeled nucleotides, [3H]-dCTPs, are incorporated into the
pDNA to produce radiolabeled pDNA. The specific activity obtained with this
procedure was 1.8 x 107 dpm/µg. [B] The integrity of tritium labeled pDNA
was confirmed on the agarose gel. The labeled pDNA showed small fragments
of 200-500 base pairs on the gel (lanes C and D), which is approximately one-
tenth of the original pDNA in size.
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Figure 3-6: Radiolabeling of pDNA by methylation. Enzyme CpG methylase
methylates specifically C-5 positions of cytosine residues within the double-stranded
dinucleotide (C-G) recognition sequences using S-adenosylmethionine (SAM, B) as
a methyl donor (A). This enzymatic methylation needs pH 7-8 and 5-fold molar
excess of SAM was used for complete methylation as demonstrated by the rejection
of BstU I restriction of methylated pDNA (C). Tritium labeled pDNA appeared very
similar to the unmodified pDNA when run on 0.8% agarose gel in terms of the
movement of two different biological structures, open relaxed (upper band) and
supercoiled form (lower band), on the gel (D). The gel segment corresponding to
[3H]-pDNA showed almost 100% DPM level of total input (E). The specific activity
achieved was 1.81 x 106 DPM /µg of pDNA.
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Figure 3-7: Radiolabeling of acrylate derivatives by acetylation. Mixture of
[14C]-acetic anhydride (1.3 x 107 dpm, 6 µCi) and cold acetic anhydride
(0.006:1) was reacted with 1.5-mole equivalent of PEG monoacrylate (average
Mn of PEO =375), 1 mole equivalent of TEA and 0.1 mole equivalent of 4-
dimethylaminopyridine. The reaction was kept under magnetic stirring for 2 hrs
at room temperature and the product was purified in column chromatography on
silica gel using the mixture of methanol and chloroform (15:85% v/v) as mobile
phase. The specific activity obtained was 1.7 x 105 dpm/mg.
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Figure 3-8: Agarose gel (0.8%) electrophoresis of nanogel-entrapped pCMV-Luc of
6.2 kbp. Molecular weight ladder (A) and pDNA alone (0.2 µg, E) were loaded as
references. Mixture of [3H]-pDNA and cold pDNA was added to aqueous phase before
polymerization (B and C, the final concentration of pDNA was 333 ug/mL TE buffer)
or mixed with polymerized cationic nanogel (D). The weight ratio between pDNA and
monomers was 1:3,000 and N/P ratio in the cationic nanogel-pDNA formulations was
approximately 1,000 (i.e., excess of positive charge). The composition of nanogels
were 10% PEGdiA and 90% HEA (B), or 10% PEGdiA, 25% AETMAC (cationic
monomer) and 65% HEA (C and D). Whole gel was cut into segments for DPM
reading after overnight incubation in 20-mL vials containing scintillation cocktail
(right panel).
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Figure 3-9: Agarose gel (0.8%) electrophoresis of [14C]-nanogel that had entrapped
pCMV-Luc of 6.2 kbp. Molecular weight ladder (A) and pDNA alone (0.15 µg, G)
were loaded as references. Mixture of [3H]-pDNA and cold pDNA was added to
aqueous phase before polymerization (B, C and D, the final concentration of pDNA
was 100 ug/mL TE buffer) or mixed with pre-made neutral (E) or cationic nanogel (F).
The weight ratio between pDNA and monomers were 1:10,000 and N/P ratios in the
cationic nanogel-pDNA formulations were 1 (C and F) and 10 (D). The composition
of nanogels were 10% PEGdiA, 4% [14C]-PEG acrylate and 86% HEA in all
formulations. Small amount of AETMAC (0.006% in C and F; 0.06% in D) was
additionally added to prepare cationic nanogels. The gel was cut into segments for
DPM reading after overnight incubation in 20-mL vials containing scintillation
cocktail (right panel).
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Figure 3-10: Condensation of pDNA by multivalent cationic molecules. [A] Spermine
was mixed with 1 µg of pDNA in 0.5 X TE buffer at varying charge ratios and
incubated for 30 min at room temperature. SYBR Gold (1 X) was added to the
mixture followed by 20-min rocking before fluorescence measurement at 495/537 nm
as excitation/emission. [B] Into a glass cuvette containing varying amount of
spermine, 20 µg of pDNA was added dropwise under vortex-mixing and the mixture
was subject to size analysis on NICOMP. [C] Into 10 µg of pDNA in 600 µL of 0.5 X
TE buffer, constant amount of PLL was consecutively added until the charge ratio
(positive to negative) reached 0.8 with 5-min mixing and 10-min size measurement
after each addition. At ratios 0.3 and 0.8, multiple size populations were observed and
the frequencies of these two size components were approximately 70 % (open bar) and
30% (gray bar) in both cases.
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Table 3-1: Size of pDNA-CTAB (Cetyltrimethylammonium Bromide) Complex at Various
N/P Ratios Measured by Dynamic Light Scattering Using Multimodal Nicomp Analysis.
N/Pa 0.1 0.2 0.4 0.6 0.8 1.1
Size
(nm)
1000 (84%)b
120 (16%)
340 (84%)
51 (16%)
459 (87%)
54 (13%)
1434 (62%)
222 (28%)
54 (10%)
1004 (78%)
116 (19%)
22 (3%)
1825 (88%)
40 (12%)
a: N/P indicates the ratio of positive charge of CTAB to negative charge of phosphate groups
in pDNA.
b: Percentage in parentheses represent the frequency of each size population.
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Figure 3-11: Size of pDNA complex with dodecyltrimethylammonium bromide
(DDTAB) (A, B, and C) and decyltrimethylammonium bromide (DTAB) (D).
DDTAB was mixed with pDNA at different concentrations in 0.5 X TE (A) or with
pDNA of 80 µg/mL in water (B). Size of DDTAB-pDNA (80 µg pDNA /mL)
complex increased linearly with increased concentration of TE buffer (C). DTAB was
mixed with pDNA of 40 µg/mL in 0.5 X TE or in water (D). Size was measured by
dynamic light scattering on NICOMP.
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Figure 3-12: Condensation of pDNA with protamine as monitored by fluorescence. [A]
Dye exclusion assay was performed by adding SYBR Gold to protamine-pDNA complex.
Open circle represents baseline fluorescence of dye alone. [B] Displacement assay was
conducted by adding protamine to the mixture of pDNA with ethidium bromide. Relative
fluorescence (FR) was calculated using the equation shown in the figure, where FM,
Fluorescence of pDNA-EtBr in the presence of protamine; FE, Fluorescence of EtBr
alone; and FED, Fluorescence of pDNA-EtBr in the absence of protamine.
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Figure 3-13: Size of pDNA-protamine complex. [A] Into a protamine solution, pDNA
was slowly and continuously added such that the final concentration of pDNA was 20
µg pDNA/mL in water. [B] Different order of mixing was studied in condensing pDNA
with protamine at N/P 0.5 and 1.0 such that the final concentration of pDNA was 20-900
µg/mL in water. [C] Increased concentration of TE buffer resulted in larger size of
protamine-pDNA complex at 20 µg pDNA/mL.
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Figure 3-14: Recovery of pDNA condensed with protamine or cationic lipids. [A]
pDNA was condensed with various condensing reagents at different N/P ratios and
radioactivity recovered in the aqueous layer was reported here. At the N/P ratios studied,
smallest complexes were observed in previous studies. [B] Dodecyltrimethylammonium
bromide (DDTAB) was complexed with pDNA at N/P=4 in PLL(25 kDa)-precoated
tubes containing water and radioactivity was measured in various sites including middle
layer and tubes. [C] pDNA recovery was assessed after adding protamine to pDNA at
the concentration of 200-500 ug pDNA/mL in water with various N/P ratios. [D] The
recovery of condensed pDNA by protamine in water at N/P=1 was affected by
increasing concentration of pDNA.
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Figure 3-15: Agarose gel (0.8%) electrophoresis of pre-condensed, neutral nanogel-
entrapped pCMV-Luc of 6.2 kbp. Molecular weight ladder (A) and pDNA alone (0.15
µg, F) were loaded as references. Mixture of [3H]-pDNA and cold pDNA was
condensed with DDTAB (C12) in PLL-precoated tube at N/P=4 (C) or with protamine
at N/P=0.2 (D) before adding to the aqueous phase for polymerization. Uncondensed
pDNA was added during polymerization (B) or mixed with pre-made neutral nanogel
(E). The weight ratio between pDNA and monomers were 1:4,000 the concentration of
pDNA was 250 µg/mL in aqueous phase, which consisted of 50% monomer/50% water
(w/w). The composition of nanogel was 20% PEGdiA and 80% HEA in all
formulations. The gel was cut into segments for DPM reading after overnight incubation
in 20-mL vials containing scintillation cocktail (right panel).
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Figure 3-16: Illustration of protamine-condensed, neutral nanogel-entrapped pDNA
after endocytosis. Plasmid DNA condensed with protamine at N/P=0.2 is entrapped
in the nanogel and internalizes the cell via endocytosis. The net charge of the
complex is negative and thus positive counter ions (+ symbol) co-exist accordingly.
Protons introduced through proton pump (square symbol) protonate weak base
moiety (triangle symbol) but chloride ions that follow in for charge balance will
have two different destinations. They bind to protonated weak base moiety on the
nanogel, remain inside of endosome, and facilitate endosomal rupture by increased
osmotic pressure (Pathway 1). Alternatively, chloride ions bind to the counter ions
(Pathway 2), have the ability to leave the endosome (Pathway 3) and provide no
help in terms of endosomal escape of the formulation.
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Figure 3-17: Agarose gel (0.8%) electrophoresis of protamine-condensed, neutral
nanogel-entrapped pCMV-Luc of 6.2 kbp. Molecular weight ladder (A) and pDNA
alone (0.15 µg, G) were loaded as references. Mixture of [3H]-pDNA and cold pDNA
was condensed with protamine at various N/P ratios (B-F) before adding to the aqueous
phase for polymerization. The weight ratio between pDNA and monomers were 1:6,000
and the concentration of pDNA was 200 µg/mL in the aqueous phase, which consisted
of 40% monomer/30% methanol/30% water (w/w). The composition of nanogel was
10% PEGdiA (F) or disulfide containing crosslinker (SSXL; B-E), 25%
morpholinoethylacrylate (MEA), and 65% HEA in all formulations. Aqueous phase of
microemulsion in all formulations contained 50% methanol. The gel was cut into
segments for DPM reading after overnight incubation in 20-mL vials containing
scintillation cocktail (right panel).
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Figure 3-18: Transfection of HeLa cells with pCMV-Luc of 6.2 kbp protamine-
condensed and entrapped in neutral nanogel. Mixture of [3H]-pDNA and cold pDNA
was condensed with protamine at various N/P ratios (B-F) before adding to the
aqueous phase for polymerization. The composition of nanogels were 10% PEGdiA
(F) or disulfide containing crosslinker, SSXL (B-E) and 25%
morpholinoethylacrylate (MEA) and 65% HEA in all formulations. pDNA (1 µg)
alone (A) or nanogel formulations containing pDNA (B-F) were added to 5 x 104
cells seeded in 24-well plate. The amount of pDNA in nanogel formulations per well
was approximately 0.01 µg based on the calculation from entrapment study (i.e.,
entrapped from initial loaded pDNA was only 0.5%). Poly(ethylenimine) was
complexed with pDNA (1 µg in G and H; 0.2 µ g in I and J) at N/P=4 (G and I) or
10 (H and J). All formulations were incubated with cells for 4 hrs and cells were
rinsed with HBSS briefly and provided with fresh growth medium. At 48-hr post
transfection, cell was lysed and the cell lysate was subject to luciferase assay and
BCA protein assay. The transfection represented by relative light unit (RLU)
normalized by protein amount.
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CHAPTER IV
COMPLEXATION OF PLASMID DNA WITH NANOGEL
4.1 Introduction
The poor performance of pDNA-entrapped neutral nanogels in transfecting cells that
was described in the previous chapter led to another approach in utilizing nanogels as gene
carriers. Adopting the very conventional polyplex system, pre-made cationic nanogels may
deliver genetic materials to intended sites of the cell (e.g., cytosol and nucleus) in efficient
way.
Non-specific binding of cationic particulate drug carriers to the cell is mediated by
the electrostatic interaction between excess positive charges on the carrier and the negative
charges on the cell surface. In contrast, active or targeted drug delivery systems can have
higher selectivity and low collateral side-effects by recognizing molecular markers, which
are often overexpressed in the cells under disease state such as tumor (Arap et al. 1998; Hood
et al. 2002; Lu et al. 2002; Kukowska-Latallo et al. 2005). The molecular recognition
processes entail ligand-receptor interactions: examples may include antibodies (Gao et al.
2004), endogenous targeting peptides or proteins (Raden and Gilmore 1998; Bellocq et al.
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2003; Faraasen et al. 2003), nucleic acid-based aptamers (Nimjee et al. 2005), and low
molecular weight compounds (Benns and Kim 2000).
Ligands bound to the corresponding receptors generally enter the cells via receptor-
mediated endocytosis. Since the concept of receptor-mediated endocytosis was formulated in
the investigation on the regulation of cellular cholesterol metabolism by low density
lipoproteins in 1974 (Goldstein and Brown), the process was recognized during the
subsequent decade as a major mechanism by which vertebrate cells internalize many
macromolecules (Pastan and Willingham 1981; Bretscher and Pearse 1984). The phenomena
were observed in various transport proteins such as cholesterol-carrying lipoprotein
(Anderson et al. 1982) and the iron transport protein transferrin (Hopkins 1985) as well as
many other non-transport plasma proteins such as asialoglycoproteins (Berg et al. 1983) and
immune complexes (Schachtschabel et al. 1996; Shimizu et al. 1996). Some growth factors
such as epidermal growth factor (Carpenter and Cohen 1979) and classical polypeptide
hormones such as insulin (Ullrich et al. 1985) also enter the cell by receptor-mediated
endocytosis.
Due to size, small MW ligand such as folic acid of MW 441 have distinct advantages
over the macromolecular ligands mentioned above in that they are usually non-immunogenic
and allow well-defined conjugation chemistry. Folate, a generic term for folic acid-related
compounds, also retains its affinity for the corresponding receptor upon conjugation via its
gamma carboxyl to a drug or drug carriers (Reddy and Low 1998; Wang and Low 1998;
Sudimack and Lee 2000). Cellular uptake of folate, an essential vitamin, is mediated by a low
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affinity but widely expressed reduced-folate carrier (Kd; ~ 1 µM) as well as a high
affinity/low capacity folate receptors (Kd; 0.1 - 1 nM) (Juillerat-Jeanneret and Schmitt 2006).
Reduced folate carrier transports primarily reduced folates such as 5-methyltetrahydrofolate.
Folate receptor (FR), also known as folate-binding protein, transports oxidized folates such
as folic acid. Human FR has three isoforms with about 70% genetic homology to one another
(Prasad et al. 1994). Two membrane-bound FR isoforms (i.e.,  and ) have been reported.
They are 38-kDa glycosylphosphatidylinositol (GPI)-anchored glycoproteins that are often
highly expressed in a number of epithelial carcinomas (Antony 1996; Wu et al. 1999) but
present in only a limited number on normal cells (Sapra and Allen 2003). These FR isoforms
show distinctive tissue distribution patterns. FR- is frequently expressed in many malignant
tissues of epithelial origin including ovary, uterus, brain and kidney (Ross et al. 1994;
Weitman et al. 1994; Toffoli et al. 1997). The expression of FR- is amplified in
hematopoietic, nonepithelial cells such as in spleen and thymus (Ross et al. 1994),
myelogenous leukemias (Garin-Chesa et al. 1993) and activated macrophages (Nakashima-
Matsushita et al. 1999). In contrast to GPI-anchored isoforms, FR- and its truncated form -’
lack the anchor and exist as soluble forms of the folate receptors at very low levels (Shen et
al. 1994). FR- is one of the most widely utilized strategies for site-specific drug delivery
based on a receptor-mediated endocytosis (Kamen and Capdevila 1986; Leamon and Low
1991; Sabharanjak and Mayor 2004; Kelemen 2006; Salazar and Ratnam 2007).
There have been conflicting reports on the mechanism involved in the internalization
and trafficking of FR and folate conjugates (Rothberg et al. 1990; Anderson et al. 1992;
Mayor et al. 1994). The fate of the cargo when they are released from the endocytosed
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conjugate is also not clearly understood. Monovalent folate conjugate appears to undergo a
rapid receptor recycling to plasma membrane via moderately acidic compartment,
presumably following caveolae-dependent lipid-raft pathway (Sabharanjak and Mayor 2004;
Yang et al. 2007). The caveolae is 50-80 nm in size and a flask-shaped cell membrane
invagination that often serves as a transcytotic shuttle for entrapped substances. Caveolae can
discharge the luminal content directly to cytosol in agreement with an earlier model of so-
called potocytosis (Mineo and Anderson 2001; Anderson and Jacobson 2002). In contrast,
when multiple copies of folate are chemically attached to a particulate drug carrier such as
liposome, FR clustering may occurs in caveolae (Sabharanjak and Mayor 2004), resulting in
a delivery of the assembly to lysosome-like compartment where luminal pH can be as low as
4.3 (Lee et al. 1996). Although the mechanism has yet to be further clarified, folates
obviously move across the plasma membrane into the cytosol (Kamen and Capdevila 1986).
Folate receptor-mediated drug delivery has expanded to in gene delivery in the past
decade. Folate-expressing liposomes (Lee and Huang 1996; Li et al. 1998) as well as
biodegradable nanospheres (Leong et al. 1998) have been formulated for the receptor-
specific cellular delivery of genes. The incorporation of flexible linker such as PEG between
the carrier and folate enhanced cell surface recognition; a spacer of approximately 25 nm
from PEG of MW 3.3 kDa appeared to allow the folate to find an unoccupied, cell surface
folate receptor most efficiently (Lee and Low 1994). The folate-PEG conjugates has been
applied to delivery of a wide range of therapeutic materials to tumor cells, including
chemotherapeutic compounds (Saul et al. 2003; Hilgenbrink and Low 2005) and
oligonucleotides (Wang et al. 1995; Leamon et al. 2003).
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In the present chapter, pDNA was complexed with pre-made cationic nanogels that
were strategically designed to target folate receptor-overexpressing tumor cells. Nanogels
were modified with folates by incorporating folate-containing monomers during
polymerization. Gene expression, represented by luciferase enzyme activity in the cell treated
with this formulation, was assessed as the dependent variable of the study.
4.2 Materials and Methods
4.2.1 Materials
Folic acid was purchased from Spectrum Chemical Manufacturing Corporation
(Gardena, CA) and used as received. All ACS grade organic solvents including dimethyl
sulfoxide, diethyl ether, heptane and dichloromethane and 1 N NaOH standard solution were
purchased from Fisher Scientific. N-hydroxysuccinimide, N,N,N-triethylamine, PEI of 25
kDa, and acryloyl chloride were purchased from Aldrich. The sources of monomers used in
the preparation of nanogel were represented in the previous chapter. Poly(ethylene glycol)
bisamine (average MW of 3350 g/mol) and dicyclohexylcarbodiimide (DCC) were purchased
from Sigma. Ethidium bromide at 10 mg/mL in Tris-acetate-EDTA (TAE) buffer was
purchased from Fluka and stored at - 4oC. Plasmid DNA (pCMV-Luc) at 1 mg/mL in water
was purchased from Elim Biopharmaceutical (Hayward, CA). Agarose gel was purchased
from Denville Scientific (Metuchen, NJ). Folate-free RPMI 1640, antibiotics, fetal bovine
serum, Opti-MEM, Hank’s balanced salt solution (HBSS) and DL-dithiothreitol were
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purchased from Gibco BRL (Gaithersburg MD). Lipofectamine 2000 were purchased from
Invitrogen (Carlsbad, CA) and used following the instruction from the manufacturer.
Charcoal-stripped fetal bovine serum was purchased from Gemini Bio-Products (West
Sacramento, CA).
4.2.2 Preparation of Folate-Containing Monomers
4.2.2.1 Activation
The synthetic scheme of folate containing, acrylate monomer is represented in Figure
4-1. Activated ester and PEG conjugate of folate were synthesized based on Guo and Lee
(1999) with appropriate alteration in stoichiometry. One gram of folate (2.27 mmol) was
dissolved in 12 mL of anhydrous DMSO at room temperature. Dicyclohexylcarbodiimide
(0.94 g, 4.56 mmol) was dissolved in 8 mL of DMSO and added to the reaction while
magnetic stirring followed by the addition of two equivalents of N-hydroxysuccinimide (0.52
g, 4.52 mmol). N,N,N-triethylamine (0.5 mL, 3.59 mmol) was added as a proton scavenger.
Reaction was protected from light by wrapping the vessel with aluminum foil and stirred at
room temperature. After 14 hrs, reaction was filtered through glass wool to remove insoluble
byproduct (i.e., dicyclohexylurea), evaporated to dryness (5 hrs at 55oC with 4 torr) and
reconstituted in 10 mL of anhydrous diethyl ether to precipitate out the product. After ether
wash 3X, the precipitates were filtered using a sintered glass filter and dried in an oven at
60oC for 30 min. The yield based on both carboxyl groups (i.e., in alpha and gamma
positions) on folate activated was approximately 93%.
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4.2.2.2 Coupling
Activated folate (229 mg, 0.36 mmol, compound 5 in Figure 4-1) was dissolved in 15
mL of DMSO and added dropwise to 1 g (0.3 mmol) of PEG bisamine in 6 mL of DMSO.
The reaction was stirred at room temperature protected from the light. After 3 hrs, three
volumes of distilled water was added to the reaction to deactivate remained succinimide
moieties on the folic acid. After stirring 10 min, the reaction mixture was filtered using a
sintered glass filter and concentrated at 55-60oC for 3 hrs under vacuum. The concentrated
reaction mixture (~ 1.5 mL) in DMSO was mixed with 3.5 mL of water before loading on a
Sephadex G-25 (Sigma) column using water as an eluant. The elution rate/sample size was 8
mL/4 min/tube and the void volume was approximately 30 mL. After the chromatography,
10 fractions were collected, concentrated at 37oC for 4 hrs under vacuum, filtered using a
sintered glass filter (70-100 micron), and lyophilized for 20 hrs. On a silica gel TLC plate
(Aldrich), the reaction mixture contained multiple spots that were UV-detectable (folate) and
charred (PEG) with ammonium sulfate spray as well (methanol:chloroform:acetic acid =
30:65:5 as a developing solvent). Yield calculated using average MW of 3770 g/mol was
approximately 52%.
4.2.2.3 Acylation
Two equivalent of triethylamine (20 µL, ~ 0.14 mmol) was added to compound 8
(258 mg, ~ 0.07 mmol) dissolved in 13 mL of cold anhydrous dichloromethane while
magnetic stirring. Into the reaction mixture, 1.5 equivalent of acryloyl chloride (9 µL) in 2
138
mL of dichloromethane was added dropwise. The reaction was kept on the ice for 2 hr
followed by additional 2-hr incubation at room temperature with magnetic stirring. After 4
hrs, reaction mixture was evaporated to dryness under vacuum (room temperature for 15
min), reconstituted in 4 mL of distilled water, and loaded on a Sephadex G-25 column using
water as eluant. The elution rate/sample size was 8 mL/4 min/tube and the void volume was
approximately 29 mL. Four fractions were collected, concentrated under vacuum (room
temperature for 30 min), dialyzed against water using dialysis cassettes (MWCO 2 kDa,
Pierce Biotechnology, Rockford, IL) for 20 hrs while changing water every 6-8 hrs, and
lyophilized for 20 hrs. The reaction yield calculated based on the average MW of 3830 g/mol
was approximately 76%.
4.2.3 Gel Electrophoresis
In the present study a plasmid containing a luciferase reporter gene (pCMV-Luc, 6.2
kbp) was used as a model pDNA. Retardation of the pDNA bound to cationic nanogels was
observed on 0.8% agarose gel. Agarose gel was prepared in TAE buffer and contained 0.5%
(v/v) ethidium bromide. Cationic nanogels composed of PEGdiA:AETMAC:HEA
(10%:6%:84%, w/w) was mixed with 0.2 µg of pDNA to achieve various N/P ratios (0, 1, 2,
4, 10, 20, and 40), stirred briefly, and incubated at room temperature for 10 min before gel
loading. Electrophoresis was run for 45 min at 90 volts in 1 X TAE buffer and ethidium
bromide-intercalated pDNA was detected under UV using a Bio-Rad Versa Doc Model 1000
Imaging System (Bio-Rad Laboratories, Inc., Hercules, CA). For assessing the release of
pDNA from nanogel with N/P ratio 4 or 10, nanogel was mixed with pDNA (0.2 µg) in water,
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stirred briefly, and incubated 10 min at room temperature before the addition of various
concentration (0, 0.01, 0.05, 0.2, 1, 2, and 10 mM as final concentration) of dithiothreitol.
The complex was further incubated at 37oC for 3 hrs and was loaded on 0.8% agarose gel
containing 0.5% (v/v) ethidium bromide. Electrophoresis was performed under the same
condition as described in the retardation study.
4.2.4 Size Measurement
Hydrodynamic diameters of nanogel or nanogel-pDNA complex were measured at
23oC using viscosity of 0.933 centipoise and refraction index of 1.333 on a NICOMP Model
370 dynamic light scattering instrument (Particle Sizing Systems, Santa Barbara, CA),
equipped with a 30-mW laser (632.8-nm wavelength) and an Avalanche photodiode detector.
The concentration of nanogel in size measurement was 2-4 mg/mL in water. The scattered
light intensity detected at a 90o angle was treated using the Gaussian or multimodal Nicomp
analysis, depending on the polydispersity of the samples, and the data presented corresponds
to the volume-weighted distribution. The mean diameters shown were averages of duplicated
measurements performed on different samples for periods of time long enough (from 10 to
40 min) to collect statistically reliable data.
4.2.5 Determination of Folate Concentration in Nanogels
Nanogels were prepared following the procedure described in Chapter II. The folate-
containing monomer (12 in Figure 4-1) was added to the aqueous phase before forming
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microemulsion. In order to measure a concentration of folate in nanogel formulations,
standard curve was prepared by mixing regular control nanogel (10% PEGdiA, crosslinker
and 90% HEA) in water with known concentration of folate. The concentration of nanogels
in all the mixtures was fixed at around 3.4 mg/mL. Regular and folate-containing nanogels
were lyophilized and reconstituted in 0.5 N NaOH followed by 20-min sonication in a high-
power bath-type sonicater (Model G112SP1T, Laboratory Supplies Co. Inc., Hicksville, NY).
The final concentration of nanogels in both formulations was adjusted to 10 mg/mL.
Absorbance of nanogel solutions was measured at 259 nm using nanodrop Model 1000
(NanoDrop Technologies, Wilmington, DE). Absorbance at 259 nm from regular nanogels
was used as a background value and subtracted from that of folate-containing nanogels.
4.2.6 Transfection
The human squamous cell carcinoma of the oral cavity, KB cells, were purchased
from UNC tissue culture facility and maintained in folate free RPMI 1640 supplemented with
100 U/mL penicillin, 100 µg/mL streptomycin, and 10% FBS for the initial 3 weeks. The
cells transfected with the first set of nanogel-pDNA complexes (N/P ratio 2 and 10) were
cultured in the folate-free RPMI with charcoal-stripped FBS (i.e., folate-free FBS) for
another 3 days and seeded in 24-well plates (5 x 104 cells/well) under this media condition
one day prior to transfection. Regular tissue culture media were not used because they
contain micromolar levels of folate (i.e., order of magnitudes higher than that of the
physiological level) and may block receptor binding of folate conjugates. The KB cells
treated with a second set of nanogel-pDNA complexes (N/P ratio 4) were cultured in folate-
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free RPMI with charcoal-stripped FBS for 2 weeks. These KB cells were then maintained
and seeded in folate free RPMI with 5% regular FBS. Sixteen hours later, medium was
removed and nanogel-pDNA complex was added to the cells. The cells were incubated in 1
mL of Opti-MEM or folate free RPMI with 5% FBS for 4 hrs.
One microgram (or 3 µg in NG-pDNA complex with N/P ratio 4) of pDNA and 0.1
mg of NG were mixed, stirred briefly, and stored at room temperature for 10 min before the
treatment. For the competition experiments, 50- to 1,000-fold molar excess of free folate was
added to the cells along with the test groups. Dimethyl sulfoxide or 1 N NaOH was used to
dissolve folate and the final concentration of dimethyl sulfoxide or NaOH during transfection
was 0.03% (v/v) and 1 mM, respectively. Lipofectamine 2000 was mixed with pDNA by
1.5:1.0 (µL:µg) ratio and incubated 10 min before treatment. Poly(ethylenimine) of 25 kDa
was complexed with pDNA at N/P ratio 4 and 10. The N/P ratio was calculated assuming the
-NH-CH2-CH2- moiety as a unit positive charge. Based on this calculation, one microgram of
pDNA was mixed with 0.52 µg and 1.3 µg of PEI for N/P ratio 4 and 10, respectively, and
the complex was introduced to the cells after 10-min incubation. After 4-hr transfection,
Opti-MEM or RPMI was removed from the cells and the cells were rinsed with 0.5 mL of
HBSS and supplemented with 1 mL of folate-free RPMI containing charcoal-stripped FBS
followed by additional 44-hr incubation at 37oC in a 5% CO2 humidified atmosphere. For the
second set of experiment with N/P ratio 4, cells were maintained in folate free RPMI
containing 5% regular FBS for the additional 44-hr incubation period.
142
4.2.7 Luciferase Assay
At 48 hrs post-transfection, media was removed, rinsed with 0.2 mL of 1 X PBS, and
added 100 µL of cell lysis buffer (Promega Corporation, Madison, WI). Cell lysates were
collected in 1.5-mL polypropylene tubes, vortexed for 10 sec, and centrifuged for 2 min at
12,000 x g. An aliquot of supernatant was used in quantifying luciferase gene expression
using a commercial kit (Promega Corporation, Madison, WI) and a luminometer (Monolight
3010, Analytical Luminescence Laboratory, San Diego, CA). The results were expressed as
relative light units (RLU) integrated over 10 sec per mg cell protein lysate (i.e., RLU/mg of
protein) using the bicinchoninic acid (BCA) assay (Pierce Biotechnology, Rockford, IL). The
errors bars represent standard deviation derived from quadruplicate transfection experiments
(± S.D., n=4).
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4.3 Results and Discussion
4.3.1 Preparation of Folate-Containing Monomer
Structural identification of all intermediates involved (compounds 5 and 8 in the
Figure 4-1) and the final product (compound 12 in Figure 4-1) was carried out using 1H-
NMR in DMSO-d6. Figure 4-2B shows 1H-NMR (Gemimi 300) spectrum of N-
hydroxysuccinimide-activated folate (compound 5 in Figure 4-1). Since two molar
equivalents of N-hydroxysuccinimide (compound 3) was used in the first step, in some
products both - and -carboxyl groups could have been activated. It was difficult to
distinguish mono-activated (i.e., alpha or gamma only) species from doubly activated product
through NMR. According to an early investigation (Atkinson et al. 2001), -carboxyl group
is approximately 2x more reactive than the one at -position. The identification of the
product (compound 5) was not further investigated because it would not affect the eventual
outcome of the synthesis. The next step involves coupling with a primary amine 7 in almost
1:1 stoichiometry. Under this reaction condition, even if the product has two activated
moieties, only one of them will react with 7 while the other one become deactivated when
water is introduced.
The superiority of modified folate in one carboxyl group over the other in terms of
recognition by folate receptor still remains unresolved (Wang et al. 1996; Leamon et al.
2003). Figure 4-2B shows that activated folate 5 has an unresolved signal at 2.9 ppm from
succinimide moieties (l’’ in the spectrum) that is absent in the original folate (Figure 4-2A),
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while the unique signals from folate (g and f in the both spectra) remains intact. Extra signals
shown in Figure 4-2B probably represent impurities coming from the reaction byproduct,
dicyclohexylurea 6. Dicyclohexylurea is a typical byproduct from a carboxyl-alcohol
conjugation reaction mediated by dicyclohexylcarbodiimide 2 and is very difficult to remove
completely.
In the next coupling step, a slight excess of (1.2 equiv.) of N-hydroxysuccinimide
activated folate 5 was used in reacting with PEG-based bisamine 7. This stoichiometry would
produce the mixture of the intended product 8 and trace amount of byproduct with both
amine groups coupled with compound 5. However, this byproduct, if any, is not expected to
react with acryloyl chloride 11 in the next acylation step, and eventually will be removed
during nanogel preparation that involves dialysis using 100-kDa MWCO dialysis bag. It is a
better situation than having an unreacted PEG bisamine after coupling reaction, which could
react with acryloyl chloride 11 to result in incorporating unwanted primary amines in the
final the nanogel formulation. Figure 4-3A shows that the long chain of PEG moiety (m in
the spectrum) is clearly indicated by the NMR spectrum of the coupling product 8. The
primary amine (n in the spectrum) in the compound 8 was very difficult to detect clearly
because it was buried under the signal of methylene protons (k in the spectrum).
The next and final step entails the introduction of acrylate moiety to the folate-PEG
conjugate for providing a free radical receiving site in polymerization. As represented in
Figure 4-3B, proton signals from acrylate moiety (o, p and q) clearly appeared in the
spectrum, verifying that compound 8 with primary amine was successfully synthesized in the
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previous step. The final product 12 was lyophilized under high vacuum at - 45oC for storage.
The product was finally purified using a dialysis cassette with MWCO of 2 kDa, removing
low molecular weight species of product. Note that product was derived from a PEG mixture
of various MW with an average value of 3350 g/mol. The molecular weight of compound 12,
approximately 3.8 kDa, which was not that far from the exclusion cut off size of dialysis bag.
Nevertheless, the reaction yield of acylation was relatively high (76%).
4.3.2 Determination of Folate Concentration in Nanogel
The concentration of folate moiety in the nanogel was measured spectrophoto-
metrically. Folate in alkalic solution (i.e., pH 13) has two UV-Vis  at 259 and 368 nm with
extinction coefficient of 3.23 x 104 and 7.41 x 103, respectively. As shown in the Figure 4-4,
the concentration of folate in the nanogel prepared with folate monomer (compound 12 in
Figure 4-1) was found to be 21 µM. This value is very close to the anticipated concentration,
26 µM that is calculated from the initial amount of folate-containing monomer incorporated
in the polymerization (i.e., 1.0% w/w of total monomers). Taken together, the present
observation demonstrated that folate was indeed incorporated in the nanogel with intended
weight percent. No attempt was made to determine how much of these were indeed
expressed on the surface of nanogels. It is tempting to speculate that the hydrophobic folate
moiety of compound 12 may prefer to reside in the heptane phase while PEG may prefer the
aqueous phase such that the conjugate is concentrated at the interface of microemulsion. If
this is the case, folate group will stay primarily on the surface of the polymerized nanogel,
facilitating recognition by cell surface folate receptor.
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4.3.3 Transfection of KB Cells with Nanogel-Plasmid DNA Complex
The overall scheme of nanogel formulation is illustrated in Figure 4-5. The
formulation contains disulfide bond aiming for the facile release of pDNA upon reaching a
reducing environment in the cell. Weak bases for the proton sponge effect and targeting
ligand, folate, were also included in the formulation. Introducing pDNA into the rationale-
based nanogel was followed by cellular transfection in folate receptor expressing KB cells.
As shown in the upper panel of Figure 4-6, all the nanogel formulations turned out to
be less efficient, as much as by 4 orders of magnitude, in gene expression than PEI and
Lipofectamine 2000. Poly(ethylenimine) at N/P ratio 10, represented as P in the figure,
showed a higher transfection efficiency than at N/P ratio 4 (O) by 2 orders of magnitude,
which is in agreement previous reports (Boussif et al. 1995). Nanogel formulations, however,
increased gene expression by up to 15-fold compared to pCMV-Luc alone (A) that serves as
a negative control. Performance of nanogel formulations without controls is summarized in
the lower panel of Figure 4-6 on a linear scale. There was a trend that nanogels targeted with
folate increased gene expression by up to 8-fold except for nanogels that do not contain weak
base with N/P =10 (L and M). In these test groups, the binding of nanogels to the cell could
have been mediated mainly by charge interaction between negative charges on the cell
surface and excess amount of positive charges on the nanogels. Such a non-specific binding
could have overwhelmed the chance for targeting ligands on the nanogels to bind to the
folate receptor on the cell. Upon co-incubation with 50-fold excess free folate, transfection
efficiency decreased in most of the test groups (gray bars on the figure). The present
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observation agrees well with a previous study, which reported that targeting effect was more
evident at low N/P ratios with slightly positively charged DNA complexes (Guo and Lee
1999).
The incorporation of weak base such as histidine in the polymer has been reported to
enhance gene transfer in mammalian cells due to its endosomal buffering capacity (Midoux
and Monsigny 1999; Benns et al. 2000; Pack et al. 2000). The presence of weak base in the
nanogel improved transfection efficiency only in the targeted, disulfide crosslinker-
containing nanogels with N/P ratio 2 (closed bars in B and D compared to closed bar in F).
Interestingly, these test groups showed most obvious targeting effect, which was clearly
abolished in the presence of free folates as represented in the gray bars of B and D.
Dimethylamine-derived nanogels (D) showed slightly better transfection than imidazole-
containing formulations (B) with the same composition. In all test groups, incorporation of
the cleavable linker improved gene expression by up to 4-fold and the improvement appeared
to be more profound in the targeted formulations at lower N/P ratio (see B vs. C and D vs. E).
Agarose gel electrophoresis run with pDNA-nanogel complex (Figure 4-7) shows
that pDNA was not released at N/P ratio 10 from either disulfide crosslinked or non-
cleavable linker-containing nanogels even in the presence of 10 mM dithiothreitol a reducing
reagent, when incubated at 37oC for 3 hrs (left panel in Figure 4-7). In contrast, pDNA was
released from the nanogels with N/P ratio 4 when incubated with dithiothreitol of 1 mM or
higher. At 10 mM, a physiologically relevant (i.e., cytosolic) concentration (Kosower and
Kosower 1978), a significant amount of pDNA was released from nanogels within 3 hrs
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(right panel in Figure 4-7). The facile release of pDNA from the nanogels with N/P ratio 2
could contribute to the increase in transfection. At N/P ratio 10, the electrostatic association
of pDNA to cationic nanogels might have overridden rendering free pDNA less accessible
for eventual nuclear entry.
Figure 4-8 represents the retarded movement of pDNA on the agarose gel when
bound to cationic nanogels at various N/P ratios. Nanogel-bound pDNA even moved upward
on the gel (i.e., toward cathode) at N/P ratio 10 or higher. Most of pDNA were bound to
nanogel at N/P ratio around 4 while a significant portion of pDNA remained as free form (i.e.,
unbound to nanogel) at N/P ratio 2. The loose binding could cause a decrease in the actual
amount of pDNA that had an access to nucleus because of the premature degradation during
the cellular transfection steps. As shown in Figure 3-18, which dealt with PEI formulations
with 0.2 or 1.0 µg of pDNA, transfection efficiency is not simply proportional to the amount
of pDNA present in the formulation. Thus a formulation containing more pDNA with
optimal N/P ratio could induce much more profound gene expression.
As shown in Figure 4-9A, the size of nanogel before mixed with pDNA was different
depending on the composition. Compared to the size of regular control nanogels (~80 nm,
dotted line in the figure), imidazole-containing nanogels were bigger (~120 nm) but
dimethylamine-containing formulations tended to be smaller (~60 nm). In the preparation of
disulfide-containing nanogels, 50% (w/w) methanol had to be added in the aqueous phase
due to the solubility of disulfide crosslinker. The addition of methanol appeared to influence
the formation of microemulsion and increased the eventual size of the particles. There was no
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significant difference in the size between targeted nanogels and non-targeted counterparts or
between the formulations prepared with two different N/P ratios. As shown in Figure 4-9B,
after mixed with pDNA, the size of the complex increased within a few minutes,
approximately 2- to 3-fold with N/P ratio 2 and 10, respectively. The size of nanogel-pDNA
complex at N/P ratio 2 continuously increased with time while the complex at N/P ratio 10
remained the same after the immediate size increase. The size increase of the complex may
well be due to the aggregation, which is usually more severe in the case of neutral particles.
The present observation demonstrated very a similar phenomenon.
For the subsequent study, dimethylamine-containing, cleavable (i.e., disulfide
crosslinked) nanogel at N/P ratio 4 that was grafted with targeting ligand was selected in
performing KB cell transfection. The KB cells used were confirmed for their expression of
folate receptor using anti-FR- monoclonal antibody and FITC-PEG-folate conjugate in a
flow cytometer (data not shown). According to the electrophoresis result (Figure 4-8), most
of the pDNA remained bound to nanogel at an N/P ratio 4 and thus this value was chosen for
the study. N/P ratio 2 and 10 may have some disadvantage over 4 because at these ratios
pDNA is either incompletely or too tightly bound to nanogels.
In this series of experiments, the substitution level (i.e., incorporation percentage) of
folate-containing monomer in nanogel formulation was fixed at 0.1 mol % (3 weight %).
Various incorporation levels of folate targeting ligand in the lipid- or polymer-based
formulation have been attempted from 0.03 mol % up to 5% on in vitro as well as in vivo
settings (Hofland et al. 2002; Reddy et al. 2002; Bruckheimer et al. 2004; Hattori and
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Maitani 2005). Reddy et al. (2000) showed that the incorporation level of targeting ligand
had some optimal range for more efficient targeting effect. They used 0.1 mol % of targeting
ligand in the formulation. In the competition group for the present study, the concentration of
free folic acid was 1 mM, which was close to 1,000-fold molar excess over that of folate
ligand on the nanogel. The amount of pDNA per well also increased from 1 to 3 µg to obtain
higher resolution in terms of gene expression among test groups. As shown in the upper
panel of Figure 4-10, nanogel test groups again showed inferior gene expression compared
to all other commercially available transfection reagents by 2 to 4 orders of magnitude.
Dimethylamine-containing nanogels showed a marginal improvement in gene expression (1.5
to 3.5 fold) compared to pDNA alone. Interestingly, cleavable nanogels without any weak
base but grafted with targeting ligand (closed bar in D in the upper panel of Figure 4-10)
represented a significant increase, ~ 400-fold vs. pDNA alone. Formulations without weak
base showed a clear trend of improvement in gene expression by the presence of cleavable
linkers (D vs. E). The trend was also seen in the previous formulation with N/P ratio 10 (see
L vs. M in the lower panel of Figure 4-6). In the present study, however, the incorporation
of targeting ligand to the nanogels without weak base also contributed to the enhancement of
transfection efficiency, which agrees with the case of N/P ratio 2 previously shown in the
lower panel of Figure 4-6.
In a separate set of experiment, transfection was carried out in the presence of 5%
serum to see its effect on the transfection of KB cells with formulations. As shown in the
lower panel of Figure 4-10, the difference in transfection efficiency between nanogel
formulations and commercial reagents did not diminish significantly. There was
151
approximately 3-fold increase in gene expression by the presence of weak base in non-
cleavable nanogels regardless of targeting ligand incorporation (C vs. E). However, in the
cleavable nanogels (i.e., disulfide-containing nanogels) nanogels without weak base worked
better (D vs. B). Throughout the test groups, targeted nanogels showed improved gene
expression by approximately 5-fold compared to non-targeted formulations and most
improvement was observed without weak base, cleavable linker possessing nanogels by 50-
fold increase vs. pDNA alone (closed bar in D). Again, the presence of disulfide crosslinker
improved transfection efficiency only in nanogels without weak base.
Figure 4-11 summarizes the overall gene expression normalized to free pDNA alone
when 5 x 104 cells were treated with 1 µg of pDNA. At a lower N/P ratio such as 2, the net
charge of nanogel-pDNA complex was close to neural and the presence of weak base
increased transfection efficiency especially in the targeted and cleavable linker containing
formulations (A). This is attributed to their buffering capacity inside of endosomes.
Unexpectedly, however, this was the only group that showed a significant benefit from the
incorporation of weak base. As the excess amount of positive charges in nanogels increased
(i.e. with N/P ratios 4 and 10), there was no improvement from the presence of weak base in
the formulations (E - P). Decrease in apparent pKa of weak base containing nanogel by pre-
existing positive charges may explain the present observation. Weak base-containing
formulations with higher N/P ratios showed a far inferior transfection efficiency to
formulations without weak base. It is not known the cause of the present findings.
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Although it is difficult to determine how much weak base will be needed in order to
expect the ‘proton sponge’ effect, more weak bases may well induce an improved acid
buffering ability in the endosome. For example, as high as 75% (w/w) of imidazole was
conjugated to PLL and the formulation showed a significant improvement in transfection
efficiency (Putnam et al. 2001). Unfortunately, the maximum amount of weak bases that can
be incorporated in the present nanogel was 25% (w/w) because the higher concentration of
weak base caused phase separation of microemulsion. The amount of weak base in the
present nanogel formulations might be thus suboptimal. Alternatively, the buffering ability of
weak base incorporated in the nanogel might not have contributed to the improvement of the
gene expression, as indicated by a minimal correlation between buffering capacity of
imidazole-containing polymer and gene expression (Kulkarni et al. 2005). The present study
also raised a question about the role of pH buffering in the endocytosis and gene delivery.
With a larger excess of positive charges in the nanogel-pDNA complexes, non-
specific bindings (i.e., electrostatic interaction between cationic nanogel and anionic cell
surface) appeared to override a specific receptor-ligand binding. Nanogel formulations in this
category showed reduced or almost no targeting effects as represented in the formulation
with N/P ratio 10 (K and L in Figure 4-11). According to the present study, the optimal
formulation would be a cleavable (i.e., disulfide-containing), targeted nanogel with the net
charge of close to the neutral. Even though some improved transfection was observed in
lower N/P ratio formulation, weak base may not be a necessary element under present
condition. With certain type of targeting ligand such as folate in the formulation, it may
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trigger cytosolic translocation of genes or gene-carrier complexes following the endocytic
cellular entry by ambiguous mechanism(s) (Turek et al. 1993).
The overall inferior ability of nanogel formulation could be also caused by poor
pDNA stability in the formulations. Although gel retardation data (Figure 4-8) demonstrated
that majority of pDNA remained bound to the nanogel at certain N/P ratios and pDNA was
expected to be intact in this condition, the stability of pDNA in the cellular system was not
verified in this study. Compared to the status in the commercial transfecting reagents, pDNA
in the nanogel system could be more vulnerable to the given cellular environment. A further
uncertainty is associated with nuclear entry. Once released into the cytosol, the transfecting
pDNA must enter the nucleus to be transcribed. The double membrane structure surrounding
nucleus contains an octagonal opening, known as nuclear pore complex, that allow the
transport of water-soluble molecules across the nuclear envelope. The functional diameter of
this complex is known to be approximately 25 nm (Fahrenkrog and Aebi 2003). This narrow
opening is expected to limit nuclear transport of pDNA. There is some indication that PEI
has an ability to facilitate pDNA translocation into the nucleus in addition to its proposed
buffering capacity (Pollard et al. 1998). Although the present study started with an
assumption that endosome-to-cytosol translocation of polyplex would be a critical obstacle in
transfection, the observation made with nanogels here may highlight the necessity of
additional strategic modification to attain nuclear entry. The efforts to increase nuclear
import include a coupling of peptides containing nuclear localization sequences to pDNA.
Electrostatic interactions or peptide nucleic acid-mediated hybridization has been involved in
the coupling strategies (Branden et al. 1999; Subramanian et al. 1999). Taken together, the
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different ability in transporting pDNA into the nucleus might have resulted in a significant
difference in transfection efficiency between nanogel formulations and the commercially
available transfecting reagents such as PEI.
4.4 Conclusions
The present study was an extension of promising results shown in the previous
literature that demonstrated surface modification using PEG-folate conjugates to gene vectors
led to selective gene expression in folate-expressing cells in vitro (Lee and Low 1994; Guo
and Lee 1999; Leamon et al. 1999; Reddy et al. 1999). Although the overall transfection
efficiency of the test formulations did not surpass commercial transfecting reagents, the
present investigation highlights several factors for the optimal gene carrier formulations to
possess. First, the incorporation of cleavable linker to the carrier matrix can facilitate gene
release from the carrier. The present findings with disulfide crosslinker-containing nanogels
thus support the early investigation by McKenzie et al. (2000). They reported that
substitution of some lysine residues by cysteine increased the gene transfer efficiency of the
PLL polyplex. These observations strongly indicate that pDNA release is triggered by the
intracellular reduction of disulfide bonds. Secondly, the conjugation of targeting ligand
improves gene expression via selective and specific binding to the cell. Lastly but not in the
least, the net charge of the overall polyplex should be close to neutral to achieve a specific
ligand-receptor binding in transfection. That is, targeting capacity of the ligand-coated carrier
can overcome non-specific binding only when the electrostatic attraction is minimal.
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Figure 4-1: Synthetic scheme of PEG-based, acrylate-containing monomer. The overall
scheme consists of three parts, activation of folate with N-hydroxysuccinimide, coupling
with PEG bisamine, and acylation with acryloyl chloride. Numbers in the squares
represent stoichiometry of the respective reaction. Byproducts, dicyclohexylurea, 6 from
activation and N-hydroxysuccinimide, 9 from coupling reaction were also shown in the
figure. Detailed reaction conditions are described in Materials and Methods.
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Figure 4-2: 1H-NMR (300 MHz) spectra of folate (A) and N-hydroxysuccinimide-
activated folate (B) dissolved in DMSO-d6. Characteristic peaks in folate (g and f) were
monitored to identify folate moiety in the present and the subsequent synthesis. The
number of succinimide moiety in the activated folate (B) was not well established in the
present study but assumed to be two per one molecule of the product (compound 5 in
Figure 4-1) according to the integration.
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Figure 4-3: 1H-NMR (300 MHz) spectra of PEG-conjugated folate (A) and acrylate-
containing PEG-folate conjugate (B) dissolved in DMSO-d6. Appearance of new peak(s)
was monitored in the respective product: long carbon chain, m in A; and acrylate
protons, o, p and q in B.
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Figure 4-4: Spectrophotometric determination of the folate concentration in
nanogels. Nanogels were lyophilized overnight and reconstituted in 0.5 N-NaOH
followed by 20-min sonication prior to spectrophotometric measurement at 259
nm. The measured concentration of folate in the nanogel, 21 µM, was found to
agree well with the anticipated concentration, 26 µM.
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Figure 4-5: Schematic illustration of pDNA complex with strategically-designed
nanogel. The typical weight percent of each component in the nanogel was 10%,
25%, and 3 % for disulfide crosslinker, weak base, and folate ligand,
respectively. Nanogel was complexed with pCMV-Luc with positive-to-negative
charge ratio (N/P ratio) 2, 4, or 10.
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Figure 4-6: Transfection of KB cells with pDNA-nanogel complex. Cationic nanogel (0.1
mg) was complexed with 1 µg of pDNA at two different N/P ratios and the complex was
treated to 5 x 104 KB cells per well in 24-well plate. Transfection was continued for 4 hrs.
Subsequently the formulation-containing medium was replaced with fresh media and cells
were further incubated for additional 44 hrs before luciferase assay. Data was represented
as log (upper panel) or normal (lower panel) scale of gene expression in Y-axis versus
test formulations in X-axis. Test groups in graphs A and B are represented as follows: A,
pDNA alone; B, D, F, H, J, and L, disulfide crosslinked nanogel; C, E, G, I, K, and M,
non-cleavable crosslinker containing nanogel; B, C, H, and I, imidazole-containing
nanogel; D, E, J, and K, dimethylamine-containing nanogel; F, G, L, and M, nanogels
without weak base; N, Lipofectamine 2000; and O and P, PEI of 25 kDa at N/P ratio 4
and 10, respectively.
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Figure 4-7: Agarose gel electrophoresis run with nanogel-pDNA complex in the
presence of dithiothreitol. Cationic nanogel containing cleavable crosslinker (lane
C-I) or non-cleavable crosslinker (lane J-N) was complexed with pDNA at N/P
ratio 10 (right panel) or 4 (left panel) and incubated for 3 hrs at 37oC in the
presence of varying concentration of dithiothreitol. The concentrations of
dithiothreitol were 0 (lane C and J), 0.01 (lane D), 0.05 (lane E), 0.2 (lane F and
L), 1 (lane G and L), 2 (lane H and M), and 10 (lane I and N) mM. Control pDNA
in the absence (lane B) or in the presence of 10 mM dithiothreitol (lane O) and 1
kbp molecular weight ladder (lane A) were also loaded as references.
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Figure 4-8: Gel retardation study with nanogel-pDNA complex at
various N/P ratios. Cationic nanogel was complexed with pDNA at
different N/P ratios (i.e., positive to negative charge ratio: 0 to 40)
and the complex was loaded on 0.8% agarose gel. Electrophoresis
was conducted at 90 volts for 45 min at room temperature.
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Figure 4-9: Size of nanogels in various compositions (A) and nanogel-
pDNA complexes at different N/P ratios (B). [A] Size of nanogel at 2-4
mg/mL in water was measured in NICOMP for 15 min at room
temperature. Nanogel contained disulfide crosslinker (SSXL) or regular
non-cleavable crosslinker (XL) along with imidazole (IPAA) or
dimethylamine (DMAEA) moiety. The dotted line represents typical size
of polymerized nanogel, 80 nm. [B] Into 0.5 mg nanogel in 0.5 mL water, 5
µg of pDNA water solution (5 µL) was added to form the complex.
Following a brief vortex, the complex was loaded on the NICOMP for size
measurement with channel width of 15 µsec.
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Figure 4-10: Transfection of KB cells with nanogel-pDNA complex in
Opti-MEM (upper panel) or in the presence of serum (lower panel).
Cationic nanogel (0.1 mg) was complexed with 3 µg of pDNA at N/P ratio
4 and the complex was fed to 5 x 104 KB cells per well in 24-well plate.
Transfection was continued for 4 hrs. Formulation-containing medium was
then replaced with fresh media and cells were further incubated for
additional 44 hrs before luciferase assay. Data were represented as gene
expression (relative light unit, RLU) normalized by protein amount in Y-
axis versus test formulations in X-axis. Test groups in graphs A and B are
represented as follows: A, pDNA alone; B and D, disulfide crosslinked
nanogel; C and E, non-cleavable crosslinker containing nanogel; B and C,
dimethylamine-containing nanogel; D and E, nanogels without weak base;
F, Lipofectamine 2000; and G and H, PEI of 25 kDa at N/P ratio 4 and
10, respectively.
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Figure 4-11: Summary of transfection studies with various nanogel-pDNA complexes
in KB cells. Cationic nanogel was complexed with pDNA at different N/P ratios and the
complex was treated to 5 x 104 KB cells per well in 24-well plate. Transfection scheme
for the respective experiment was described in Figures 4-6 and 4-10. Gene expression
was measured using luciferase assay and normalized by the amount of pDNA (i.e., 1
µg). Data was represented as fold increase in gene expression compared to pDNA alone
in Y-axis versus test formulations with various N/P ratios in X-axis. Test groups are
represented as follows: A, C, E, G, I, K, M, and O, disulfide crosslinked nanogel; B, D,
F, H, J, L, N, and P, non-cleavable crosslinker containing nanogel; A, B, E, F, I, J, M,
and N, dimethylamine-containing nanogel; and C, D, G, H, K, L, O, and P, nanogel
without weak base. In M-P, transfection was performed in the presence of 5 % serum
containing media.
166
4.5 References
Anderson R.G., Brown M.S., Beisiegel U. and Goldstein J.L. (1982). "Surface distribution
and recycling of the low density lipoprotein receptor as visualized with antireceptor
antibodies." J Cell Biol 93 (3): 523-31.
Anderson R.G. and Jacobson K. (2002). "A role for lipid shells in targeting proteins to
caveolae, rafts, and other lipid domains." Science 296 (5574): 1821-5.
Anderson R.G., Kamen B.A., Rothberg K.G. and Lacey S.W. (1992). "Potocytosis:
sequestration and transport of small molecules by caveolae." Science 255 (5043):
410-1.
Antony A.C. (1996). "Folate receptors." Annu Rev Nutr 16: 501-21.
Arap W., Pasqualini R. and Ruoslahti E. (1998). "Cancer treatment by targeted drug delivery
to tumor vasculature in a mouse model." Science 279 (5349): 377-80.
Atkinson S.F., Bettinger T., Seymour L.W., Behr J.P. and Ward C.M. (2001). "Conjugation
of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties
of the toxin and permits targeting to folate receptor positive cells." J Biol Chem 276
(30): 27930-5.
Bellocq N.C., Pun S.H., Jensen G.S. and Davis M.E. (2003). "Transferrin-containing,
cyclodextrin polymer-based particles for tumor-targeted gene delivery." Bioconjug
Chem 14 (6): 1122-32.
Benns J.M., Choi J.S., Mahato R.I., Park J.S. and Kim S.W. (2000). "pH-sensitive cationic
polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) comb
shaped polymer." Bioconjug Chem 11 (5): 637-45.
Benns J.M. and Kim S.W. (2000). "Tailoring new gene delivery designs for specific targets."
J Drug Target 8 (1): 1-12.
Berg T., Blomhoff R., Naess L., Tolleshaug H. and Drevon C.A. (1983). "Monensin inhibits
receptor-mediated endocytosis of asialoglycoproteins in rat hepatocytes." Exp Cell
Res 148 (2): 319-30.
Boussif O., Lezoualc'h F., Zanta M.A., Mergny M.D., Scherman D., Demeneix B. and Behr
J.P. (1995). "A versatile vector for gene and oligonucleotide transfer into cells in
culture and in vivo: polyethylenimine." Proc Natl Acad Sci U S A 92 (16): 7297-301.
Branden L.J., Mohamed A.J. and Smith C.I. (1999). "A peptide nucleic acid-nuclear
localization signal fusion that mediates nuclear transport of DNA." Nat Biotechnol
17 (8): 784-7.
167
Bretscher M.S. and Pearse B.M. (1984). "Coated pits in action." Cell 38 (1): 3-4.
Bruckheimer E., Harvie P., Orthel J., Dutzar B., Furstoss K., Mebel E., Anklesaria P. and
Paul R. (2004). "In vivo efficacy of folate-targeted lipid-protamine-DNA (LPD-PEG-
Folate) complexes in an immunocompetent syngeneic model for breast
adenocarcinoma." Cancer Gene Ther 11 (2): 128-34.
Carpenter G. and Cohen S. (1979). "Epidermal growth factor." Annu Rev Biochem 48: 193-
216.
Fahrenkrog B. and Aebi U. (2003). "The nuclear pore complex: nucleocytoplasmic transport
and beyond." Nat Rev Mol Cell Biol 4 (10): 757-66.
Faraasen S., Voros J., Csucs G., Textor M., Merkle H.P. and Walter E. (2003). "Ligand-
specific targeting of microspheres to phagocytes by surface modification with poly(L-
lysine)-grafted poly(ethylene glycol) conjugate." Pharm Res 20 (2): 237-46.
Gao X., Cui Y., Levenson R.M., Chung L.W. and Nie S. (2004). "In vivo cancer targeting
and imaging with semiconductor quantum dots." Nat Biotechnol 22 (8): 969-76.
Garin-Chesa P., Campbell I., Saigo P.E., Lewis J.L., Jr., Old L.J. and Rettig W.J. (1993).
"Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in
immunopathology and molecular identification as a folate-binding protein." Am J
Pathol 142 (2): 557-67.
Goldstein J.L. and Brown M.S. (1974). "Binding and degradation of low density lipoproteins
by cultured human fibroblasts. Comparison of cells from a normal subject and from a
patient with homozygous familial hypercholesterolemia." J Biol Chem 249 (16):
5153-62.
Guo W. and Lee R.L. (1999). "Receptor-targeted gene delivery via folate-conjugated
polyethylenimine." AAPS PharmSci 1 (4): E19.
Hattori Y. and Maitani Y. (2005). "Folate-linked lipid-based nanoparticle for targeted gene
delivery." Curr Drug Deliv 2 (3): 243-52.
Hilgenbrink A.R. and Low P.S. (2005). "Folate receptor-mediated drug targeting: from
therapeutics to diagnostics." J Pharm Sci 94 (10): 2135-46.
Hofland H.E., Masson C., Iginla S., Osetinsky I., Reddy J.A., Leamon C.P., Scherman D.,
Bessodes M. and Wils P. (2002). "Folate-targeted gene transfer in vivo." Mol Ther 5
(6): 739-44.
Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R. and Cheresh D.A.
(2002). "Tumor regression by targeted gene delivery to the neovasculature." Science
296 (5577): 2404-7.
168
Hopkins C.R. (1985). "The appearance and internalization of transferrin receptors at the
margins of spreading human tumor cells." Cell 40 (1): 199-208.
Juillerat-Jeanneret L. and Schmitt F. (2006). "Chemical modification of therapeutic drugs or
drug vector systems to achieve targeted therapy: Looking for the grail." Med Res
Rev??? (???): ???
Kamen B.A. and Capdevila A. (1986). "Receptor-mediated folate accumulation is regulated
by the cellular folate content." Proc Natl Acad Sci U S A 83 (16): 5983-7.
Kelemen L.E. (2006). "The role of folate receptor alpha in cancer development, progression
and treatment: cause, consequence or innocent bystander?" Int J Cancer 119 (2):
243-50.
Kosower N.S. and Kosower E.M. (1978). "The glutathione status of cells." Int Rev Cytol 54:
109-60.
Kukowska-Latallo J.F., Candido K.A., Cao Z., Nigavekar S.S., Majoros I.J., Thomas T.P.,
Balogh L.P., Khan M.K. and Baker J.R., Jr. (2005). "Nanoparticle targeting of
anticancer drug improves therapeutic response in animal model of human epithelial
cancer." Cancer Res 65 (12): 5317-24.
Kulkarni R.P., Mishra S., Fraser S.E. and Davis M.E. (2005). "Single cell kinetics of
intracellular, nonviral, nucleic acid delivery vehicle acidification and trafficking."
Bioconjug Chem 16 (4): 986-94.
Leamon C.P., Cooper S.R. and Hardee G.E. (2003). "Folate-liposome-mediated antisense
oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivo."
Bioconjug Chem 14 (4): 738-47.
Leamon C.P. and Low P.S. (1991). "Delivery of macromolecules into living cells: a method
that exploits folate receptor endocytosis." Proc Natl Acad Sci U S A 88 (13): 5572-6.
Leamon C.P., Weigl D. and Hendren R.W. (1999). "Folate copolymer-mediated transfection
of cultured cells." Bioconjug Chem 10 (6): 947-57.
Lee R.J. and Huang L. (1996). "Folate-targeted, anionic liposome-entrapped polylysine-
condensed DNA for tumor cell-specific gene transfer." J Biol Chem 271 (14): 8481-7.
Lee R.J. and Low P.S. (1994). "Delivery of liposomes into cultured KB cells via folate
receptor-mediated endocytosis." J Biol Chem 269 (5): 3198-204.
Lee R.J., Wang S. and Low P.S. (1996). "Measurement of endosome pH following folate
receptor-mediated endocytosis." Biochim Biophys Acta 1312 (3): 237-42.
Leong K.W., Mao H.Q., Truong-Le V.L., Roy K., Walsh S.M. and August J.T. (1998).
"DNA-polycation nanospheres as non-viral gene delivery vehicles." J Control
Release 53 (1-3): 183-93.
169
Li S., Deshmukh H.M. and Huang L. (1998). "Folate-mediated targeting of antisense
oligodeoxynucleotides to ovarian cancer cells." Pharm Res 15 (10): 1540-5.
Lu Z.R., Shiah J.G., Sakuma S., Kopeckova P. and Kopecek J. (2002). "Design of novel
bioconjugates for targeted drug delivery." J Control Release 78 (1-3): 165-73.
Mayor S., Rothberg K.G. and Maxfield F.R. (1994). "Sequestration of GPI-anchored proteins
in caveolae triggered by cross-linking." Science 264 (5167): 1948-51.
McKenzie D.L., Kwok K.Y. and Rice K.G. (2000). "A potent new class of reductively
activated peptide gene delivery agents." J Biol Chem 275 (14): 9970-7.
Midoux P. and Monsigny M. (1999). "Efficient gene transfer by histidylated
polylysine/pDNA complexes." Bioconjug Chem 10 (3): 406-11.
Mineo C. and Anderson R.G. (2001). "Potocytosis. Robert Feulgen Lecture." Histochem
Cell Biol 116 (2): 109-18.
Nakashima-Matsushita N., Homma T., Yu S., Matsuda T., Sunahara N., Nakamura T.,
Tsukano M., Ratnam M. and Matsuyama T. (1999). "Selective expression of folate
receptor beta and its possible role in methotrexate transport in synovial macrophages
from patients with rheumatoid arthritis." Arthritis Rheum 42 (8): 1609-16.
Nimjee S.M., Rusconi C.P. and Sullenger B.A. (2005). "Aptamers: an emerging class of
therapeutics." Annu Rev Med 56: 555-83.
Pack D.W., Putnam D. and Langer R. (2000). "Design of imidazole-containing
endosomolytic biopolymers for gene delivery." Biotechnol Bioeng 67 (2): 217-23.
Pastan I.H. and Willingham M.C. (1981). "Journey to the center of the cell: role of the
receptosome." Science 214 (4520): 504-9.
Pollard H., Remy J.S., Loussouarn G., Demolombe S., Behr J.P. and Escande D. (1998).
"Polyethylenimine but not cationic lipids promotes transgene delivery to the nucleus
in mammalian cells." J Biol Chem 273 (13): 7507-11.
Prasad P.D., Ramamoorthy S., Moe A.J., Smith C.H., Leibach F.H. and Ganapathy V. (1994).
"Selective expression of the high-affinity isoform of the folate receptor (FR-alpha) in
the human placental syncytiotrophoblast and choriocarcinoma cells." Biochim
Biophys Acta 1223 (1): 71-5.
Putnam D., Gentry C.A., Pack D.W. and Langer R. (2001). "Polymer-based gene delivery
with low cytotoxicity by a unique balance of side-chain termini." Proc Natl Acad Sci
U S A 98 (3): 1200-5.
Raden D. and Gilmore R. (1998). "Signal recognition particle-dependent targeting of
ribosomes to the rough endoplasmic reticulum in the absence and presence of the
nascent polypeptide-associated complex." Mol Biol Cell 9 (1): 117-30.
170
Reddy J.A., Abburi C., Hofland H., Howard S.J., Vlahov I., Wils P. and Leamon C.P. (2002).
"Folate-targeted, cationic liposome-mediated gene transfer into disseminated
peritoneal tumors." Gene Ther 9 (22): 1542-50.
Reddy J.A., Dean D., Kennedy M.D. and Low P.S. (1999). "Optimization of folate-
conjugated liposomal vectors for folate receptor-mediated gene therapy." J Pharm
Sci 88 (11): 1112-8.
Reddy J.A. and Low P.S. (1998). "Folate-mediated targeting of therapeutic and imaging
agents to cancers." Crit Rev Ther Drug Carrier Syst 15 (6): 587-627.
Reddy J.A. and Low P.S. (2000). "Enhanced folate receptor mediated gene therapy using a
novel pH-sensitive lipid formulation." J Control Release 64 (1-3): 27-37.
Ross J.F., Chaudhuri P.K. and Ratnam M. (1994). "Differential regulation of folate receptor
isoforms in normal and malignant tissues in vivo and in established cell lines.
Physiologic and clinical implications." Cancer 73 (9): 2432-43.
Rothberg K.G., Ying Y.S., Kolhouse J.F., Kamen B.A. and Anderson R.G. (1990). "The
glycophospholipid-linked folate receptor internalizes folate without entering the
clathrin-coated pit endocytic pathway." J Cell Biol 110 (3): 637-49.
Sabharanjak S. and Mayor S. (2004). "Folate receptor endocytosis and trafficking." Adv
Drug Deliv Rev 56 (8): 1099-109.
Salazar M.D. and Ratnam M. (2007). "The folate receptor: what does it promise in tissue-
targeted therapeutics?" Cancer Metastasis Rev 26 (1): 141-52.
Sapra P. and Allen T.M. (2003). "Ligand-targeted liposomal anticancer drugs." Prog Lipid
Res 42 (5): 439-62.
Saul J.M., Annapragada A., Natarajan J.V. and Bellamkonda R.V. (2003). "Controlled
targeting of liposomal doxorubicin via the folate receptor in vitro." J Control Release
92 (1-2): 49-67.
Schachtschabel U., Pavlinkova G., Lou D. and Kohler H. (1996). "Antibody-mediated gene
delivery for B-cell lymphoma in vitro." Cancer Gene Ther 3 (6): 365-72.
Shen F., Ross J.F., Wang X. and Ratnam M. (1994). "Identification of a novel folate receptor,
a truncated receptor, and receptor type beta in hematopoietic cells: cDNA cloning,
expression, immunoreactivity, and tissue specificity." Biochemistry 33 (5): 1209-15.
Shimizu N., Chen J., Gamou S. and Takayanagi A. (1996). "Immunogene approach toward
cancer therapy using erythrocyte growth factor receptor-mediated gene delivery."
Cancer Gene Ther 3 (2): 113-20.
171
Subramanian A., Ranganathan P. and Diamond S.L. (1999). "Nuclear targeting peptide
scaffolds for lipofection of nondividing mammalian cells." Nat Biotechnol 17 (9):
873-7.
Sudimack J. and Lee R.J. (2000). "Targeted drug delivery via the folate receptor." Adv Drug
Deliv Rev 41 (2): 147-62.
Toffoli G., Cernigoi C., Russo A., Gallo A., Bagnoli M. and Boiocchi M. (1997).
"Overexpression of folate binding protein in ovarian cancers." Int J Cancer 74 (2):
193-8.
Turek J.J., Leamon C.P. and Low P.S. (1993). "Endocytosis of folate-protein conjugates:
ultrastructural localization in KB cells." J Cell Sci 106 ( Pt 1): 423-30.
Ullrich A., Bell J.R., Chen E.Y., Herrera R., Petruzzelli L.M., Dull T.J., Gray A., Coussens
L., Liao Y.C., Tsubokawa M. and et al. (1985). "Human insulin receptor and its
relationship to the tyrosine kinase family of oncogenes." Nature 313 (6005): 756-61.
Wang S., Lee R.J., Cauchon G., Gorenstein D.G. and Low P.S. (1995). "Delivery of
antisense oligodeoxyribonucleotides against the human epidermal growth factor
receptor into cultured KB cells with liposomes conjugated to folate via polyethylene
glycol." Proc Natl Acad Sci U S A 92 (8): 3318-22.
Wang S., Lee R.J., Mathias C.J., Green M.A. and Low P.S. (1996). "Synthesis, purification,
and tumor cell uptake of 67Ga-deferoxamine--folate, a potential radiopharmaceutical
for tumor imaging." Bioconjug Chem 7 (1): 56-62.
Wang S. and Low P.S. (1998). "Folate-mediated targeting of antineoplastic drugs, imaging
agents, and nucleic acids to cancer cells." J Control Release 53 (1-3): 39-48.
Weitman S.D., Frazier K.M. and Kamen B.A. (1994). "The folate receptor in central nervous
system malignancies of childhood." J Neurooncol 21 (2): 107-12.
Wu M., Gunning W. and Ratnam M. (1999). "Expression of folate receptor type alpha in
relation to cell type, malignancy, and differentiation in ovary, uterus, and cervix."
Cancer Epidemiol Biomarkers Prev 8 (9): 775-82.
Yang J., Chen H., Vlahov I.R., Cheng J.X. and Low P.S. (2007). "Characterization of the pH
of folate receptor-containing endosomes and the rate of hydrolysis of internalized
acid-labile folate-drug conjugates." J Pharmacol Exp Ther 321 (2): 462-8.
CAHPTER V
CONCLUSIONS AND FUTURE PROSPECTS
5.1 Summary of Conclusions
The present dissertation work describes a series of successive efforts to develop a
potent gene delivery system using the polymeric nanogel that was developed earlier by our
colleagues on this UNC campus (McAllister et al. 2002). The current study deals with the
modification of the nanogel with three specific goals. First, the addition of weak bases to the
nanogel imparts an acid buffering capacity for endosomal escape. Secondly, disulfide bonds
incorporated in the nanogel matrix should trigger site-specific degradation of the nanogel and
facilitate the release of pDNA from the nanogel polyplex. Lastly, the conjugation of folate as
a targeting ligand promotes the cell-specific binding of the nanogel polyplex to result in
enhanced transfection efficiency. All of these modifications were achieved by synthesizing
weak base-, disulfide-, and folate-containing monomers and preparing nanogels from those
monomers. The successful syntheses of the first two monomers were represented in Chapter
II. The weak base-containing nanogel showed buffering capacity around the pKa of the
incorporated base monomer. Interestingly, morpholine- and imidazole-containing nanogels
represented almost 2-fold higher buffer capacities at endosomal pH (~6) than PEI.
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A series of attempts were made to entrap pDNA inside the neutral nanogel. It is the
polarity of pDNA that makes this scenario feasible since pDNA expects to stay in aqueous
phase during the microemulsion formation and the subsequent polymerization. The final
nanogel formulation was intended to entrap pDNA inside the matrix without any electrostatic
interaction. Chapter III addresses two important issues in preparing pDNA-entrapped
nanogel formulation; 1) how stable pDNA would be under free-radical-initiated
polymerization, and 2) how much pDNA could be entrapped in the nanogel. It was
established that pDNA remained intact during polymerization when added at a relatively high
concentration. Pre-condensation of pDNA using protamine improved the entrapment
efficiency up to 56% of initially loaded pDNA. However, transfection efficiency of this
formulation was only modest. We attribute this to the minimal amount of pDNA entrapped in
the nanogel. We speculate that this was in turn caused by compromised microemulsion
system in the presence of methanol that was added to dissolve crosslinkers. It is also possible
that the energetic involved in pDNA association with the aqueous phase of a microemulsion
was not sufficient enough to bend and compact pDNA.
Chapter IV is concerned with complexing pDNA with pre-made cationic nanogel. In
this approach, the nanogel also expressed folic acid as a targeting ligand. It was synthesized
as a monomer and incorporated into the nanogel during polymerization. The overall
transfection efficiency using this formulation was inferior to those with commercial
transfecting reagents by 3-4 orders of magnitude. Nevertheless, this part of study led to the
following conclusions. First, targeting strategy will be needed for the cell-specific binding of
gene vectors. Second, the incorporation of a cleavable liker will be necessary even with the
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presence of targeting ligands. Most importantly, the present finding strongly implies that the
electrostatically neutral gene vector will be favored for the success of targeting strategy.
5.2 Future Prospects
Although only a minimal level of transfection was achieved by pDNA-entrapping
nanogel (Chapter III), entrapment of pDNA inside nanogel is still an attractive formulation.
Very low or almost no positive charges will be required in this formulation, which could
reduce vector-mediated cytotoxicity. By retaining pDNA inside, it could provide enhanced
protection from a premature degradation by nucleases when used in vivo. The hypothesis
behind this formulation was that the energetics involved in pDNA bendability could be
overcome by simply forming microemulsion as implied in Budker et al. (2002). However,
the aqueous phase in the present microemulsion system did not appear to provide energy
enough to condense pDNA. Accordingly, condensing reagents such as protamine had to be
added to ensure pDNA packing prior to the entrapment. Since a regular emulsion system
usually contains much larger amount of aqueous layer than does a microemulsion (i.e., 30%
vs. 3%), it could afford more energy to compact pDNA more efficiently.
Microemulsion is in essence a ternary phase system consisting of aqueous phase,
continuous phase, and interface. Equilibrium via a balanced weight ratio among these phases
is elemental to form a microemulsion, which could be disturbed by any additional
components. Although addition of a small amount of methanol and an increased amount of
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monomers did not affect the eventual nanogel formation significantly, reduced entrapment
efficiency and the subsequent instability of pDNA were observed. Better understanding of
the stability of the pDNA tertiary structure under this system will be required to achieve an
advanced pDNA-entrapping formulation.
One of the key findings in Chapter IV was that a high N/P ratio in pDNA-containing
complexes can diminish specific binding of the targeted formulation to the cell. The
importance of neutral charge of the vector formulation can be found in several other
investigations. Lee and Huang (1996) showed that transfection efficiency of folate-
containing liposome-polylysine (PLL)-DNA, so-called LPD, particle in KB cells is
significantly higher when the net charge of LPD particle was slightly positive or negative.
Too much cations or anions on the particles reduced gene expression. Interestingly, more
profound targeting effect was observed in the negatively charged particles. Dendrimer-
containing, targeted lipoplex system developed by Reddy and colleagues (1999) also showed
an effective transfection efficiency only when the lipoplex system was slightly cationic.
Anionic or additional positive charge containing systems represented significantly reduced
gene expression. Another noticeable observation from these studies is that zero charge on the
vector system will cause aggregation and reduce transfection efficiency. However, there is no
agreement on which charge in excess (i.e., slightly positive or slightly negative) will provide
better gene transfection. It appears to be dependent on the individual vector system.
Preparing virus-sized DNA particles without using any pre-made particulate system
has drawn a great deal of attention among many investigators (Blessing et al. 1998; Ouyang
et al. 2000). These approaches exploited the electrostatic interaction of cationic surfactants
toward pDNA and consequential pDNA collapse. Alternatively, Leamon and colleagues
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(1999) used PLL of 331 kDa modified with folate-PEG conjugate to form a condensed
pDNA particle and demonstrated a promising transfection capacity of the complex.
Integrating all of these previous findings and the knowledge learned from this
dissertation research, one can develop a following approach. First, use protamine as a
condensing reagent. Protamine has already been demonstrated to possess a superior
capability in condensing pDNA through multiple previous investigations including the
present dissertation work (see Chapter III and the references therein). Protamine can be
modified with pre-made folate-PEG conjugate (e.g., compound 8 in Figure 4-1) before
forming a complex with pDNA. Since protamine is exceptionally efficient in condensing
pDNA even with low N/P ratio (i.e., positive-to-negative charge ratio of less than one) and a
relatively small molecule (5.1 kDa), further modification such as disulfide incorporation may
be superfluous. An example of PEG modification of protamine can be found in Chang et al.
(2005). However, the effect of PEG modification on the DNA condensing capability of
protamine has not yet been determined. The success of this approach thus will be dependent
on the integrity of the condensing ability of the modified protamine. Also, the overall charge
of the final complex will need to be systemically monitored as an independent variable. This
part of the proposed study is an ongoing project conducted by Dr. David Gaul.
The size of gene vectors appears to play an important role in many aspects.
Extracellulary, it affects the blood circulation time, extravasation, and entry into target cells
(Stolnik et al. 1995; Ishida et al. 1999). Many investigators including Nakanishi and Noguchi
(2001) implied that there must be an optimal size range of particles for transfection efficiency.
However, the results reported by different authors are still somewhat contradictory. As
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shown in Figure 4-9A, the sizes of nanogels were different depending on the composition,
ranging from 60 to 180 nm. The changes in size are inevitable in preparing the nanogels of
different compositions. For this reason, any further investigation on the effect of nanogel size
on the transfection efficiency should not continue as an extension of the present dissertation
work. The discrepancy or the lack of agreement in the effect of size of gene vectors might
well be due to the heterogeneity within a conventional vector system and a variety of
compositions represented by different systems.
In this context, the PRINT (see Appendix I) technology could offer a valuable
opportunity to draw more conclusive results on the size effect of gene vectors. With a
relatively little amount of efforts on the optimization, PRINT particles can have a potential to
provide virtually homogeneous gene vector mimics especially in size. It is also possible to
have a series of particles in different sizes of broad spectrum while other independent
variables (e.g., compositions, charges, surface properties, and surface modification) remain
exactly the same. However, the difficult task would be how to accommodate all the
components into the PRINT particles that are required in overcoming the cellular barriers in
gene transfection discussed in Chapter I.
Unlike virus that has a full package of strategies to unravel various hurdles in
transporting its genetic information into the nucleus, current non-viral vectors do not or
cannot have such a multifunctional ability. From this realistic viewpoint alone, it would be
imperative to determine the rate-limiting steps in the overall transfection process. The task
would entail determining the actual amount of pDNA present in the endosome, the efficiency
of pDNA escaping into the cytosol, the cytosolic stability, the number of copies that reach to
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and translocate into the nucleus and the eventual transcription efficiency. There have been
several efforts to decipher the inside of the cellular trafficking. The methodology involves
confocal-image-assisted three dimensionally integrated quantification (Hama et al. 2006),
and cytoplasmic/nuclear microinjection of gene vectors (Pollard et al. 1998; Cornelis et al.
2002). Although elaborate experimental design is required, such strategically designed
experiments will provide an exact understanding of the actual relevance of each of the
intracellular barriers.
5.3 Concluding Remarks
One of the ideal structures of a gene vector would be an environment-reacting device,
simply as smart as the virus. Although numerous investigations in the past have accumulated
significant amounts of knowledge to improve gene vectors, the science of non-viral vectors is
still in its infancy. The present dissertation work started with several theories previously
addressed on the way of developing a novel gene vector. Efforts on the physically entrapping
of pDNA inside the nanogel matrix encountered multiple obstacles in the preparation. This
approach might have been too ambitious at this stage but the unsuccessful results left behind
many lessons. On the other hand pDNA-nanogel complex was also not able to surpass the
current ‘holy grail’ transfecting reagents such as PEI. Nevertheless, all the findings and every
piece of the information obtained from this dissertation work may broaden our knowledge on
this field and should be a part of the elaborate efforts to develop a new generation of vectors
for more efficient gene therapy.
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APPENDIX I
PHARMACOKINETICS AND BIODISTRIBUTION OF
PRINT PARTICLES IN MICE
A.1 Introduction
Biomedical applications of synthetic particles of submicron to micron size were
pioneered by the investigators in diagnostic field as exemplified by use of particulates in
gamma scintigraphy for lymphatics (Trubetskoy et al. 1996). Since the burst of
developmental activities with particulate drug carriers including emulsions in early 1980s,
intense research in drug delivery over the past few decades has witnessed the design and
construction of valuable nanocarriers such as liposomes, micelles, dendrimers, polymer
particles, and colloidal precipitates (Barenholz 2001; Torchilin 2004; Lee et al. 2005;
Moghimi et al. 2005; Vicent and Duncan 2006). However, the biomedical applications of the
fabricated particles are on hold mainly due to lack of basic understanding of the particle-host
interaction at both organ/tissue and (sub)cellular level as dictated by physicochemical
properties of the particles. As expected, these particles are considered as foreign by the host
when systemically administered. The clearance of colloidal particles from the blood
circulation has been reported to occur by phagocytes and/or endothelial cells, mainly in the
liver, the spleen, and the bone marrow as well as lung endothelia (e.g., Senior 1987; McLean
et al. 1997). The pharmacokinetic fate and relative distribution of the injected particles in
these organs are known to depend on various factors such as the size, surface properties of
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the particles, compositions and the type of serum proteins adsorbed onto the surface of
particles. Particle size has been reported to play a key role in blood clearance. For example,
microspheres with hydrodynamic radii of over 200 nm exhibited a more rapid rate of
clearance than particles with radii under 200 nm (Moghimi et al. 1993). The final
biodistribution is also affected by particle size. Particles having a diameter of below 150 nm
produced an increased uptake in the bone marrow of rabbits, whereas particles of 250 nm in
diameter were mostly sequestered in the spleen and liver with a reduced uptake by the bone
marrow (Porter et al. 1992). The difference in the uptake and biodistribution of particles
having different compositions may well imply the presence of opsonins that are specific to a
certain type of phagocyte. For instance, cholesterol-rich liposomes were found to be more
accumulated in spleen than liver probably due to the adsorption of opsonins specific to
splenic phagocytes instead of Kupffer cell-specific opsonins (Moghimi and Patel 1988).
When introduced directly to systemic circulation, these particles are rapidly cleared by
reticuloendothelial system (RES) (Breton et al. 1998) and significant reduction of RES
uptake of particles has been reported when particle surface is modified (e.g., PEGylation)
(Harper et al. 1991; Stolnik et al. 1994; Lacasse et al. 1998).
Poly(ethylene glycol) derivatives are known to impart biocompatibility, solubility,
stability, and increased circulation times to proteins, liposomes, and other synthetic particles
(Allen et al. 1995; Gregoriadis 1995; Papisov 1998; Torchilin 1998; Woodle 1998). PEG
chains larger than 2 kDa are required in order to expect a significant coating effect
(Kenworthy et al. 1995) by imposing a major steric pressure between particles and opsonins
(Jeon et al. 1991). This may well be due to the conformational flexibility of PEG chains and
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resulting polarity increase. The density of PEG chains on the surface of particles also
determines the success of steric stabilization since low surface chain density can lead to gaps
in the PEG protective layer where opsonins can freely bind to the particle surface while too
high surface coverage can restrict the motion of PEG chains and decrease the steric hindrance
properties of PEG layer (Storm et al. 1995). Closely related to this issue, a minimum
effective hydrodynamic layer thickness has been suggested to be around 5% of the particle’s
diameter (Stolnik et al. 1995). While use of larger molecular weight PEG was found to lead
to longer blood circulation for the particles in vivo, another general trend was that
PEGylation shifted the final biodistribution of particles toward the spleen over the liver
(Peracchia et al. 1999). Lastly, the effect of surface charges on in vivo pharmacokinetics and
biodistribution of particulates [e.g., poly (D, L-lactic-co-glycolic acid)] has also been
intensively explored by many investigators (e.g., Vinogradov et al. 2002; Torchilin and
Lukyanov 2003).
Synthetic particles as a drug carrier attract more attention from investigators in
various fields especially in delivering biochemically labile substances such as siRNA and
oligonucleotides since these sensitive cargos need to remain intact during the transition to the
target site. In many instances, the site of action is cytoplasm or nucleus in a specific cell type
in a given tissue or organ. Although the pharmacokinetic behaviors of particulate drug
carriers have been intensively investigated as exemplified with liposomes (Senior 1987),
most of these studies are dealing with relatively heterogeneous particulates in terms of size,
composition and shape. These particulates are also unstable in the blood. The incomplete
assessment of the pharmacokinetic profile and biodistribution of particulate drug carriers
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might lead to premature rejection of a viable new formulation entering the drug development
(Duncan 2003). Thus, a model particle system that possesses real homogeneity in size,
charge, surface property and stability could provide more reliable information on the
pharmacokinetic behavior and biodistribution of the respective systems.
New particle fabrication procedure, called PRINT (Particle Replication In Non-
wetting Templates), has been recently developed exploiting the low surface energy of novel
fluoropolymeric molds (Rolland et al. 2005). The molds are derived from liquid
perfluoropolyether precursors, which can be photochemically crosslinked at room
temperature. The resulting elastomeric solids enable high-resolution imprint lithography, a
technique found in the microelectronics field, to fabricate a variety of organic particles of
precisely defined size and shape. The preparation of particles using this technique requires
very mild processing conditions, which allow for labile cargos such as nucleic acids to be
loaded more readily. Since PRINT features precise control over size, shape, composition,
porosity, texture, and modulus of the particles through the judicious choice of a master
template, it provides a unique opportunity to investigate the pharmacokinetic fate and
biodistribution of a population of truly homogeneous particles with a variety of independent
variables that can be varied with ease. In this chapter, the first in vivo study of PRINT
particles is documented following i.v. bolus tail vein injection of fluorescently- or radio-
labeled PRINT particles into healthy mice.
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A.2 Materials and Methods
A.2.1 Materials
FluorocurTM, the perfluoropolyether used as the molding material in the PRINT
process, was purchased from Liquidia Technologies (Product # 2M-140). Silicon templates
used for PRINT processing were obtained from Benchmark Technologies.
Trimethylolpropane ethoxylate triacrylate (Mn = 428 g/mol) was purchased from Aldrich and
was passed through a short plug of alumina prior to use to remove inhibitor. Poly(ethylene
glycol) dimethyl ether (Mn = 550 g/mol) and 2,2-diethoxyacetophenone were purchased from
Aldrich and used as received. Poly(ethylene glycol) monomethyl ether monomethacrylate
(Mn = 1,000 g/mol) was purchased from Polysciences (Warrington, PA) and used as
received. Para-hydroxystyrene [10% (w/w) in propylene glycol] was purchased from Alfa
Aesar (Ward Hill, MA) and used as received without further purification. Fluorescein O-
acrylate, 5-(iodoacetamido) fluorescein, and PBS were purchased from Sigma. Dialysis
cassettes (3.5 kDa MWCO) and Iodogen® pre-coated tubes were purchased from Pierce
Biotechnology (Rockford, IL). Radioactive iodide (Na125I) was purchased from Perkin Elmer
Life and Analytical Sciences, Inc (Waltham, MA) as 100 mCi/mL in 10-5 M NaOH.
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, Maine).
Ketamine HCl (100 mg/mL) was purchased from Abbott Laboratories (Abbott Park, IL) and
diluted with equivalent volume of 1 X PBS before injection. All animal experiments were
conducted in accordance with guidelines set forth by The University of North Carolina at
Chapel Hill, and approval was obtained for the completion of these experiments.
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A.2.2 Preparation of PRINT Particles
A.2.2.1 Fluorescently-Labeled PRINT Particles
The fabrication of patterned FluorocurTM molds, a low surface energy
perfluoropolyether molds, has been described elsewhere (Rolland et al. 2005). Briefly,
20 mL of FluorocurTM resin containing 0.1% (w/w) of 2,2-diethoxyacetophenone was pooled
in the center of an 8 inch patterned master (with feature sizes of 200 nm) that was set up
inside an enclosed UV chamber. Ten minutes was allowed to pass so that the FluorocurTM
resin was spread out over the entire 8-inch wafer. The entire system was then purged with
nitrogen for 3 minutes. Following this, the coated wafer was exposed to UV irradiation ( =
365 nm, power > 20 mW/cm2) for 2 min to cure the FluorocurTM resin. The elastomeric mold
was then removed from the master template by gently peeling it away from the silicon
surface.
From the mold obtained above, PRINT particles were prepared by Dr. DeSimone’s
lab in UNC Chemistry Department. The preparative procedure described elsewhere (Gratton
et al. 2007) was slightly modified to incorporate fluorescent monomers. The composition of
PRINT particles were; 77% (w/w) PEG triacrylate (Mn = 428 g/mol), 20% PEG monomethyl
ether monomethacrylate (Mn = 1000 g/mol), 1% 2,2-diethoxyacetophenone, and 2%
fluorescein O-acrylate. A 10% (w/v) solution of this mixture in 2-propanol (filtered through a
0.22 µm PTFE filter) was prepared. This solution (1 mL) was then sprayed onto a
FluorocurTM patterned mold using an air brush and residual 2-propanol was allowed to
evaporate over 10 min. A poly(ethylene) sheet (American Plastics Company, Beltsville, MD)
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was then placed over the 8-inch (diameter) mold ensuring that the entire active area was
covered. This poly(ethylene) sheet was then peeled back at a rate of approximately
2.5 cm/min. Following this, the mold was placed in a UV curing chamber. The chamber was
purged with nitrogen for 3 min and UV irradiation was applied ( = 365 nm, power >
20 mW/cm2) for 2 min. To facilitate removal of the particles from the mold, a physical means
for harvesting the particles was utilized. Specifically, a 2 mL aliquot of acetone (filtered
through a 0.22 µm PTFE filter) was placed on the particle-filled mold and this drop of
acetone was gently moved along the surface of the mold using a slide glass. The movement
of the slide glass facilitated release of the particles from the mold.
The suspended particles were collected in a 50-mL Falcon tube and diluted to the 50-
mL mark with filtered acetone. The suspension was vortexed for 10 min and was centrifuged
at 2,500 x g for 30 min using IEC CENTRA CL2 Centrifuge (Thermo Electron Corporation,
Waltham, MA). The supernatant was removed via aspiration and the particle pellet was re-
dispersed in 50 mL of fresh acetone by vortexing for 10 min followed by centrifugation for
an additional 30 min. This process was repeated once again. After aspiration, the particles
were re-dispersed in 5 mL of distilled water by sonicating the dispersion for 15 min. The
particle dispersion was filtered through a 20-µm filter into a fresh 50-mL Falcon tube, and
diluted to the 50 mL mark with acetone. This particle suspension was then centrifuged for
one hour. The supernatant was removed via aspiration and the particle pellet was re-dispersed
in 50 mL of fresh acetone by vortexing for 10 min followed by centrifugation for an
additional 30 min. This process was repeated once again (with acetone) and after aspiration
the particles were re-dispersed in a minimal amount of acetone, transferred to a tarred
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Eppendorf tube, and centrifuged for 20 min. The supernatant was removed and the pellet was
dried in a vacuum oven overnight, massed, and dispersed in the appropriate amount of sterile
water to make a 10 mg/mL dispersion of particles.
For the study described below, four different sizes of cylinders with a diameter 0.2,
0.5, 1, or 7 µm were fabricated and one of the test groups (7 µm) was prepared to mimic
erythrocytes. Different porosities of 7 µm-particles were also manipulated by adding 50%
PEG dimethyl ether (Mn = 550 g/mol) as porogen during harvesting. Aspect ratio (i.e., ratio
of height to diameter) was 1.0 in all the particle groups except for 7 µm, in which it was 0.2.
A.2.2.2 Radiolabeled PRINT Particles
The generation, purification and harvesting of radiolabeled particles was conducted
similarly to the procedures used for fluorescently labeled particles mentioned above. But, the
composition was modified to incorporate phenol moieties on the particles. The PRINT
particles were derived from a mixture composed of 78% (w/w) PEG triacrylate, 20% PEG
monomethyl ether monomethacrylate, 1% 2,2-diethoxyacetophenone, and 1% p-hydroxy-
styrene (PHS).
A.2.3 Characterization of Fluorescently-Labeled PRINT Particles
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A.2.3.1 Stability of Fluorescein-Conjugated Particles in Liver Homogenate
PRINT particles (0.2 mg) of 0.2 or 2 µm were diluted in 0.3 mL PBS or liver
homogenate derived from a virgin mouse. The 2-µm particles used here were prepared in the
same manner as described above but not used for animal study. These samples were
introduced to a dialysis cassette of 3.5 kDa MWCO, which were then placed in a 100-mL
beaker containing 70 mL of PBS. Dialysis was performed at 37oC for 24 hrs. At specified
time points, 1 mL of diffusate was collected from outside of the cassette and replaced with 1
mL of fresh PBS. Fluorescence intensity was measured, after 1- to 5-fold dilution, on a
Perkin Elmer LS50B spectrofluorometer (Perkin Elmer Life and Analytical Sciences, Inc.,
Waltham, MA) using 495/520 nm for excitation/emission wavelength and a slit width of
15/20. As a positive control for dialysis setting, 5-(iodoacetamido) fluorescein of MW 515.3
was added to a separate dialysis cassette and monitored along with other test groups. Liver
homogenate alone was also incubated under the same condition and used for obtaining a
background value.
A.2.3.2 Kinetics of Fluorescence Intensity from Particles in NaOH
Into 0.4 mL of 1 N NaOH or distilled water, 100 µL of a particle stock solution in
water (0.1 mg/mL) was added and incubated at 37oC for a designated time (i.e., 0, 20, 40 min,
1.5, 6, 16, and 24 hrs). At each time point, 2 µL of reaction mixture was removed and subject
to fluorescence measurement using Nanodrop Model 3300 (NanoDrop Technologies,
Wilmington, DE) at 520 nm for emission.
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A.2.4 Pharmacokinetic and Biodistribution Studies of Fluorescently-Labeled PRINT
Particles
Female C57BL/6J mice were housed under specific pathogen-free conditions for one
week and were used at 8 weeks of age (~18 g). Animals were injected intravenously via
bolus tail vein administration with 0.32 mg of fluorescently-labeled PRINT particles in 100
µL of PBS At 10, 30 min, 1, 3, and 8 h after dosing, groups of four mice were anesthetized
by intraperitoneal injection of 100 µL of ketamineHCl solution in PBS (50 mg/mL). Blood
was collected via cardiac puncture and serum was separated by centrifugation (Eppendorf
Centrifuge 5415D) at 12,000 x g for 10 min at 4°C. Organs and tissues harvested (liver,
kidneys, spleen, lungs, and heart) were weighed, homogenized (Power Gen 700, Fisher
Scientific) and centrifuged (Beckman GS-6R, Fullerton, CA) at 250 x g for 5 min. Serum and
supernatant from organs/tissues were collected into a 2-mL polypropylene microcentrifuge
tube (Fisher Scientific) and 0.1 mL of each sample was added into the mixture of 0.39 mL of
1 N NaOH and 0.01 mL of 5% deoxycholic acid. The mixture was then incubated at 37oC
water bath (Fisher Scientific) for 24 hrs before analysis. Fluorescence intensity was measured
by loading 2 µL of hydrolyzed sample on Nanodrop Model 3300 (NanoDrop Technologies,
Wilmington, DE) at 520 nm.
To convert relative fluorescence intensity into actual amount of particles, a calibration
curve was prepared in each organ/tissue for all the particle test groups with different sizes by
adding a series of known amounts of fluorescently-labeled particles into constant weight of
organs or tissues. After thorough homogenization, supernatant was separated, hydrolyzed as
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mentioned above, and subject to fluorescence measurement. In case of blood samples,
standard particles were added to constant volume of blood aliquots followed by serum
separation. After hydrolyzed in the same manner as in organ samples, serum was subject to
fluorescence measurement to obtain a calibration curve.
A.2.5 Iodination of PRINT Particles
PRINT particles were prepared similarly to fluorescently labeled particles. The
monomer composition was 78% PEG428 triacrylate, 20% PEG1000 monomethoxymethacrylate,
1% p-hydroxystyrene, and 1% 2,2-diethoxyacetophenone (w/w). Into an Iodogen® pre-
coated tube, 10 mg of particles suspended in 1 mL of water was added. Each tube contained
50 µg of Iodogen as an oxidizing agent. PBS (10 X) was added to the tube in such a way the
final concentration of PBS in the reaction was 0.5 X. It was then followed by the addition of
10 µL (1 mCi) of Na125I at 100 mCi/mL in 10-5 M NaOH (pH 8-11). Iodogen oxidizes iodine
to iodous ion that is a good electrophile and chemically attached to the ortho position of
phenyl moiety on the particles. The reaction was allowed to proceed for 15 min at room
temperature while swirling the tube gently every 1 min for 30 sec. After 15 min, the reaction
mixture was transferred to a clean pre-weighed 2-mL microcentrifuge tube to stop the
reaction. For safety, KI was added to the microcentrifuge tube to a final concentration of 1
mM. The original reaction tube was rinsed with 100 µL of water twice and both washes were
combined into the microcentrifuge tube containing the reaction mixture. As a reducing agent,
1 µmol of NaHSO3 was added and vortex-mixed.
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The reaction mixture was centrifuged for 10 min at 15,000 x g using a
microcentrifuge (Eppendorf, Westbury, NY) at room temperature. Supernatant was removed
and 500 µL of fresh distilled water was added to the particles for wash. Washing step was
repeated until CPM measured by a hand-held radioactivity counter Model Monitor 4/4EC (S.
E. International, Inc., Summertown, TN) in the supernatant reached baseline value or plateau
(~ 200 CPM). Supernatant was removed and the pellet was dried using a Speed-Vac (Savant
SC 110, Global Medical Instrumentation, Inc, Ramsey, MN) for 20 min. The tube containing
dried particles was weighed to get the net weight of labeled particles. Particles were re-
dispersed in 500 µL of freshly distilled water. This served as a stock solution for specific
activity measurement and animal injection. Specific activity was determined by putting 3 µL
of purified particles suspended in water to a 12 x 75 mm glass tube (Fisher Scientific) and
reading radioactivity in a gamma counter (Beckman Gamma 5500B, Beckman, Fullerton,
CA). The specific activity, calculated from the CPM measured and the mass of particles
remained as pellet, was 1.23 x 107 CPM/mg of particles.
A.2.6 Pharmacokinetic and Biodistribution Studies of Radiolabeled PRINT Particles
Female C57BL/6J mice were housed under specific pathogen-free conditions for one
week and were used at 8 weeks of age (~18 g). Animals were injected intravenously via tail
vein at a dose of 0.32 mg of [125I]-labeled PRINT particles with a specific activity of
1.4 µCi/mg in 100 µL of PBS. At 10, 30 min, 1, 3, and 8 h after dosing, groups of four mice
were anesthetized by intraperitoneal injection of 100 µL of ketamine HCl solution in PBS
(50 mg/mL). Blood was collected via cardiac puncture and subject to for radioactivity
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measurement as whole blood. Samples of blood and tissues harvested (liver, kidneys, spleen,
lung, heart, femur bone marrow, thyroid and whole tail) were weighed and analyzed for the
total radioactivity in a Beckman Gamma 5500B gamma counter (Beckman, Fullerton, CA).
Additional four animals were kept in a metabolic cage after injection of the [125I]-labeled
PRINT nanoparticles. At 24 h post-injection, urine and feces accumulated were collected for
radioactivity measurements without any further treatment.
After animals were sacrificed the blood as well as the organs were removed, weighed,
and analyzed for radioactivity. Fat (perirenal site), muscle (right or left leg thigh), head, legs,
intestines, and the remainder of the body were also analyzed for additional radioactivity. For
data presentation, % ID (injected dose) was calculated and presented for each organs or
tissues collected. Elemental pharmacokinetic parameters in blood were attained by fitting
data to two-compartment model using WinNonlin 5.0.1 (Pharsight Corporation, Mountain
View, CA).
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A.3 Results and Discussion
A.3.1 Characterization of Fluorescently-Labeled PRINT Particles
As shown in Figure A-1, particles prepared from FluorocurTM mold were all
cylindrical with an aspect ratio of 1 or 0.2 (only for 7 µm particles). Scanning electron
microscopy performed in dried particles and dynamic light scattering of particles dispersed in
PBS showed that the actual sizes were smaller, especially in the height than anticipated
(Table A-1). Scanning electron microscopy measurement was closer to the size of master
template than that of DLS. The diameter of mice erythrocytes (6.6-6.7 µm) is known to be a
bit smaller than that (> 7 µm) of rats or monkeys (Gregory 2000). The size of erythrocyte
mimics (i.e., 7 µm non-porogen) tested in this study turned out to be very close to that of
mouse cells. PEG dimethyl ether (Mn = 550 g/mol) was added to another set of 7 µm
particles to see how the addition of porosity affects on the bioenvironmental behavior of
erythrocyte mimics. Unfortunately, the diameter of porogen-containing particles (~ 5 µm)
was significantly smaller that that (~ 6.3 µm) of non-porogen counterpart. The difference in
size as well as in porosity of erythrocyte mimics might change the response of the body that
encountered those particles following systemic administration.
Prior to the main PK study of fluorescently labeled PRINT particles, the stability of
fluorescent label was established in PBS as well as liver homogenate. This is important since
the label is to serve as a probe of particles in vivo. Liver was selected for this test because it
is abundant in enzymes (Imai 2006) and is an organ where foreign particulates are expected
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to accumulate. Figure A-2A shows that no fluorescence was detected outside the dialysis bag
(3.5 kDa MWCO) that contained fluorescein-PRINT particles of 2 µm in PBS up to 22 hrs at
37oC. Fluorescence intensity measured outside the dialysis bag gradually increased when
particles (200 nm or 2 µm) were incubated with liver homogenate. This is attributed to
leakage of liver component as the background value from liver homogenate alone was also
increased in similar manner. A small MW (515 g/mol) fluorescent molecule, 5-
(iodoacetamido) fluorescein, was incubated with liver homogenate and served as positive
control group. As expected, rapid increase of fluorescence intensity was observed. When
fluorescence intensities were measured inside of dialysis bags containing fluorescein-
particles in PBS or liver homogenate at 22 hrs of incubation at 37oC, no significant loss of
intensity was observed while only 5% of initial fluorescence intensity remained in the bag
containing 5-(iodoacetamido) fluorescein (Figure A-2B). Taken together, these data clearly
support that the linkage between fluorescein molecule and PRINT particle remains intact in
the presence of liver enzymes at least during the tested period of time.
Self-quenching of fluorescein and other xanthene-type dyes is due to homo resonance
energy transfer (HRET) between fluorescein molecules and has been studied by many
investigators (e.g., Lakowicz et al. 2003). The so-called Forster distance for HRET is about
4.2 nm (Kawski 1983). Thus HRET is expected to occur when a particle contains more than a
single fluorescein molecule and the distance between the fluorophores is smaller than 4.2 nm.
The overall net result will be decreased intensities with increasing labeling density. If each
molecule of fluorescein can be released (i.e., by hydrolysis of ester bonds) from the particle
in the tissue samples after collection, the intensity would increase and the analytical
196
sensitivity gets higher. As shown in Figure A-3, when serum and organ homogenate
containing PRINT particles are incubated with NaOH in the presence of deoxycholic acid,
the particle could be degraded, releasing fluorescein molecules. To optimize the incubation
time of hydrolysis, PRINT particles of various sizes were incubated at 37oC with 1 N NaOH
until the fluorescence intensity leveled off (Figure A-4). In all cases, fluorescence intensity
in the NaOH-treated particles significantly increased compared to their counterparts in water
and reached a plateau by 24 hrs of incubation (Figure A-4).
However, the maximum intensity observed was not identical among particles of
different sizes; highest in 7 µm porogen particles and lowest in 7 µm non-porogen. It is likely
due to the fact that porogen particle is associated with high porosity that would facilitate
more extensive hydrolysis. This interpretation is consistent with the finding that 200-nm
particle featuring a high surface area-to-volume ratio also showed a high intensity (i.e., the
ratio is 6.25- and 25-fold larger than that of 500-nm and 1-µm particles, respectively). There
was, however, a discrepancy between the actual rank order of maximum intensity and the
theoretical expectation in 500-nm and 1-µm particles. No explanation is offered for this
finding at present.
A.3.2 Pharmacokinetic and Biodistribution Studies of Fluorescently-Labeled PRINT
Particles
Upon IV injection, 200-nm and 500-nm particles stayed in the circulation fairly well
up to 8 hrs in contrast to 500-nm particles (Figure A-5 and A-6A). No measurable amount
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of 1-µm particles was found in the blood throughout the study period while rapid
accumulation was observed in organs such as liver and spleen. In some instances a
significant amount of injected dose could have been retained in the injection site (i.e., tail),
verified in a subsequent experiment (see more later). The total recovery of 1-µm particles at
10 and 30 min was quite low (~ 15-20%) while it was respectably 40 to 90% at later time
points (Figure A-7), supporting the speculation. As shown in Figure A-7, the total recovery
(~ 15-60%) with 7-µm particles fluctuated with time but was rarely close to 100%. These
recoveries may also reflect those retained in the injection site on the tail. Indeed there has
been some concern about injected compounds remaining in the tail with high probability
(Groman and Reinhardt 2004). Unfortunately, evaluation of particle retention in the tail was
not determined in particular series of study. However, it was measured with radiolabeled
particles. It is discussed in section A.3.3.
The life span of red blood cells was reported to be approximately 40 days in mice
(Van Putten and Croon 1958), which is shorter than in rats (~ 60 days) or in human (~ 120
days, Shemin and Rittenberg 1946). The rapid disappearance of 7-µm, erythrocyte-
mimicking particles observed here clearly indicate an ample room for improvement.
Nonetheless it is most interesting to note that as much as 10-20% of 7-µm porogen particles
(Figure A-5E) remained in the blood up to 3 hrs while 7-µm regular particles (Figure A-5D)
disappeared rapidly within 30 min. Effect of particle density and elasticity implied with the
observation warrants further investigation.
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For 200-nm, 500-nm and 1-µm particles (Figure A-5A-C and Figure A-6B and D),
the main organs of accumulation were liver and spleen. An earlier indication that blood
vessel capillaries have organ-related differences has been verified with transmission electron
microscopy in the 1950s (e.g., Bennett et al. 1959). These studies identified three general
types of capillaries; continuous, fenestrated, and discontinuous. Unlike the capillaries
containing fenestrated (e.g., renal glomeruli and intestinal villi) or continuous (e.g., heart,
lung and brain) endothelium, sinusoidal capillaries in liver, spleen and bone marrow are lined
with discontinuous endothelium. They have transcellular openings not covered by a
diaphragm and permit the extravasation of macromolecules (Majno and Joris 1978;
Pasqualini et al. 2002). Thus, the observation made in the present study is consistent with this
notion and earlier reports with other foreign particulates (Wisse and De Leeus 1984; Senior
1987). For instance, the predominant uptake of liposomes by reticuloendothelial system (e.g.,
macrophages in liver, spleen and lymph nodes) has been well established in earlier studies
(Schwendener et al. 1984; Senior 1987; Moghimi et al. 1991).
In the case of 500-nm particles, a significant amount was also found in the lungs
(Figure A-5B), the first organ that particles would encounter upon tail vein injection. Again
it was also the main organ of accumulation in both cases of 7-µm particles (Figure A-5D and
E, see Figure A-6F also). Fidler and colleagues (1980) investigated the retention of
liposomes of different sizes and compositions in the lung following systemic administration
in mice. They found that large liposomes such as multilamellar vesicle (> 1 µm in diameter)
were retained in the lung more efficiently (by 3-5 fold) than were small unilamellar vesicles
(< 100 nm). Interestingly, reducing the size of multilamellar vesicle by extruding them
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through membrane filters (1-µm pore size) reduced lung retention by 2-fold. The effect of
size on the lung accumulation was also reported by other groups (e.g., Finkelstein and
Weissmann 1978). Liposomal composition was also found to be a significant factor in
determining retention within the lungs with negatively charged liposomes more efficiently
retained than neutral or positively charged ones (Kimelberg 1976; Fidler et al. 1980).
Noticeably, lung becomes more important organ to investigate under disease states since it
represents a major site of metastatic diseases such as cancer (Fidler 1980). Although it is not
known the cause of the present finding, physical trapping of transiently aggregated particles
could explain the relatively high accumulation in the lung.
A.3.3 Pharmacokinetic and Biodistribution Studies of Radiolabeled PRINT Particles
Several different monomers were added to introduce specific functionality into the
PRINT nanoparticles. Poly(ethylene glycol) monomethyl ether monomethacrylate (Mn=1000
g/mol) was used to increase steric pressure between particles and opsonins and reduce RES
uptake. The phenol-containing monomer, p-hydroxystyrene (A in Figure A-8), provided a
chemical handle for a gentle radioiodination of the particles. In this study, 200-nm [125I]-
labeled PRINT particles were administered into healthy C57BL/6J mice via tail vein bolus
injection. The particles were radiolabeled using Iodogen® (C in Figure A-8) following the
procedure recommended by the supplier (Pierce Biotechnology). Iodogen oxidizes iodide (I-)
to electrophilic iodous ion (I+) that conjugates to the ortho position of phenol moiety on the
particle. Small amount of radiolabeled (hot) particles (D in Figure A-8) was mixed with cold
particles (B in Figure A-8) to achieve the dose of 1.4 µCi (3 x 106 dpm) / 0.32 mg / mouse.
200
The tissue distribution was monitored using a gamma counter, and the percent recovery of
injected dose was calculated from the measured radioactivity.
Figure A-9 shows the tissue distribution of 200-nm PRINT nanoparticles at 10 min,
30 min, 1 h, 3 h, 8 h, and 24 h post-injection. Throughout the time-course of the study, the
200-nm PRINT particles were distributed mainly in the liver and spleen. The total recovery
from these two organs amounts to as much as 30% over the 24-hr study period. This is in
agreement with the observation in the previous study using fluorescein-labeled particles and
consistent with fact that the sinusoidal walls of these organs are lined with discontinuous
endothelium, allowing passive entrapment of foreign particulates (see section A.3.2).
Although the present study does not provide any direct evidence for or against it, it is likely
that these particles are eventually taken up by the resident macrophages possibly subsequent
to opsonization with serum proteins (Chonn et al. 1995).
The particle accumulation was not significant in other organs harvested, often ~ 1%
of the injected dose was found in the kidneys, heart, and lungs. Incomplete removal of
residual blood in these organs could lead to a slight overestimation on the extent of particle
accumulation reported. Tails were collected in an effort to monitor the amount of
nanoparticles that were retained at the injection site. A significant amount of injected
particles were found in the tail, especially for the initial 3-hr period. Upon injection of a large
number of fine particles in relatively short period (~ 100 billion particles in 5 seconds), blood
vessels could rupture and create endothelial gaps for particle retention. Finally, a trace but
significant amount of radioactivity was observed in thyroid gland, possibly indicating the
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biodegradation of particles, yielding radioactive iodine (I2). The thyroid gland accounts for
80% of the body's iodine pool and converts iodine into the thyroid hormones thyroxine (T4)
and triiodothyronine (T3). These hormones are released into the bloodstream, controlling the
body's metabolism (Cavalieri 1997). Production of iodine from biochemical degradation of
iodinated proteins or peptides is not uncommon (Wolf et al. 1993) and may explain at least in
part the observation that total recovery decreased steadily over the 24 h period studied.
Total recovery of the radioiodinated particles was found to decrease with time,
beginning with an 82% at 10 min post-injection and ending with a 25% recovery after 24 hrs
(Figure A-10). Here, the total recovery was calculated from radioactivity measured only
from the blood, liver, kidneys, spleen, lungs, heart, tail, bone marrow, and thyroid. In an
effort to achieve a full mass balance, additional four mice were kept in a metabolic cage for
24 hrs to collect urine and feces for analysis. For these mice, additional tissues and body
parts such as fat, muscle, head, legs, intestines, and the remainder of the body were also
analyzed for additional radioactivity. It was found that with these additional measurements,
the total recovery at 24 hr post-injection improved from 25% to 59%. The appearance of
radioactivity in the thyroid gland throughout the study period (approximately 1% of injected
dose) and in urine 24 hr after dosing (as much as 8.6%) may suggest particle degradation
(Takakura and Hashida 1996). Another hypothesis for the time-dependent decrease in total
recovery of radioactivity is that volatile radioactive iodine could be formed and expelled
continuously out of the body via the lungs. This hypothesis has yet to be tested using a closed
circuit type of metabolic cages.
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As shown in Figure A-11, the disappearance of PRINT particles from circulation was
bi-exponential. The data set was fitted to a two-compartmental pharmacokinetic model with
reversible distribution between central and peripheral compartments and with elimination
from the central compartment (see Figure A-12 for the model used). The pharmacokinetic
parameters (Table A-2) obtained using WinNonlin 5.0.1 show the initial phase of rapid
distribution with an apparent t1/2 of 17 min. Close examination of the individual parameters
shows that the movement of particles from central to peripheral compartment (k12, 1.26 hr-1)
is approximately 1.5-fold faster than the reverse directional input to the central compartment
from peripheries (k21, 0.82 hr-1) and 2-fold faster than the disappearance from the central
compartment (k10, 0.54 hr-1). The rapid distribution is not surprising considering that the
PRINT particles were grafted with a low molecular weight PEG chain (9 mol %, 20% w/w of
1-kDa PEG monomethyl ether). It has been suggested that the optimal coating for the
developing long-circulating liposomes is 3-7 mol % of 2-5 kDa PEG (Moghimi et al. 2001)
.
The shorter PEG chains used in the current particle formulation may not offer a sufficient
thickness of PEG cloud to effectively block the adsorption of opsonic proteins and or
interaction with phagocytes. The subtle combination of the degree of PEG incorporation and
the molecular weight of PEG in prolonging the circulatory t1/2 is well documented for other
types of nanocarriers (Drummond et al. 1999; Moghimi et al. 2001; Owens and Peppas 2006).
Volumes of distribution in central and peripheral compartments were found to be 3
and 5 mL, respectively. Considering the blood volume of approximately 1.7 mL/20 g mouse,
liver of 0.8 g, and spleen of < 0.1 g, these values appear to be somewhat exaggerated,
however, they certainly rule out any significant extravasation. Since the stability of the
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radiolabel is not well established in the present study and since it is the radioactivity that is
monitored, it is difficult to unambiguously interpret the slow phase of radioactivity decay in
the later time-points with an apparent t1/2 of 3.8 hrs. The appearance of radioactivity in urine
strongly suggests that these PRINT particles and/or their degradation products must be
cleared readily from the blood. Thus, the slow elimination phase may well represent slow re-
distribution of particles or particle remnants between the blood and organs/tissues.
The AUC, a measure of total availability of particles in the circulation for organ
distribution extrapolated to infinite time, was determined to be 189 µghr/mL. Unmodified,
conventional liposomes show dose-dependent pharmacokinetic parameters, including
AUC upon intravenous administration. A liposome dose equivalent to the dose studied in
the present study, 18 mg/kg, shows AUC values of approximately 70 to 700 µghr/mL,
and the present data are certainly in agreement with that reported for liposomes (Allen and
Hansen 1991).
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A.4 Conclusions
This chapter is concerned with the in vivo characterization of nanofabricated particles
that are monodisperse in size and shape. Herein reported is the first pharmacokinetic
evaluation of PRINT-derived cylinders of various sizes, ranged from 200 nm to 7 µm.
For 200-nm particles, 5-20% of injected dose stayed in the blood up to 8 hrs while
particles of 500 nm showed relatively rapid disappearance from the blood. No measurable
amount of 1-µm particles was found in the blood throughout the study period. Most
interestingly, as much as 10-20% of 7-µm porogen particles remained in the blood up to 3 hrs
while 7-µm regular particles disappeared rapidly within 30 min. For 200-, 500-nm and 1-µm
particles, the main organs of accumulation were livers and spleen, organs of which sinusoids
are with discontinuous endothelium. Increased amount of 500-nm particle was found in the
lungs, the first organ that particles would encounter upon tail vein injection. Again it was the
main organ of accumulation in both cases of 7-µm particles. During the 24-hr period studied,
close to 100% of injected dose was recovered from the harvested organs and blood except the
7-µm particles. The low recovery of these may well represent those retained in the injection
site on the tail.
The biodistribution of radiolabeled particles was performed to verify the previous
investigation using fluorescently labeled particles. 200-nm PRINT particles showed similar
tissue distribution to that of fluorescently-labeled particles (i.e., liver and spleen were the
main organs of accumulation upon i.v. injection). The findings that trace but significant
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amount of particles were accumulated in thyroid glands and urine appears to support possible
degradation of particles. Radiolabeled particles were cleared from the blood rapidly with
elimination half-life of 3.8 hrs.
PRINT particles are associated with unprecedented monodispersity as well as the
ability to address several different design criteria comprehensively, simultaneously, and
independently. Thus they offer an excellent opportunity to test the effects of size, shape,
composition, surface properties, and the addition of biological targeting ligands on the
biological fate of particles as drug carriers. The basic understanding of their pharmacokinetic
behavior will ultimately leads to optimizing pharmacodynamics of drug-carrying PRINT
particles.
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Figure A-1: Scanning electron micrographs of PRINT particles (data from S. Gratton
and P. Pohlhaus in DeSimone Lab of UNC chemistry Department): A, 200 nm; B, 500
nm; C, 1 µm; D, 7 µm; and E, 7 µm containing 50% PEG550 dimethyl ether (porogen).
Hitachi Model S-4700 was used with samples prepared by placing a drop of particle
dispersions (0.5 mg/mL) on a slide glass followed by Pd/Au alloy (1.5 nm) coating.
Sample was in dry condition during observation conducted under low vacuum (10-3 
Torr).
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Table A-1a: Particle Sizes Measured by SEM and DLS
Size by SEMc (µm)
Test Group Master Templateb
Width (Diameter) Height
Size by DLSd
(µm)
200 nm 0.2 x 0.2 µm 0.20 ± 0.01 0.16 ± 0.01 0.27 ± 0.02
500 nm 0.5 x 0.5 µm 0.41 ± 0.03 0.43 ± 0.02 0.39 ± 0.05
1 µm 1 x 1 µm 0.97 ± 0.04 0.68 ± 0.05 0.62 ± 0.02
7 µm 7 x 1.4 µm 6.30 ± 0.20 0.90 ± 0.20 N/A
7 µm w/ 50% porogen 7 x 1.4 µm 5.00 ± 0.20 0.80 ± 0.10 N/A
a; Data were from S. Gratton and P. Pohlhaus of DeSimone Lab of UNC Chemistry
Department.
b; Size of mold could represent intended sizes of particles.
c; Scanning electron microscopy (SEM) was performed on Hitachi Model S-4700 by placing
a drop of particle dispersions (0.5 mg/mL) on a slide glass followed by Pd/Au alloy (1.5
nm) coating. Sample was in dry condition during observation conducted under low
vacuum (10-3 Torr).
d; Dynamic light scattering (DLS) was carried out to measure the sizes of particles dispersed
in PBS solution (0.5 mg/mL) using a 90Plus Particle Size Analyzer at 25 oC.
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Figure A-2: Stability of PRINT particles in liver homogenates as studied in a dialysis set-
up. Dialysis cassette (3.5 kDa MWCO) containing 0.2 mg of PRINT particles (200 nm or
2 µm) in 300 µL liver homogenate from mouse or PBS was incubated in a 100-mL beaker
containing 70 mL of PBS. The cassette was placed in 37°C water bath and incubated for
22 hrs. At a given specified time point, aliquot of diffusate was removed and subject to
fluorescence measurement (A). Relative fluorescence intensity (B) was calculated by
subtracting initial fluorescence (T = 0 hr) from the fluorescence measured at each time
point (i.e. 0 and 22 hrs). As a positive control, 5-(iodoacetamido) fluorescein (IAF) was
incubated in liver homogenate and dialysis was performed in the same manner as the
other test groups.
209
Figure A-3: Hydroxide ion-catalyzed hydrolysis of fluorescein-labeled PRINT
particles. Fluorescein molecules are released from the surface and the matrix of
particles by base treatment. The hydrolyzed product was expected to have same
excitation and emission wavelengths as those of parent molecule. Tissue
homogenate hydrolyzed was then subject to fluorescence measurement without
any further purification.
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Figure A-4: Kinetics of fluorescence intensity from PRINT particles that were
incubated with NaOH. Particles (10 µg) of various sizes in water (100 µL) were
added into 0.4 mL of 1 N NaOH or distilled water and the mixture was incubated at
37oC up to 24 hrs. At a given time interval (i.e., 0, 20, 40 min, 1.5, 6, 16, and 24 hrs),
2 uL of reaction mixture was removed and subject to fluorescence measurement. A
Nanodrop Model 3300 was used using 520 nm for emission.
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Figure A-5: Biodistribution of fluorescently-labeled PRINT particles of various sizes
(A, 200 nm; B, 500 nm; C, 1 µm; D, 7 µm; and E, 7 µm with 50% porogen) following
IV bolus tail vein injection of 0.32 mg particles per mouse (n=3 or 4). Animals in D
and E were monitored only up to 3 hrs post-injection. Serum was separated from
blood collected through heart puncture. Other organs were harvested at a specified
time point, homogenized and supernatant was separated using low speed
centrifugation (250 x g, 5 min). Fluorescence measurement in serum and organ
homogenates was performed after NaOH-hydrolysis at 37oC for 24 hrs. The
fluorescence was then converted into the amount of particles using a pre-established
calibration curve. The percent injected dose was calculated from the amount of
particles in samples and initially administered dose.
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Figure A-6: Biodistribution of fluorescently-labeled PRINT particles represented by
organ or tissue (A, Serum; B, Liver; C, Kidney; D, Spleen; E, Heart; and F, Lung).
Serum and organ samples were collected and processed for fluorescence measurement
as described in Figure 5-5. The fluorescence was then converted into the amount of
particles using a pre-established calibration curve. The percent injected dose was
calculated from the amount of particles in samples and initially administered dose, 0.32
mg/mouse.
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Figure A-7: Total recovery of fluorescein-labeled PRINT particles. Percent recovery
of injected dose in all the organs including serum were combined and the sum was
represented as a function of time. Erythrocyte mimic (i.e., 7 µm) and its porogen-
containing derivative (7 µm Porogen) were tested only up to 3 hrs post-injection.
0
20
40
60
80
100
120
140
160
10 100 1000 10000
Time (min)
%
In
jec
te
d
D
o
se
0.2 um
0.5 um
1 um
7 um
7 um Porogen
%
In
jec
te
d
D
o
se
214
OH
p -hydroxy-styrene (PHS)
OH
O
ClCl
Cl
O
Cl
OH
Na125I
125I
B D
A
C
Figure A-8: Iodination of PRINT particle using Iodogen pre-coated tube. Para-
hydroxystyrene (A) was incorporated into particle and served as chemical handle for
iodination. PRINT particle containing phenol moiety (B) was incubated for 15 min
in an Iodogen (C) pre-coated tube in the presence of Na125I. Iodinated particle (D)
was rinsed with distilled water several times and mixed with cold particle (B) in
such a way each mouse was dosed with 1.4 µCi / 0.32 mg particle.
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Figure A-9: Biodistribution of [125I]-PRINT particles of 200 nm following IV bolus tail
vein injection of 1.4 µCi (0.32 mg particles) per mouse. Radioactivity of whole blood
and organs were measured using a gamma counter without any additional treatment or
homogenization after harvesting at designated time points. The percent injected dose
was calculated from the direct reading of CPM in samples and initial dose.
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Figure A-10: Total recovery of 200 nm [125I]-PRINT particles. Percent recovery of
injected dose in all the organs and tissues including blood were combined and the
sum is presented as a function of time. This data do not contain the amount found in
excreta (urine and feces) or in other tissues collected at 24-hr time point such as fat,
muscle, leg, head, intestine, and rest of the body.
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Figure A-11: Blood concentration as a function of time following IV bolus tail vein
injection of 1.4 µCi (0.32 mg particles per mouse) [125I]-PRINT particles of 200 nm
in mice (n=3 or 4). The data was fitted to two-compartment model shown in Figure
A-12. The line was obtained from WinNonlin 5.0.1 with the parameters presented in
Table A-2.
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Figure A-12: Two-compartment model used in the calculation of PK parameters in
blood. Represented in the scheme are initial dose (Xo, intravenous bolus injection),
volume of distribution of central compartment (Vc), volume of distribution of
peripheral compartment (Vp), total clearance of the central compartment (Cl),
distribution clearance (Cld), elimination constants from central compartment (k10),
central to peripheral compartment (k12), and peripheral to central compartment (k21).
Central Peripheral
Xo
Vc Vp
k12
k21
k10
Cl
Cld(i.v. bolus)
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Table A-2: Blood PK Parameters Estimated from Two-Compartment Model
Parameters Equation applied
Aa WinNonlin value 73 µg/mL
Ba WinNonlin value 29 µg/mL
a WinNonlin value 2.44 hr-1 
a WinNonlin value 0.18 hr-1 
Vcb Dose/(A+B) 3.1 mL
Clb Dose/[(A/)+(B/)] 1.7 mL/hr
k21b (A*+B*)/(A+B) 0.82 hr-1 
k10b (*)/k21 0.54 hr-1 
k12b +-k21-k10 1.26 hr-1 
Cldb k12*Vc 4.0 mL/hr
Vpb (k12*Vc)/k21 4.9 mL
AUC (A/)+(B/) 189 µghr/mL
t1/2 
c 0.693/ 17 min
t1/2 
d 0.693/ 3.8 hr
a; Parameters shown in the following equation for two-compartment model, C=A*e-
(*t)+B*e-(*t), wherein C, comprehensive concentration; A, initial concentration of
distribution phase; B, initial concentration of terminal phase; , elimination constant of
distribution phase; , elimination constant of terminal phase; and t, time.
b; Parameters described in Figure A-12.
c; Half-life of distribution phase
d; Half-life of terminal phase
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Abstract
A novel method for the fabrication of polymeric particles on the order of tens of
nanometers to several microns is described. This imprint lithographic technique called
PRINTTM (Particle Replication In Non-wetting Templates), takes advantage of the unique
properties of elastomeric molds comprised of a low surface energy perfluoropolyether
network, allowing the production of monodisperse, shape-specific nanoparticles from an
extensive array of organic precursors. This engineered nature of particle production has a
number of advantages over the construction of traditional nanoparticles such as liposomes,
dendrimers, and colloidal precipitates. The gentle “top down” approach of PRINT enables
the simultaneous and independent control over particle size and shape, composition, and
surface functionality, and permits the loading of delicate cargos such as small organic
therapeutics and biological macromolecules. Thus, this single tool serves as a comprehensive
platform for the rational design and investigation of new nanocarriers in medicine, having
applications ranging from therapeutics to advanced diagnostics. Preliminary in vitro and in
vivo studies were conducted, demonstrating the future utility of PRINT particles as delivery
vectors in nanomedicine. Monodisperse neutral 200 nm poly(ethylene glycol)-based (PEG)
particles were fabricated using PRINT methodology and characterized via scanning electron
microscopy and dynamic light scattering. Incubation with HeLa cells showed very little
cytotoxicity, even at high concentrations. The biodistribution and pharmacokinetics of [125I]-
labeled particles were studied in healthy mice following tail vein bolus intravenous
administration. The particles were distributed mainly to the liver and the spleen with an
apparent distribution t1/2 of approximately 17 min followed by slow redistribution with a t1/2
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of 3.3 h. The volume of distribution for the central and peripheral compartments was found
to be approximately 3 and 5 mL, respectively.
Key words: PRINT, biodistribution, nanoparticles, pharmacokinetics, nanomedicine
1. Introduction
Despite continued progress in the identification, characterization, and synthesis of
advanced therapeutics, the full potential of such innovations can only be achieved with the
concomitant realization of in vivo profiles ideal for pharmacological intervention. In the
realm of drug discovery, the hindrance to obtaining such a profile may be as simple as poor
solubility in biological media. For instance, it has been reported that ten percent of marketed
drugs suffer from solubility problems, over a third of pipeline drugs are poorly soluble, and
almost two-thirds of drugs coming from early pre-clinical development have low solubility
[1]. As such, almost forty percent of all possible drug targets fail early due to poor solubility
characteristics. More complex problems with drug candidates may include unfavorable
pharmacokinetics, and high systemic toxicity. Particular attention must also be given when
considering the delivery of biochemically labile substances such as siRNA and other
oligonucleotides for gene therapy, as these sensitive cargos need to be protected during
circulation. In addition, they need to be delivered to the appropriate tissue or organ, and
released intracellularly into the cytosol or nucleus to be effectively used as therapeutics.
Finally, the efficient delivery of detection and imaging agents is an extremely important step
in the early diagnosis and treatment of disease.
The development and utilization of nanocarriers in response to many of the
aforementioned problems encountered in vivo has led to dramatic improvements in the
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biological profile of important therapies. Intense research in drug delivery over the past few
decades has seen the design and construction of valuable nanocarriers such as liposomes,
micelles, dendrimers, polymer particles, and colloidal precipitates [2-9]. However, only a
handful of drugs and imaging agents delivered using these classical approaches have made it
into the clinic [1,8]. One underlying reason for the delayed development is that none of these
approaches offers the ability to comprehensively, simultaneously, and independently address
several different design criteria. The ability to meet such demanding parameters is
quintessential to the design of effective delivery vectors and has been the focus of intense
research in our laboratory. Herein, we report the utilization of recent breakthroughs in the
nanofabrication of polymeric particles to develop an effective platform delivery system for
use in nanomedicine.
Our technique, called PRINT (Particle Replication In Non-wetting Templates), is
based on the exploitation of the low surface energy of novel fluoropolymeric molds (Fig. 1)
[10-12]. The molds are derived from liquid perfluoropolyether (PFPE) precursors, which can
be photochemically crosslinked at room temperature. The resulting elastomeric solids enable
high-resolution imprint lithography, an emerging technique from the microelectronics
industry, to fabricate a variety of organic particles. PRINT is therefore an adaptation of the
highly precise mass production technologies used today for the fabrication of nanoscale,
silicon-based devices found in the microelectronics field. By developing lithographic
technologies that are able to fabricate transistors that are smaller and smaller, companies
have been able to increase the number of transistors on a microprocessor to over one billion:
this represents an increase of over six orders of magnitude since the early 1970’s [13,14].
The minimum feature size currently found on each individual transistor is under 100 nm
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(approximately the size of an individual virus particle) [15,16]. The state-of-the-art in the
microelectronics industry has finally reached the size scale appropriate for the ideal drug
delivery vector. It is now timely to envision and propose the use of lithographic techniques
found in the microelectronics industry to fabricate carriers of precise size for use in
nanomedicine. Indeed, transistors in today’s microelectronic devices are even smaller than
traditional drug delivery carriers that have been studied over the last 25 years: micelles,
liposomes, and polymer particles.
In hindsight it may be easy to envision the connection between emerging technologies
in the microelectronics industry and unfulfilled needs in the field of nanomedicine, however
several key challenges are standing in the way of implementing such techniques to fabricate
organic carriers. Electronic devices are made from silicon, other inorganic materials, and
metals; and the highly developed and proven techniques used to fabricate microprocessors
are harsh, often involving the use of oxygen and chlorine etching plasmas, high temperatures,
corrosive solvents, acids, bases, and extremely intense deep UV radiation (today 193 nm
excimer laser). Moreover, the transistors are permanently adhered to, or are made a part of a
two-dimensional surface, with no interest paid to delamination from the surface or bulk
collection. Therefore, in order to be successful for nanomedicine, significant re-engineering
and innovation is needed. For example, there is no known method or strategy in the suite of
available microelectronics fabrication technologies that allows one to make nanoscale
structures on a surface and then to harvest those structures to yield isolatable nano-objects or
particles. Indeed, particles are the antithesis of the microelectronics industry and are avoided
at all costs in the fabrication facilities where class 10 clean rooms are the norm (no more than
10 particles exceeding 0.5 microns per cubic feet of air) to avoid defects in the finished
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products. In addition, ideal carriers for therapeutics would require the use of very mild
processing conditions since the carriers, cargos, and targeting ligands would be composed of
delicate organic molecules (e.g. bioabsorbable materials, siRNA, therapeutics, antibodies,
etc.). PRINT technology addresses these issues and allows gentle imprint lithography to be
employed in the high-resolution fabrication of organic nanocarriers.
The nature of PRINT technology takes drug delivery for the first time into the
uncharted realm of engineered drug therapies given its á la carte approach and versatility.
This innovative tool allows for the simultaneous control over all of the parameters that are
essential in the rational design of conventional delivery vectors in nanomedicine. PRINT
allows for the precise control over particle size (20 nm to >100 µm) through use of an
appropriately designed master template. The advanced imprint lithography of PRINT ensures
replication of the identical master features to afford particles that are truly monodisperse.
Particle shape is also controlled through the judicious choice of a master, and geometries
such as spheres, cylinders, discs, and toroids with defined aspect ratios can be
accommodated. The composition of particles made using PRINT is also readily tunable and
amendable to the inclusion of a variety of organic matrices including albumin, hydrogels,
PLLA, PLGA, etc. (Fig. 2). Moreover, the porosity, texture, and modulus of the particles can
be altered in a logical fashion through careful alteration of the matrix formulation. In view of
the fact that PRINT is compatible with a wide range of chemistries and the gentle nature in
which particles are fabricated, this technology enjoys the straightforward incorporation of a
variety of cargos. The inclusion of hydrophilic or hydrophobic therapeutic molecules,
biologicals, peptides, proteins, oligonucleotides, siRNA, contrast agents, radiotracers, and
fluorophores can be accommodated through inclusion in the particle matrix. The
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concentration of such cargos in the particles can be exactly chosen to meet specific needs and
standards since PRINT does not rely on the kinetic trapping of external molecules during
particle fabrication as is the case with liposomes and micelles. Finally, particle surface
properties are readily modified though either the matrix composition or post-
functionalization with surface moieties. Thus, particle surfaces are amenable to decoration
with targeting peptides, antibodies, aptamers, avidin/biotin complexes, cationic/anionic
charges, and “stealth” poly(ethylene glycol) (PEG) chains for steric stabilization. We believe
that PRINT is the only technology that can independently design in these attributes to create
truly engineered nanovectors for drug therapies. For the first time, key therapeutic parameters
such as bioavailability, biodistribution, and target-specific cell penetration can be
simultaneously designed into a therapy. In this report we document the first in vivo study of
PRINT particles administered intravenously into healthy mice. The promising biodistribution
profile and blood pharmacokinetics of 200 nm non-targeted radiolabeled PEG-based
nanogels fabricated using PRINT methodology are discussed.
2. Materials and Methods
2.1 Materials
FluorocurTM, the perfluoropolyether used as the molding material in the PRINT
process, was purchased from Liquidia Technologies (Product # 2M-140).
Trimethylolpropane ethoxylate triacrylate (Mn = 428 g/mol) (Aldrich), was passed through a
short plug of alumina prior to use to remove inhibitor. Poly(ethylene glycol) monomethyl
ether monomethacrylate (Mn = 1,000 g/mol) (Polysciences), para-hydroxystyrene (Alfa
Aesar, 10% (w/w) in propylene glycol) and 2,2-diethoxyacetophenone (Aldrich) were used
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as received without further purification. Iodogen® pre-coated tubes were purchased from
Pierce Biotechnology, Inc., and radioactive iodine (Na125I) was purchased from Perkin Elmer
Life and Analytical Sciences, Inc. as 100 mCi/mL in 10-5 M NaOH. HeLa cells and all cell
culture media (MEM, OptiMEM) were purchased from the tissue culture facility at The
University of North Carolina at Chapel Hill. CellTiter 96* AQueous One Solution Cell
Proliferation Assay (MTS) was purchased from Promega Corporation. The lysis agent used
for negative controls in in vitro viability studies with HeLa cells was the lysis solution
contained in the CytoTox-ONETM Homogeneous Membrane Integrity Assay kit (Promega).
Silicon templates used as masters were obtained from Benchmark Technologies. C57BL/6J
mice were purchased from The Jackson Laboratory. Ketamine HCl (100 mg/mL) was
purchased from Abbott Laboratories. Cholesterol and 1,2-Distearoyl-sn-Glycero-3-
Phosphocholine (DSPC) were purchased from Avanti Polar Lipids, Incorporated.
AbraxaneTM (for Injectable Suspension) was purchased from The University of North
Carolina at Chapel Hill pharmacy and reconstituted with water immediately prior to use. All
animal experiments were conducted in accordance with guidelines set forth by The
University of North Carolina at Chapel Hill, and approval was obtained for the completion of
these experiments.
2.2 Preparation of PRINT nanoparticles
The fabrication of patterned FluorocurTM molds has been described elsewhere [10].
Briefly, 20 mL of FluorocurTM resin containing 0.1% (w/w) of 2,2-diethoxyacetophenone
was pooled in the center of an 8 inch patterned master (with feature sizes of 200 nm) which
was set up inside an enclosed UV chamber. Ten minutes was allowed to pass so that the
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FluorocurTM resin was spread out over the entire 8 inch wafer. The entire system was then
purged with nitrogen for 3 minutes. Following this, the coated wafer was exposed to UV
irradiation ( = 365 nm, power > 20 mW/cm2) for 2 minutes to cure the FluorocurTM resin.
The elastomeric mold was then removed from the master template by gently peeling it away
from the silicon surface.
In these experiments, the PRINT particles were derived from a mixture composed of
78% (w/w) PEG triacrylate, 20% (w/w) PEG monomethyl ether monomethacrylate, 1%
(w/w) 2,2-diethoxyacetophenone, and 1% (w/w) para-hydroxystyrene. A 10% (w/v) solution
of this mixture in 2-propanol (filtered through a 0.22 µm PTFE filter) was prepared. This
solution (1 mL) was then sprayed onto a FluorocurTM patterned mold using an air brush and
residual 2-propanol was allowed to evaporate over 10 minutes. A poly(ethylene) sheet
(American Plastics Co.) was then placed over the 8 inch (diameter) mold ensuring that the
entire active area was covered. This poly(ethylene) sheet was then peeled back at a rate of
approximately 2.5 cm/min. Following this, the mold was placed in a UV curing chamber.
The chamber was purged with nitrogen for 3 minutes and UV irradiation was applied
( = 365 nm, power > 20 mW/cm2) for 2 minutes.
To facilitate removal of the particles from the mold, a physical means for harvesting
the particles was utilized. Specifically, a 2 mL aliquot of acetone (filtered through a 0.22 µm
PTFE filter) was placed on the particle-filled mold and this drop of acetone was gently
moved along the surface of the mold using a glass slide. The movement of the glass slide
facilitated release of the particles from the mold. The suspended particles were collected in a
50 mL Falcon tube and diluted to the 50 mL mark with filtered acetone after particle
collection was complete. The suspension was vortxed for 10 minutes and was centrifuged at
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3200 rpm for 30 minutes using a IEC CENTRA CL2 Centrifuge (Thermo Electron
Corporation). The supernatant was removed via aspiration and the particle pellet was
redispersed in 50 mL of fresh acetone by vortexing for 10 minutes followed by centrifugation
for an additional 30 minutes. This process was repeated once more and after aspiration the
particles were redispersed in 5 mL of distilled water by sonicating the dispersion for 15
minutes. The particle dispersion was filtered through a 20 µm filter into a fresh 50 mL Falcon
tube, and diluted to the 50 mL mark with acetone. This particle suspension was then
centrifuged for one hour. The supernatant was removed via aspiration and the particle pellet
was redispersed in 50 mL of fresh acetone by vortexing for 10 minutes followed by
centrifugation for an additional 30 minutes. This process was repeated once more (with
acetone) and after aspiration the particles were redispersed in a minimal amount of acetone,
transferred to a tarred Eppendorf tube, and centrifuged in a microfuge (Fisher Scientific) for
20 minutes. The supernatant was removed and the pellet was dried in a vacuum oven
overnight, massed, and dispersed in the appropriate amount of sterile water to make a 10
mg/mL dispersion of particles.
2.3 Preparation of liposomes
Lipids (DSPC:Cholesterol, 55:45 mol) were dissolved in chloroform and evaporated
to dryness in a rotary evaporation under reduced pressure at 50°C. After leaving the lipid film
overnight under reduced pressure, the film was hydrated with PBS at pH 7.0. Unilamellar
liposomes were formed by extrusion with 20 passes through a double-stacked polycarbonate
membrane (Whatman Nucleopore) with a pore size of 200 nm, resulting in a liposome
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diameter of 177 nm with a polydispersity of 0.026 as determined by dynamic light scattering
[17,18].
2.4 Particle size analysis of PRINT nanoparticles using scanning electron microscopy (in the
dry state)
The size of PRINT nanoparticles was analyzed via scanning electron microscopy
(Hitachi model S-4700). Particle dispersions were prepared at concentrations of 0.5 mg/mL,
and a drop of this solution was placed on a glass slide. The drop was then allowed to dry, and
the glass slide was coated with 1.5 nm of Pd/Au alloy using a Cressington 108 auto sputter
coater (Cressington Scientific Instruments Ltd.). The Pd/Au coated glass slide was then
adhered to the sample holder using double-sided adhesive tape, and placed inside the vacuum
chamber of the SEM and observed under low vacuum (10-3 Torr).
2.5 Particle size analysis of PRINT nanoparticles, liposomes, and AbraxaneTM using dynamic
light scattering (in suspension)
The size and polydispersity of PRINT nanoparticles was analyzed via dynamic light
scattering (DLS) using a 90Plus Particle Size Analyzer (Brookhaven Instruments
Corporation). The particles were dispersed in PBS at a concentration of 0.5 mg/mL and
measured without filtration at 25 °C and 37 °C. AbraxaneTM (for Injectable Suspension) was
reconstituted with 0.9% (w/v) NaCl to a concentration of 0.5 mg/mL, and the DSPC:CHOL
liposomes were diluted using PBS to a concentration of 0.5 mg/mL, and both were measured
under the same conditions as PRINT particles.
237
2.6 Zeta potential measurements
The zeta potential of PRINT nanoparticles was measured using a ZetaPlus Zeta
Potential Analyzer (Brookhaven Instruments Corporation). The nanoparticles were dispersed
in water at a concentration of 0.3 mg/mL and the zeta potential was measured.
2.7 Radiolabeling of PRINT nanoparticles with 125I
PRINT nanoparticles were radiolabeled using IodogenTM solid phase oxidant in the
presense of Na125I. Briefly, 10 mg of PRINT particles in 1 mL of H2O, 53 µL of phosphate
buffered saline, and 1 mCi of Na125I in 10 µL of 10-5 M NaOH were added to an IodogenTM
pre-coated tube (50 µg of IodogenTM reagent) and the tube was swirled every other minute
for 15 minutes. The radiolabeled particle solution was then transferred to a pre-weighed 1.5
mL Eppendorf tube. The original reaction tube was rinsed with one 20 µL portion of 1 mM
KI and with two 100 µL portions of water and the rinsing solutions were added to the tube
containing radiolabeled particles followed by the addition of NaHSO3 (1 µmol/10 µL). The
particle dispersion was then centrifuged for 10 minutes at 15,000 x g using an Eppendorf
centrifuge 5415 D (Eppendorf). The supernatant was removed and the particles were washed
with four 500 µL portions of water and evaporated to dryness in a SpeedVac SC100 (Savant
Instruments). The total mass recovered was 9.45 mg. The specific activity was measured with
a Beckman Gamma 5500B gamma counter (Laboratory Technologies) and found to be 5.5
µCi/mg PRINT particles.
238
2.8 In vitro cytotoxicity
HeLa cells were seeded in 100 µL of media [Minimum Essential Medium (MEM)
containing Earle’s salts and supplemented with 1 mM sodium pyruvate and non-essential
amino acids] at a density of 5 x 103 cells per cm2 into a 96-well microtitre plate. Cells were
allowed to adhere for 24 h before MEM was replaced with Opti-MEM (90 µL per well) and
the particle preparation (10 µL per well in PBS). Positive controls contained PBS alone.
HeLa cells were incubated with the PRINT particles for 4 h at 37 °C in a humidified 5% CO2
atmosphere. After the 4 h incubation period, negative controls were prepared by the addition
of 2 µL of lysis solution to a few wells containing cells only. After 2 minutes, the MTS assay
solution was added (20 µL per well) into each well. The cells were then incubated for an
additional 1 h at 37 °C in a humidified 5% CO2 atmosphere. The optical density at 450 nm
was measured using a BioRad Model 3550 microplate reader (BioRad Laboratories). The
viability of the cells exposed to neutral PRINT particles was expressed as a percentage of the
viability of cells grown in the absence of particles.
2.9 Biodistribution of [125I]-labeled PRINT particles
Mice were housed under specific pathogen-free conditions for one week and were
used at 8 weeks of age (~18 g). Animals were injected intravenously via bolus tail vein
administration with 0.32 mg of [125I]-labeled PRINT particles with a specific activity of
4.3 µCi/mg in 100 µL of PBS (phosphate buffered saline, Sigma-Aldrich). At 10 min, 30 min,
1, 3, and 8 h after dosing, groups of four mice were anesthetized by intraperitoneal injection
of 100 µL of ketamine HCl solution in PBS (50 mg/mL). Blood was collected via cardiac
puncture. Samples of blood and organs harvested (liver, kidneys, spleen, lungs, and heart)
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were weighed and counted to determine the total radioactivity in a Beckman Gamma 5500B
gamma counter (Laboratory Technologies). An additional four animals were kept in a
metabolic cage after injection of the [125I]-labeled PRINT nanoparticles. At 24 h post-
injection, urine and feces were accumulated for radioactivity measurements. After these
animals were sacrificed (as described above) the blood as well as the organs were removed,
weighed, and assayed for radioactivity.
3. Results and Discussion
3.1 The Print Process
In the PRINT process (Fig. 1), the permanent silicon master template is fabricated
using advanced lithographic techniques. The liquid PFPE fluoropolymer is then added to the
surface of the master template. A positive spreading coefficient allows the perfluoropolyether
to wet the nanoscale features of the master template with extremely high fidelity. After the
fluoropolymer has wet the master template it is photochemically cross-linked and peeled
away to generate a precise mold having nanoscale cavities. The low surface energy and high
gas permeability of the PRINT mold enables the organic liquid precursor to the drug carrier
particles to fill the cavities through capillary action, but it does not form an inter-connecting
“flash” layer of liquid wetting the land area between the cavities. Such specific wetting and
filling enables the fabrication of freestanding and harvestable particles that have the same
precise shape of the silicon master template from which they were derived. Once the liquid in
the mold cavities is converted to a solid using a wide range of gentle chemistries, the array of
organic particles can be removed from the mold either by physical methods or by bringing
the mold in contact with an adhesive layer (e.g. surgical adhesive/water soluble excipient
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layer). Physical methods were used herein to harvest the PRINT particles which were then
purified, characterized, and radiolabeled for biodistribution studies.
3.2 Characterization of PRINT Nanoparticles
The particle composition was engineered to produce biologically relevant delivery
vectors. Several monomers were added to introduce specific functionality into the hydrogel
nanoparticles: poly(ethylene glycol) triacrylate, poly(ethylene glycol) monomethyl ether
monomethacrylate, and p-hydroxystyrene (PHS) (Fig. 3). Poly(ethylene glycol) derivatives
have long been known to impart biocompatibility, solubility, stability, and increased
circulation times to proteins, liposomes, and particles [19-23]. The phenol-containing
monomer, PHS, was selected as a chemical handle so that gentle radioiodination of the
particles was possible. The uniformity of size and shape of the hydrogels was confirmed
using scanning electron microscopy (SEM, Fig. 4). The micrographs show the isolation of
thousands of virtually identical cylindrical particles, thus verifying PRINT’s ability to copy
the nanoscale features of a patterned wafer with high precision. The diameter of the particles
in the dry state was determined from the scanning electron micrographs to be 201 ± 10 nm
and the height was determined to be 155 ± 10 nm. A dry sample is required for SEM and thus
the micrographs obtained do not represent the dispersion the particles have once in solution.
The nanocarriers used most frequently today for the delivery of therapeutics in the
clinic can best be classified under the general heading of self-assembled structures.
Nanovectors fitting this description include micelles, liposomes, and protein aggregates. As a
result of their inherent dynamic nature, these nanoparticles derived from the self-assembly of
small molecules would be expected to undergo structural changes once in vivo. As such, it is
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difficult to make a direct connection between the particle formulation prior to administration
and the therapeutic outcome. As an example of this behavior, the size and polydispersity of
liposomes, AbraxaneTM (albumin-bound paclitaxel), and PRINT particles in water were
investigated via dynamic light scattering at room temperature (25 °C) and then at
physiological temperature (37 °C) over the course of several hours (Fig. 5). At 25 °C all three
particles have a low polydispersity immediately upon formation or dispersion. Upon heating
to 37 °C, the mean diameter and polydispersity of liposomes changes dramatically as a
function of time. After 3 h at 37 °C, the Abraxane particles decompose as expected. Over the
time course of 6 h at physiological temperature, the PRINT particles remain stable as
observed by a steady size and polydispersity. This could be an important attribute in the
design of nanocarriers, since it is expected that the size and polydispersity of dynamic
structures may change even more rapidly once in the serum.
3.3 Cytotoxicity studies in vitro
The cytotoxicity of the PRINT nanoparticles was assessed in a cursory manner using
a MTS cell viability assay [24]. This particular assay is a colorimetric evaluation that
determines the number of living cells by quantifying the amount of formazan product present,
which is directly proportional to the number of viable cells. The MTS assay solution (a
modified version of the MTT assay) contains a tetrazolium compound [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, MTS]
and an electron-coupling reagent, phenazine ethosulfate, which forms a stable compound that
is soluble in cell culture media. MTS is reduced into formazan by living cells only, which can
be quantified by its absorbance. Figure 6 shows high absorbance of the formazan relative to
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the negative control, supporting the non-toxic nature of the nanoparticles, even at high
concentrations (100 µg/mL is equivalent to 800,000 particles/cell). Based on the toxicity data
obtained, the PRINT nanoparticles appear biocompatible and suitable for future in vivo
studies.
3.4 In vivo biodistribution studies of PRINT particles in healthy mice
In this study, 200 nm [125I]-labelled PRINT particles were administered into healthy
C57BL/6J mice via tail vein bolus injection at a dose of 20 mg/kg. The particles were
radiolabeled using Iodogen® following the procedure recommended by the supplier (Pierce).
The tissue distribution was monitored using a gamma counter, and the percent recovery of
injected dose was calculated from the measured radioactivity. Figure 7 shows the tissue
distribution of 200 nm PRINT nanoparticles at 10 min, 30 min, 1 h, 3 h, 8 h, and 24 h post-
injection. Throughout the time-course of the study, the 200 nm PRINT particles were
distributed mainly in the liver and spleen. The total recovery from these two organs amount
to as much as 30% over the 24 h study period. This observation is consistent with the fact
that the sinusoidal walls of these organs are lined with discontinuous endothelium that allows
for passive entrapment of foreign particulates [25,26]. Although the present study does not
provide any direct evidence for or against it, it is likely that these particles are eventually
taken up by the resident macrophages possibly subsequent to opsonization with serum
proteins [27].
The particle accumulation was not significant in other organs harvested, often ~ 1%
of the injected dose was found in the kidneys, heart, and lungs. The extent of particle
accumulation reported in these organs may slightly over-represent the actual accumulation
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since the organs were not thoroughly rinsed to remove residual blood. Tails were collected in
an effort to monitor the amount of nanoparticles that were retained at the injection site. A
significant amount of injected particles were found in the tail, especially for the initial 3 h
period. This may be due to the rupture of blood vessels upon rapid injection of a large
number of fine particles in a short period of time (< 5 seconds), creating endothelial gaps for
particle retention. Finally, a trace but significant amount of radioactivity was observed in
thyroid gland, possibly indicating the biodegradation of particles, yielding radioactive I2.
Production of iodine from biochemical degradation of iodinated proteins or peptides is not
uncommon and is also consistent with the observation that total recovery decreased steadily
over the 24 h period studied (vide infra) [28].
Total recovery of the radioiodinated particles was found to decrease with time,
beginning with an 81 ± 6 % recovery at 10 minutes post-injection and ending with a
24 ± 7 % recovery after 24 h (data not shown). Here, the total recovery was calculated from
radioactivity measured only from the blood, liver, kidneys, spleen, lungs, heart, tail, bone
marrow, and thyroid. In an effort to achieve a full mass balance, four mice were kept in
metabolic cages for 24 h so that urine and feces could be collected and analyzed. For these
mice, additional tissues and body parts such as fat, muscle, head, legs, intestines, and the
remainder of the body were also analyzed for additional radioactivity. It was found that with
these additional measurements, the total recovery at 24 h post-injection improved from
24 ± 7 %, with the main organs only, to 58 ± 4 %. The appearance of radioactivity in the
thyroid gland throughout the study period (approximately 1% of injected dose) and in urine
24 h after dosing (as much as 8.6%) may suggest particle degradation [29]. This is also
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consistent with a hypothesis that loss of volatile radioactive iodine via the lungs could have
contributed to the time-dependent decrease in total recovery of radioactivity observed.
As shown in Figure 8, the disappearance of PRINT particles from circulation was bi-
exponential. The data set was fitted to a two-compartmental pharmacokinetic model with
reversible distribution between central and peripheral compartments and with elimination
from the central compartment. The pharmacokinetic parameters obtained using WinNonLin
5.0.1 (Pharsight Corporation) show the initial phase of rapid distribution with an apparent t1/2
of 17 min. The rapid distribution is not surprising considering that the steric coat on the
PRINT particles is only a low molecular weight PEG chain (9 mol %, 20% w/w of 1-kDa
PEG monomethyl ether). It has been suggested that the optimal coating for the creation of
long-circulating liposomes is 3-7 mol % of 2-5 kDa PEG [30]. The shorter PEG chains used
in the current particle formulation may not offer a radius of protection that is sufficient to
effectively block the adsorption of opsonic proteins. The subtle nuances that both the degree
of PEG incorporation and the molecular weight of PEG play in prolonging the circulatory t1/2
are well documented for other types of nanocarriers [30-32].
Volumes of distribution of central and peripheral compartments were found to be 3
and 5 mL, respectively. Considering the blood volume of approximately 1.7 mL/20 g mouse,
liver of 0.8 g, and spleen < 0.1 g, these values appear to be somewhat exaggerated, however,
they certainly rule out any significant extravasation. Since the stability of the radiolabel is not
well established in the present study and since it is the radioactivity that is monitored, it is
difficult to unambiguously interpret the slow phase of radioactivity decay in the later time-
points with an apparent t1/2 of 3.3 h. The appearance of radioactivity in urine strongly
suggests that these PRINT particles and/or their degradation products must be cleared rapidly
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from the blood. Thus, the slow elimination phase may well represent slow re-distribution of
particles or particle remnants between the blood and organs/tissues.
The AUC, a measure of total availability of particles in the circulation for organ
distribution extrapolated to infinite time, was determined to be 191 µgh/mL. Unmodified,
conventional liposomes show dose-dependent pharmacokinetic parameters, including AUC
upon i.v. administration. A liposome dose equivalent to the dose studied in the present study,
20 mg/kg, shows AUC values of approximately 70 to 700 µgh/mL, and the present data are
certainly in agreement with that reported for liposomes [33].
4. Conclusions
This paper is concerned with the characterization of nanofabricated particles that are
monodisperse in size and shape. It includes the first pharmacokinetic evaluation of PRINT-
derived cylinders of 200 nm. PRINT allows for powerful realizations regarding
pharmacokinetics of nanoparticles since intersubject variation can be ascribed fully to the
subject and not to variations of the nanocarrier. This is a significant step in pharmacokinetic
analysis since it eliminates the effect that polydisperse samples can have on biodistribution.
This in turn allows us to be able to precisely demonstrate the effect of size, composition, the
addition of cargo, modulus, and functionalization on biodistribution, which has never been
possible until now. Current efforts are focused on the creation of long-circulating PRINT
particles for the eventual use in engineered drug therapies. Results will be reported in due
course.
PRINT is the first general, singular method capable of forming organic nanoparticles
in which critical design parameters can be precisely and independently tailored bringing a
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greater understanding of cause-and-effect to the field of nanomedicine. With the
unprecedented ability of PRINT technology to control particle size, shape, composition,
modulus, cargo, and surface properties, questions such as “what interrelated role does shape,
size and mechano-chemico functionality play on the biodistribution of carriers in vivo?” and,
“how can this understanding translate into more efficacious detection, diagnosis, therapeutic
and prevention strategies?” can finally begin to be answered. As such, PRINT is a significant
scientific and technological breakthrough, which will allow the fabrication of heretofore
inaccessible populations of nanobiomaterials which are poised to revolutionize and accelerate
our translational understanding, detection, and treatment of disease.
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Fig. 1. Illustration of PRINT. Fabrication of the silicon master template (box, upper left);
Wetting of the silicon master with (green) liquid fluoropolymer, followed by curing
(top row); PFPE elastomeric mold produced with nanoscale features from the
master (upper right); Confining (red) organic liquid to cavities by applying pressure
between mold and a PFPE surface (middle row); Removal of organic particles from
mold with adhesive layer (bottom left); Dissolution of adhesive layer producing free
particles (bottom right)
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Fig. 2. Results of the PRINT Process. Top row, left to right: A) SEM of an etched silicon
wafer master template of 3 µm posts having a height of 1.7 µm; B) Cured PFPE
mold of the master template shown in A; C) PFPE mold containing PEG particles
prior to harvesting; D) Harvested and dispersed PEG PRINT particles. Bottom row,
left to right: E) SEM of an etched silicon wafer patterned with approximately 400
billion posts that are 100 nm in diameter and 400 nm tall; F) A cured PFPE mold of
the silicon master template shown in E; G) 100 nm PEG particles made using
PRINT and transferred to a medical adhesive layer for surface functionalization and
subsequent harvesting
A B C D
E F G
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Fig. 3. Chemical structures of monomers and a partial structure of the PRINT nanogel. p-
Hydroxystyrene was introduced for radioiodination at 1% (w/w). Throughout the
present study, it is assumed that iodinated PRINT nanogels behave the same as
unmodified particles.
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Fig. 4. Scanning electron micrographs of 200 nm PRINT particles used in the present study
1 µm 3 µm 10 µm
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Fig. 5. A time-dependent study of the mean diameter, polydispersity and stability of PRINT
particles (left), liposomes (middle), and AbraxaneTM (right) using dynamic light
scattering
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Fig. 6. MTS assay depicting the non-toxic nature of 200 nm PRINT particles incubated with
HeLa cells. Approximately 103 cells were plated per 1 cm2. Cells were exposed to
varying concentrations of PRINT particles in 0.1 mL media for 4 h at 37 °C before
the MTS assay was performed. Control wells, where the cells were exposed to only
PBS serve as 100% in normalization. Vertical bars stand for one SD with n = 5.
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Fig. 7. Biodistribution of 200 nm [125I]-labeled PRINT particles in healthy mice subsequent
to bolus tail vein injection at a dose of 20 mg/kg. The organ accumulation is
expressed as a percent of injected dose after animals were sacrificed at 10 min, 30
min, 1, 3, 8, and 24 h post-intravenous injection. The organ data is presented as the
mean ± SD with n = 4. The recovery found in the blood assumes a blood volume of
2.18 mL/25 g mouse [34].
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Fig. 8. Blood pharmacokinetic profile of PRINT particles in healthy C57BL/6J mice. At
given time intervals, four animals were sacrificed and blood was collected via cardiac
puncture. Radioactivity observed was converted to particle concentration using the
specific radioactivity measured and assuming a total blood volume of 2.18 mL/25 g
mouse [34]. The data was subject to two-compartmental analysis (WinNonlin)
resulting in pharmacokinetic parameters discussed in the text. For simplicity, data
obtained 24 h post-injection are not shown in the figure or used for PK parameter
determination.
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